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Thousands of deaths and hospital admissions worldwide are reported every year due to carbon 
monoxide poisoning. However, current biomarkers of exposure and quantification devices 
employed for detection and diagnosis lack sufficient specificity and accuracy, leading to 
frequent errors. This results in an underestimation of the true disease burden attributable to CO 
exposure, making it a topic of concern for the clinical and public health communities. The aim 
of this doctoral research was to investigate some of the factors leading to underestimation of 
the health risks associated with CO exposure and evaluate their margins of error, in order to 
propose improvements from an analytical and epidemiologic perspective.  
The quantification of Total Blood CO (TBCO) via Airtight gas Syringe-Gas Chromtography-
Mass Spectrometry (AGS-GC-MS) was identified as more accurate, specific and less error-
prone than current biomarker carboxyhaemoglobin (COHb) and proposed as alternative 
biomarker for CO exposure. The method was validated for clinical and forensic applications 
and tested on real cases in both fields. Results for the comparison between the two biomarkers 
in the different settings (e.g. different storage conditions in clinical and postmortem cases) 
confirmed TBCO as more appropriate biomarker for CO exposure and highlighted the 
limitations of COHb. To determine the potential impact on CO exposure assessments of TBCO 
under controlled conditions and, consequently, its effect on the relative risk, the sources of 
measurement error in CO exposure assessment studies were determined and the improvement 
on measurement error was calculated on one exemplary study. The resulting relative risks were 
increased moderately, thus getting closer to the true risk of CO exposure in the population. This 
affirms the importance of even small improvements in one part of the error sources being able 
to achieve tangible changes with important public health implications. Despite COHb being a 
cheaper and more established biomarker, I currently recommend implementing TBCO for 
challenging cases and encourage further research in this area.    
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Chapter 1 - Introduction 
 
1.1 Background – The ‘Rap Sheet’ of CO 
 
Every year, approximately 50,000 emergency department (ED) visits and 2,741 deaths in the 
US are due to carbon monoxide (CO) poisoning [1]. In Europe, CO-related deaths average at 
350 annually, while in non-European states such as Australia and Japan, this number reaches 
250 and over 3,200, respectively [2]. It is thus not surprising, even for laymen, that the most 
common analogy used to describe CO is the silent killer. Mortality data shows that the majority 
of deaths are due to accidental, non-fire related (ANFR) CO poisoning. In the UK alone, around 
200 hospital admissions and 25 deaths are attributed to ANFR CO poisoning annually [3]. The 
global burden of CO on morbidity and mortality seems to be still quite substantial, despite 
emissions of CO and other air pollutants being reduced by 87% in the last three decades [4]. 
Of the total global CO emissions, 60% are anthropogenic, while 40% originate from natural 
processes [5].  
Generally, CO is generated during incomplete combustion of hydrocarbon-based materials, 
which is a phenomenon that occurs when oxygen(O2)-availability is low, such as in poorly 
ventilated fires, exhausts of petrol-, wood- or oil-fuelled engines, motors, heating and cooking 
appliances as well as smoke from cigarettes, cigars and water pipes [6–11]. Since the majority 
of these sources are of anthropogenic nature, CO concentrations tend to be higher in urban 
areas where there is a high presence of industrial activities, motor vehicles (i.e. traffic), biomass 
burning sites, etc., with background CO levels in non-urban sites mainly deriving from natural 
biological processes such as oxidation of hydrocarbons [5]. Despite the high number of CO-
generating processes, not all people living in highly populated regions are exposed to outdoor 
CO levels that have toxic effects. As the father of toxicology, Paracelsus, once said, “All things 
are poisons, for there is nothing without poisonous qualities. It is only the dose which makes a 
thing poison.”, the toxicity of CO (the poison) depends on its concentration (the dose). CO 
concentrations tend to reach higher levels at a faster rate in indoor environments, where CO is 
‘trapped’ in an enclosed space, compared to outdoors, where it can dissipate into the air [12].                  
CO is a gaseous, diatomic molecule with no taste, colour or odour – at first ‘sight’, not a 
menacing substance. However, despite its toxicokinetic and toxicodynamic mechanisms still 
Chapter 1 - Introduction 
 
 2 
not being sufficiently understood, CO is known to have the potential of causing severe adverse 
health effects involving the respiratory, cardio-circulatory and neurological systems, which 
can, in the worst cases, lead to death [13,14]. The main route of exposure to CO is through 
inhalation (Figure 1.1). CO enters the bloodstream through the lungs during the normal 
breathing process, where its high affinity for haemoglobin (Hb) (~250 times higher than that 
of oxygen), the oxygen-carrying protein in erythrocytes, causes it to competitively replace O2 
to form carboxyhaemoglobin (COHb) [15].         
While the mechanism and kinetics of CO to Hb binding are not fully elucidated yet, it is thought 
to be somewhat similar to the binding of O2 to Hb, which has been thoroughly described in the 
past. Hb is a hetero-tetramer, consisting of two alpha and two beta subunits each containing a 
coordinated iron (Fe(II)) ion, which are the binding sites of the protein. The binding mechanism 
of O2 to Hb has been described as a cooperative binding, meaning that the subunits cannot be 
seen as independent binding sites. In fact, with the binding of one O2 molecule, the 
conformation of the haeme protein changes from a tense state (T-state) to a more stable, relaxed 
state (R-state), resulting in the increased affinity of the two proximal binding sites for O2. After 
binding of the additional subunits, the affinity of the last remaining site is increased even more. 
For the oxygen to be released in the tissues, a change in the partial pressure is necessary, with 
oxygen release increasing with reduced pressure [16].   
For CO, the binding mechanism is still under discussion, with one plausible hypothesis being 
a mixture between electrostatic forces and a coordination of the carbon to the iron due to the 
favourable position of their orbitals [17]. Assumption were made the kinetics are similar to 
those of the O2-binding to Hb, with an increased affinity for CO after the first binding. 
Differently is the situation though for their dissociation, which is based on partial pressure 
gradients: while the oxygen release curve has a sigmoidal shape, the CO curve shows a 
hyperbolic shape [18]. This means that oxygen is released at higher partial pressures than CO, 
with CO being bound stronger at higher pressures and released only at lower pressures. 
Considering that O2 is released differently to the tissues based on their partial pressure gradient, 
the same difference in pressures should be valid for the release of CO. Furthermore, while O2 
is generally present even at low concentrations in tissues, CO is not. Therefore, when CO is 
inhaled and crosses the alveoli-blood barrier, a pressure gradient between blood and tissues 
automatically results, which is higher compared to the one for O2. This should lead to easier 
transfer of CO to tissues [17]. As a result of the inhibition of O2 transport to the tissues, also 
the release of CO2 from tissues is affected, mainly leading to hypoxia of vital organs such as 




Figure  1.1: Mechanism of exposure to carbon monoxide (CO). CO is emitted from sources that use hydrocarbon-based fuels into the air and is then inhaled through the 
lungs and transferred into the blood circulation, where CO binds to haemoglobin and is transported to the tissues. Depending on the concentration of CO in the inhaled air 
and the time of exposure, a variety of health effects with different degrees of severity can be experienced by an individual, which can lead to seeking medical attention or, 
in worst cases, death. The image was created by Stefania Oliverio, with some parts adapted from external sources (https://preparednessadvice.com/medical/family-eight-
died-carbon-monoxide-poisoning/, https://doctorstock.photoshelter.com/image/I0000SMQdj5CeN.w); icons were purchased from ‘Iconfinder’. 
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brain and heart. Depending on the amount of time and concentration levels of exposure to CO, 
exhibited symptoms include headache, dizziness and nausea, which can exacerbate to loss of 
consciousness, coma and, ultimately, death [19,20]. 
 
1.2 New Issues for an Old Poison 
 
One of the major issues with CO poisonings is the non-specificity of the reported symptoms, 
which often lead to misdiagnosis by both the patient and the clinician, who attribute the signs 
to other more common illnesses, such as the flu, general stress or fatigue and gastrointestinal 
issues. Due to the lack of suspicion, a test to measure the CO levels is not performed in these 
cases, which can have fatal outcomes: the exposed individual might return to the CO-
generating source and continue being exposed to the gas for a prolonged period without being 
aware of the developing poisoning until it reaches a critical point where either irreversible 
neurological damage or death occur [21–23]. 
In correctly diagnosed, acute intoxication cases, the most common therapeutic measure is to 
administer normo- or hyperbaric O2, which helps flush out CO and restore physiological O2-
levels in the body of the individual [24]. However, this treatment is not possible in instances 
where low-level, chronic exposures occur. On one hand, this is due to the mentioned lack of 
suspicion and specific symptoms, leading to misdiagnosis. On the other hand, when the 
clinician or patient might be aware of potential exposure to CO and, thus, correctly diagnose 
it, the measurement method used for detection has insufficient accuracy and the reported 
levels might be underestimated, leading to a false negative [25]. 
Supporting this hypothesis are the numerous cases describing inconsistencies between reported 
symptoms and measured CO levels, where people exposed to the same amounts of CO had 
different manifestations and different levels measured in their blood [19]. While it is possible 
that a part of these differences are related to distinct inter-personal characteristics, such as lung 
volume, ventilation rate, age, metabolic rate or various pre-existing morbidities [7,11], the 
reliability and accuracy of the methods used for CO measurement is also a highly important 
factor, since it is these values that are used to correlate CO exposure to their potential health 
effects. The choice of the measurement technique employed depends on the biomarker selected 
for the exposure measurement. In CO poisonings, this choice has fallen onto COHb, due to the 
very tight bond between the molecule and the protein, and the assumption that most CO 
entering the blood circulation binds to Hb [7,26]. However, various studies have debated the 
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percentage of CO bound to Hb, with around 10-15% of the absorbed CO being previously 
documented to bind to proteins other than Hb [20,24], some studies suggested that the 
percentage might be as high as 50% [27].  These studies also showed that CO also to other 
haemoproteins, including globins such as myoglobin (Mb), neuroglobin (Nb) and cytoglobin 
(Cb) and various other compounds such as cytochromes (cytochrome c oxidase, cytochrome 
P450, etc.) and guanylyl cyclase (Figure 1.2) [28–32]. 
Binding to myoglobin reduces the availability of oxygen in the heart and may lead to 
arrhythmias and cardiac dysfunctions as well as causing direct toxicity of skeletal muscle [28]. 
CO binding to mitochondrial cytochrome oxidase, which was reported for in vitro studies 
[29,33], impairs cellular respiration by inactivation of mitochondrial enzymes and also initiates 
an oxidative metabolism by generating oxygen free radicals [20,28,34]. Even though the 
affinity of CO for cytochrome oxidase is relatively low, the dissociation is very slow, leading 
to a prolonged impairment of oxidative metabolism, which may help explain the tardive and 
sustained effects of CO toxicity even after COHb has been cleared from the system through 
hyper- or normobaric oxygen therapy [20,24]. The loss of consciousness associated with CO 
poisoning may be caused by the stimulation of guanylyl cyclase since increases in cyclic 
guanosine monophosphate (cGMP) result in cerebral vasodilation [35,36].          
In general, the role of direct cellular toxicity seems to be underestimated in the literature. 
Binding to these other proteins does not only explain the variety of physiological and 
neurological outcomes associated with CO but could potentially be associated with the 
misdiagnosed and underestimated cases when using COHb as a sole biomarker. Therefore, it 
is important to be able to determine the total amount of CO in blood and not only COHb in CO 
poisoning cases. These misdiagnoses and underestimations do not only affect the immediate 
health status of an exposed individual, but they also have implications into the health status of 
the population. These misdiagnoses and underestimations do not only affect the immediate 
health status of an exposed individual, but they also have implications into the health status of 
the population. Air quality guidelines and required occupational air pollutant levels are set up 
based on risk and exposure assessment studies. Exposure assessment studies typically sample 
a representative amount of people in a population subgroup, measure their exposure and with 
the aid of air pollution monitoring and environmental models, extrapolate the results to the 
population [29, 30]. 
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Figure  1.2: Adverse-outcome pathway for CO poisoning. Apadted from Kao and Nañagas [20]. 
Chapter 1 - Introduction 
 
 7 
1.3 CO and Public Health 
 
It has been over 50 years that air pollution and exposure to certain environmental contaminants 
have been attributed as the underlying causes for a large portion of the global death burden 
worldwide and also associated with adverse health outcomes, including several pulmonary, 
cardiovascular, immune system and neurologic diseases [37–39].  Air pollution is defined as a 
heterogeneous mixture of gases and particulate matter (PM), the main components of which 
are ozone (O3), nitrogen oxides (NOx), carbon monoxide (CO) and sulphur dioxide (SO2) [40]. 
Due to their high toxicity and occurrence, especially in outdoor environments, and severe 
impact on the global disease burden, recent studies have mainly focused on O3, NOx and PM 
[41–45].  
CO is also a highly toxic gas, even though present in lower quantities in outdoor environments. 
It is in enclosed spaces that CO poses the greatest health risks, mainly due to the presence of 
CO-generating sources. 
In indoor environments, CO levels tend to increase at a higher rate due to generally limited 
ventilation and low oxygenation, thus posing a higher risk of acute CO poisoning. Occupational 
exposure to indoor CO also constitutes an important part of the total human CO exposure, even 
though exposure levels are usually lower than during acute exposures due to high emission 
sources, such as during a fire. Toxicity in occupational settings is usually due to chronic 
exposure to lower CO levels but is more difficult to associate with pathological outcomes 
[46,47]. Therefore, interest for low levels of indoor CO with the potential for chronic toxicity 
was only recently raised, with several studies finding a link between low-level chronic CO 
exposure and neurocognitive impairments [18,48,49]. Exposure to low concentrations of CO 
for prolonged periods of time showed symptoms of acquired brain injury (ABI), which in most 
cases were permanent [23,50–52]. Despite known health consequences following low-level 
chronic CO exposures, there are only a limited number of clinical or epidemiological studies, 
and thus, evidence, looking at how to recognise, diagnose and prevent low-level chronic CO 
exposures. These chronic exposures, even though at low levels, also constitute an essential part 
of the global burden of CO exposure.  
These are clearly of relevance for public health and should be given more importance by public 
health authorities than they are currently. The UK, driven by the Cross Government CO Group 
(COCGG), which includes all major institutions such as Public Health England (PHE), 
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PolicyConnect, the All-Parliamentary Party Carbon Monoxide Group (APPCOG) and the Gas 
Safety Trust (GST), together with institutions in Canada and the US are pioneering in the funds 
put into research for deeper understanding of low-level chronic CO exposures. Gaining more 
access to the scientific background behind CO exposures but also to their true incidence in the 
population is pivotal to inform policymakers and help them improve their decision-making 
process. For this purpose, epidemiologic studies provide an essential and unique tool to obtain 
the necessary evidence [53]. However, current knowledge is still far from being satisfactory 
for CO exposures, especially at low levels. 
 
1.4 CO exposure assessments 
 
To be able to determine the global burden of CO exposure on the population, it is important to 
determine the magnitude and role played by the part attributed to indoor CO levels. 
Epidemiologic studies that determine the distribution of indoor CO exposure and its health 
effects in the population are necessary. The part of epidemiology that allows us to obtain this 
kind of information is exposure assessments. Exposure assessment is defined as the study of 
the distribution and the determinants of compounds or factors affecting human health and aims 
at optimizing the exposure estimate and exposure-response relation by taking into account 
factors such as the distribution of the variance of exposure estimates [54]. It comprises the 
measurement of exposure and of other factors that determine the distribution and exposure 
levels relevant to human health in different population groups, environments and countries (e.g. 
elderly vs children, urban vs rural areas, underdeveloped vs developed countries) [53].  
Exposure assessments are essential from a public health perspective since they provide the 
epidemiologic evidence that from exposure estimates leads to the determination of risk 
estimates in the population, which is what public health authorities need to set up indoor and 
outdoor air quality guidelines and reference levels [53]. Improved exposure assessments, 
therefore, result in improved epidemiologic evidence that leads to a better quantification of the 
risk associated with the exposure. Consequently, it promotes evidence-based decision-making, 
which drives the setting of standards by public health authorities and can help improve 
management and prevention strategies. As a result, improved standards have the potential to 
reduce morbidity and mortality associated with exposure to the assessed pollutants.     
Therefore, exposure assessments are necessary to determine concentrations of CO in indoor 
and outdoor spaces and derive the evidence required to set up guidelines for safe living and 
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working environments for the population. The World Health Organization (WHO), United 
States Environmental Protection Agency (EPA) and authorities from other countries published 
reports from exposure assessments and guidelines on air quality criteria for most pollutants, 
including CO [55–57]. An example of these guidelines is given by the limits proposed by the 
WHO for CO levels in ppm based on the amount of exposure time [5], which were also 
correlated to COHb levels in % and typical symptoms (Figure 1.3).  
 
 
Figure 1.3: Symptomatology associated with reference levels for CO in parts per million (ppm) and 
carboxyhaemoglobin (COHb) in %. (Adapted from WHO guidelines [31]). 
 
However, recent developments regarding the toxicity of low-level CO exposures were either 
not discussed or updated in these reports. While methods to assess exposures to acute, high-
level CO concentrations are described in detail, little information is available on methods to 
assess exposures to low concentrations of CO over a prolonged time interval. Especially for 
indoor CO exposures, only brief descriptions can be found in these reports, despite the high 
complexity but also the importance of indoor environments. Factors that affect average and 
peak indoor concentrations include the type, quantity and frequency of use of pollutant-
emitting sources, the availability, frequency and rate of ventilation of the indoor environment 
as well as the human activity pattern (people tend to spend different amounts of time in different 
indoor spaces) [58].  
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These guidelines are globally applicable and employed with similar values by numerous public 
health institutes, industries and policymakers worldwide as well as being a reference in clinical 
and forensic settings.  
 
1.5 Investigation Goals 
 
Despite the general public and medical aim of preventing death and treating injury cases, it is 
also an essential task from a legal and ethical point of view to determine the cause of death 
correctly and accurately. Apart from the already mentioned issues in clinical cases, CO 
poisoning detection poses additional challenges during the analysis of post-mortem (PM) 
samples. These are due to biochemical phenomena occurring in the human body during and 
after death, the interval between time of death and body retrieval (postmortem interval – PMI) 
and time and methods for sampling and storage, causing alterations of samples biasing CO 
levels and thus affecting the interpretation of the results, which has significant juridical 
implications [59,60]. Therefore, mistakes in exposure measurements have a widespread 
relevance, ultimately having an impact on the population morbidity, mortality and risk rates 
derived from CO.        
Currently, public and medical awareness of CO exposure and the health dangers it poses are 
being improved through increased training of clinicians by experts in the field and 
advertisement in local communities as well as through broad media coverage in recognizing 
the signs of a CO poisoning. This study aims at tackling the raised issues from a scientific 
standpoint by following a path that links the toxicological to the epidemiological investigation.    
i. One of the objectives is to develop and validate an alternative analytical method for more 
accurate CO poisoning determination for clinical and forensic applications, to help 
decrease misdiagnosis due to the inconsistencies between symptoms and COHb levels.  
ii. Moreover, this research intends to determine and quantify the influence of storage 
parameters on changes in COHb/CO concentrations over time and aid in creating a model 
that allows incorporation of these alterations during the interpretation of results from CO 
poisoning determinations in individual measurements. This should also decrease the 
number of cases erroneously not attributed to CO as a cause of morbidity or mortality.  
iii. An additional aim is to identify gaps in CO exposure assessments, with a focus on 
determining and quantifying measurement error arising from recent methodological and 
toxicological advances, including part of the work conducted in this study. This will 
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enable the development of an overview of current practices and frequent errors in CO 
exposure assessment as well as generating an approach to correct for a part of these errors.  
iv. Finally, this study wants to determine the magnitude of the impact that improvements in 
methodological and analytical measurement and exposure assessment methods can have 
on the population estimates and, thus, on the relative risk related to CO. This is the 
essential step that can directly link the analytical improvements with population health.       
 
1.6 Structure of the thesis 
 
The thesis includes a total of six chapters. 
 
The first chapter is the introductory chapter, which describes the main chemical, physical and 
toxicological properties of CO and the problems associated with CO exposure and its diagnosis 
in clinical and forensic cases, but also the relation and relevance of these issues to the global 
CO burden on public health.  
 
Chapter two is a review of past and current trends in CO measurement methods in biological 
matrices, highlighting pros and cons of available methods, challenges faced during CO analysis 
in clinical and forensic cases as well as pointing out the limitations of these methods and 
potential ways to circumvent them.  
 
In chapter three, I describe the development and validation of a novel measurement method for 
CO in blood based on gas chromatography-mass spectrometry (GC-MS) and propose a novel 
biomarker for CO poisoning diagnosis, Total Blood Carbon Monoxide (TBCO). I validated the 
method for use in clinical and PM concentration ranges and applied it to a series of real cases. 
All analyses were carried out with the newly developed method as well as the “golden 
standard” spectrophotometric measurement of COHb as a comparison.  
 
The fourth chapter is dedicated to the investigation of several storage and sampling parameters 
employed in blood analyses for CO poisoning determination cases. I did not only determine 
the impact of these parameters on the results of blood analyses but also compared them in light 
of the measured biomarker and inherent measurement method, namely COHb via CO-oximetry 
and TBCO via GC-MS, to determine their differences both qualitatively and quantitatively. 
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Chapter 5 brings the results from the previous chapters together into the perspective of CO 
exposure in the population and public health-related issues, by identifying the gaps in CO 
exposure assessment methods and the influence an improved measurement method and 
improved sampling and storage parameters can have on the health risk associated with CO 
exposure. Calculations are carried out to quantify this impact in selected studies.  
 
The final chapter, chapter six, concisely summarizes the major achievements of this study as 
well as indicating both pitfalls/limitations of the approaches described and further work 
required in the field.  
 
All the toxicological in vitro analyses were carried out at the University Centre of Legal 
Medicine. These analyses were performed under routine activity at the University Centre of 
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Chapter 2 - What are the limitations 
of methods to measure carbon 
monoxide in biological samples? 
 
2.1 Introduction  
 
Carbon monoxide (CO) concentrations may be measured in exhaled breath, ambient air, or in 
blood. Due to the high affinity of CO to haemoglobin (Hb), it has been assumed that the 
majority, if not all, CO binds with Hb when introduced into the blood circulation. This has 
resulted in carboxyhemoglobin (COHb) being considered the most appropriate clinical marker 
of exposure for CO poisoning [1]. However, COHb does not represent the only reservoir of 
CO in the human body because CO may be found dissolved in blood at free state and can bind 
to other heme-containing respiratory globins, such as myoglobin in muscle, neuroglobin in the 
nervous system and, to a lesser extent, cytoglobin [2]. CO dissolved in blood in free form is 
known to have a role in the pathophysiology of CO poisonings [3], but might be more 
substantial than what studies revealed so far. This would result in under- or misestimation of 
the true CO level present in the analyzed blood sample, potentially elucidating some of the 
cases where inconsistencies between measured COHb level and reported symptoms were 
found. However, currently, there is not much data on free CO available.  
COHb in blood is measured directly or indirectly by using either optical methods (CO-
oximetry, UV-spectrophotometry or pulse-oximetry) or gas chromatographic methods in 
combination with a variety of detectors (flame ionization detector, mass spectrometer). In 
clinical cases, the “gold standard” is the measurement of COHb in blood is by CO-oximetry 
(or pulse-oximetry), either as a separate instrument or integrated into what is commonly known 
as a blood gas analyzer (BGA) or radiometer [5]. Although ultraviolet (UV)-spectrophotometry 
remains the most frequently used method in forensic cases, CO-oximetry and gas 
chromatographic methods are also widely employed in this field.  
Like any biomarker, the quantitative measurement of COHb is subject to a variety of factors 
that influence the measurement. Measurement error in analytical studies is defined as 
“uncertainty” or “bias”. Uncertainty originates when several predictable, but not always 
controllable factors affect the measured values and may potentially alter the obtained value, 
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resulting in a deviation from the true value due to these factors. In medical practice and 
especially for toxicologists, it is crucial to correctly and accurately determine a biomarker, in 
order to make the correct diagnosis and initiate the proper treatment in clinical cases and to 
determine the correct cause of death in forensic cases. Shortcomings in doing so can have 
severe clinical and legal consequences. Therefore, in this chapter, I aim to review the accuracy 
of current methods to measure CO and to determine their potential sources of error and their 




PubMed was searched in November 2018 using the keywords (“carbon monoxide” OR 
“carboxyhemoglobin”) AND (“poisoning”) AND ("measurement" OR "determination" OR 
"quantification" OR "analysis" OR "breath" OR "blood" OR "oximet*" OR "spectro*" OR "gas 
chromatography" OR "storage"); this gave 191 hits. Systematic reviews, meta-analyses and 
general review articles, retrospective, prospective, observational and clinical cohort studies 
were excluded as well as case reports, limiting included articles to those which were focused 
specifically on describing a method for analysis of CO or COHb in various tissues and those 
describing issues related to analysis of samples (storage, sample pretreatment, etc.). This left 
49 relevant articles on measurement methods and sources of errors.  
 
2.3 Measurement of CO in breath 
 
2.3.1 Analytical techniques 
 
Analysis of CO in exhaled breath was evaluated as a measurement method for clinical cases 
since a good correlation between alveolar breath CO and COHb was found by several research 
groups [6–9]. Portable devices, called MicroCOmeters or CO monitors, are often used in 
smoking cessation programs [8, 10] and may be useful when a rapid on-site assessment in 
multiple casualties is necessary, enabling the most severe cases to be identified [11]. This 
measurement is based on an electrochemical fuel cell sensor, which works through the reaction 
of CO with an electrolyte on one electrode and oxygen (from ambient air) on the other. This 
reaction generates an electrical current proportional to a CO concentration. The output from 
the sensor is monitored by a microprocessor, which detects a peak at expired concentrations of 
CO in the alveolar gas [12]. These are then converted to COHb% using the mathematical 
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relationships described by Jarvis et al. [8] for concentrations below 90 parts per million (ppm) 
and by Stewart et al. [13] for higher levels.  
 
2.3.2 Sources of errors 
 
Measurement of CO in breath cannot account for the total CO concentration present in the 
blood at the time of exposure. It is a very susceptible method and affected by a variety of factors 
that can easily alter the result into under- or overestimating the true concentration (Figure 2.1). 
A major aspect is the variation among the subjects’ abilities of breath-holding. To obtain the 
alveolar gas, it was found that the breath needs to be held for 20 s and then only the end-tidal 
expired air is used for CO measurement. Given the interpersonal differences in pulmonary 
function, capillary diffusion surface and inspiration and expiration rates, as well as the inability 
to fully control whether a subject is properly holding the breath, the portion of expired alveolar 
gas sampled and the results obtained can have a high degree of variability [6, 8, 13]. This can 
also pose an issue in susceptible groups of the population, such as elderly, children or subjects 
with respiratory diseases. Furthermore, since they were initially designed for smoking 
cessation programs, the accuracy of CO monitors is better in lower CO concentrations (0-20 
ppm) and might therefore not be sufficiently accurate for acute intoxications [14]. 
Nevertheless, CO monitors have high usefulness on sites of mass casualties or for first 
responders. They are portable and can give an indication of the gravity of the case, which can 
allow the appropriate treatment of the patient as well as proper precautions to be taken by first 
responders.            
 
2.4 Measurement of CO in blood: optical techniques CO-oximetry and 
spectrophotometry 
 
2.4.1 Analytical techniques  
 
Spectrophotometric or optical methods measure the concentration of COHb based on the 
quantity of absorbance of light when the compound is exposed to light of different wavelengths. 
In the past, single-beam UV-spectrophotometry or double wavelength spectrophotometry was 
first developed due to the spectral absorbance of the Hb structures and due to the distinct 
spectral differences between oxyhemoglobin (O2Hb) and COHb [15–17]. A similar method 
involves the measurement in the visible spectra of the differences in absorbance between 
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reduced Hb (HHb) and COHb, where a reducing agent is added to the blood sample that reduces 
O2Hb, but not COHb [18, 19].   
However, double wavelength spectrophotometry was not a very accurate and specific method 
[16], since results were based on the measurement of only two wavelengths. Automated 
differential spectrophotometry was later developed, which uses double-laser beams to 
determine the difference in absorbance of a sample compared to a negative sample, thus with 
this method, matrix effects are accounted for, resulting in better accuracy.  
CO-oximetry is a measurement technique based on multiple wavelength spectrophotometry, 
which uses the multiple wavelengths up to the full range of wavelengths for analysis, allowing 
for more accurate measurement of  COHb [20–22]. They are currently the standard analytical 
technique used for measurement of COHb, either with a separate instrument or, for hospital 
cases, integrated into a BGA [18, 23, 24].  
Despite the advantages of CO-oximetry, due to cost-efficiency UV and double wavelength 
spectrophotometers are currently still used in many developing countries and are also listed in 
the International Organization for Standardization (ISO) 27368:2008 ‘Analysis of blood for 
asphyxiant toxicants – carbon monoxide and hydrogen cyanide’ standards [25].  
 
2.4.2 Sources of error 
 
Several issues can alter the measurement results from optical methods, mainly due to the 
susceptibility of these methods to changes in sample quality in the light of poor choice of 
sample handling techniques and storage conditions (e.g., temperature, preservative, etc.) as 
well as biochemical alterations that occur over time [26]. Some of the most important potential 
errors for COHb determinations include: 
1) Type of preservative: the type of preservative used in the blood tube used to store the 
sample can alter the results due to biochemical reactions that can take place, which can 
either increase or decrease the concentration of CO[27, 28].  
2) Storage temperature: the use of different storage temperatures was shown to alter the 
results; storage over prolonged periods of time can lead to degradation of the sample, which 
can lead to in vitro CO production, resulting in overestimation of the concentration; storage 
at room or hot temperatures leads to faster degradation as compared to storage in the fridge 
or freezer [26, 28, 29].   
3) Dead volume: the different amounts of volume of headspace (HS) in the sampling tube 
(which is known as dead volume) can alter the results because of the reversibility of the 
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bond between CO and Hb; the more dead volume in the tube, the more likely there is 
dissociation of CO from Hb and release into the HS [30].  
4) Freeze-and-thaw cycles: whether a sample has been frozen and then thawed one or more 
times can also alter the resulting measurement, due to the breakdown of the erythrocytes 
[28]. 
5) Reopening of the sampling tubes: the repeated opening of the tube can lead to substance 
loss (in gaseous state when CO is not bound to Hb) with increasing number and time of 
reopening as well as increased exposure of the sample to oxygen [23, 28]. 
6) Postmortem (PM) changes: thermo-coagulation, putrefaction and PM CO production are 
all known sources of error, but they cannot be quantified due to their biological 
unpredictable nature [27, 31, 32].  
7) Instrument and personal error: errors due to the instrument or the operator are random, but 
they can be corrected by using an internal standard when possible, which minimizes the 
error [33]. 
 
These altering factors are applicable not only to optical measurements of COHb but also to gas 
chromatographic measurements of CO. Specifically for spectrophotometric methods, several 
















Figure 2.1: General steps for quantitative laboratory analysis and their respective potential sources of 
error for CO determinations. 
 
Storage studies performed earlier by Chace et al. [28] and later by Kunsman et al. [27] 
evaluated a number of storage conditions, including the amount of air present in the sampling 
tube (known as dead volume, which can alter the results because of the reversibility of the bond 
between CO and Hb and potential dissociation of the gas into the HS of the tube), storage 
temperatures, preservatives and initial COHb saturation levels. They observed decreased 
COHb levels that were related to the ratio of exposed surface area to the volume of blood (the 
higher the exposed surface area, the greater the loss), the storage temperature (the higher the 
temperature, the greater the loss) as well as initial COHb% saturation levels (the higher the 
COHb levels, the greater the loss). The hypothesis of the formation of an equilibrium between 
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CO in blood and air above the blood sample in the tube was proposed to explain the influence 
of the HS in the sampling tube [28]. Storage at room or hot temperatures of blood leads to faster 
degradation and lower sample stability, affecting the spectrophotometric measurement of CO, 
which was also confirmed by other research groups [26, 34]. Additionally, they found no effect 
from the preservative used, even though it was tested on an insufficient number of preservatives 
(only two, namely sodium fluoride (NaF) and ethylenediaminetetraacetic acid (EDTA)), which 
were compared to samples with no preservative, and only on samples stored frozen right after 
sampling over a period of two years [39]. Analysis of the samples on only two significantly 
distant time points might fail to notice changes in short-term storage due to preservative use, 
which is more relevant than long-term storage since samples are in the majority of cases 
analyzed within a few hours to days. Nevertheless, these findings are especially relevant for 
forensic or legal cases, where retrospective analyses can still provide sufficiently reliable 
information. The resulting lack of impact from the preservative might, however, be biased 
because the measurements were performed with optical methods only, which are known to be 
influenced by the blood state. Therefore smaller changes due to the preservatives might not 
have been picked up by this less sensitive measurement methods. However, Vreman et al. [35] 
were able to find that using EDTA as preservative led to falsely increased COHb values when 
measured by CO-oximetry. Nevertheless, a stronger significance of these findings would have 
been achieved with confirmation by another measurement method, such as gas chromatography 
(GC).     
Furthermore, these conditions may not only influence the CO levels present in the blood, but 
also the blood quality [28]. For samples that cannot be readily analyzed and are not stored 
under optimal conditions, a degradation of the sample occurs, which was confirmed to trouble 
the optical measurement methods used to determine COHb levels [36]. This can be a major 
issue for many laboratories where optical techniques are routinely used for sample analysis.  
Additional factors influencing the measurement of COHb-levels that have been reported in the 
literature include the presence and amount of oxygen in air [23] and, in PM samples, thermo-
coagulation in fire victims [34], putrefaction during a prolonged PM interval (PMI) [37], 
contamination due to hemolysis, high lipid concentrations or thrombocytosis, all of which 
result in turbidity of the sample troubling the measurement performed with optical techniques. 
Another recurring and significant phenomenon to be considered during the evaluation of the 
results is the PM production of CO in the organism [32, 38]. CO was found to be produced in 
significant quantities in cases that were not related to fire- or CO exposure. However, the cases 
in which this occurs are mostly cases of putrefied bodies. It was confirmed that CO is formed 
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due to the decomposition of various substances present in the body, such as erythrocytes 
catabolism, a phenomenon that occurs also in living organisms [32]. Therefore, it is important 
to differentiate those cases from the real CO intoxication cases, which can be done with the 
help of the cause of death determined with an autopsy, even though it is not always a simple 
task to completely exclude the possibility of the role played by CO in these cases [23]. As a 
result, PM decomposition currently constitutes a field with open questions that require further 
investigation. 
 
2.5 Antemortem COHb measurement by pulse CO-oximetry 
 
2.5.1 Analytical techniques 
 
In clinical settings and generally, for living patients, a noninvasive alternative to venous or 
arterial blood COHb measurement by a BGA or CO-oximetry that has been widely investigated 
is pulse CO-oximetry [39–43]. Similarly to standard CO-oximetry, pulse CO-oximetry is a 
spectrophotometric method that quantifies multiple types of haemoglobin, including COHb, 
based on the absorbance of light after exposure to different wavelengths [43]. As opposed to 
regular CO-oximeters, pulse CO-oximeters have the ability to measure COHb continuously 
and without the need of blood sampling, thus allowing the monitoring of COHb levels in real-
time and simultaneously to the administration of treatment.  
     
2.5.2 Sources of error 
 
Noninvasiveness and cost- and time-efficiency are some evident advantages of using pulse CO-
oximeters. However, for CO poisoning diagnosis, there are factors of higher importance from 
a medical perspective, such as accuracy, precision and reliability. Being able to diagnose a CO 
poisoning case quickly is necessary, but if the results obtained over- or underestimate the true 
COHb levels, this can have severe and potentially fatal consequences. Several studies have 
reported low precision and accuracy as well as an elevated false positive and negative rate, as 
opposed to regular blood measurements [5, 39–42]. Especially for COHb levels above 10%, 
pulse CO-oximeters significantly underestimated the COHb levels [39].  
Furthermore, factors such as blood pressure, oxygen saturation and body temperature also seem 
to affect the accuracy of pulse CO-oximeters [42]. Feiner et al. [40] reported low signal quality 
or no report of CO saturation levels when the oxygen saturation decreased below 85%, which 
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is indicative of hypoxia. Considering that hypoxia is one of the main effects of a CO poisoning, 
it is a severe disadvantage not to be able to measure COHb accurately in hypoxic states. 
However, a more recent study by Kulcke et al. [43] found good accuracy levels in measuring 
COHb during hypoxemia, even though a slightly higher underestimation of COHb levels is 
reported for COHb concentrations above 10%. This confirms that pulse CO-oximeters can be 
useful for monitoring exposures to low CO levels, but accuracy and precision are not 
guaranteed for more severe poisonings as well as for smokers, who generally have baseline 
COHb levels that can range from 3-8% in normal smokers but can easily reach 10-15% in 
heavy smokers [1, 2].        
In comparison to postmortem CO-oximetry, antemortem COHb measurement by pulse CO-
oximetry is not affected by storage or sampling parameters, which reduces the sources of error. 
Additionally, no laborious and time-consuming calibration of the device seems to be needed 
based on what is reported in the literature, leading to a more simplified routine analysis, even 
though there is scarce information regarding device maintenance. Similarly to general CO-
oximetry and despite good accuracy and precision, measurement of only CO bound to Hb can 
lead to underestimation of the total CO burden and thus lead to misdiagnosis. Another relevant 
point from a judicial perspective is that pulse CO-oximetry does not provide samples that can 
be used for confirmation or counter expertise in legal disputes.        
 
2.6 Measurement of CO in blood: gas chromatography 
 
2.6.1 Analytical techniques  
 
The principle behind gas chromatographic CO detection is based on the measurement of the 
released CO dissolved in blood as well as the one bound to Hb through a liberating agent (after 
red cell lysis). Therefore, the sample is firstly treated with a hemolytic agent, such as saponin, 
Triton X-100 or other detergents, and subsequently acidified to liberate the CO in blood [34, 
44–47]. The reaction of COHb with a powerful acid/oxidizing agent was found to efficiently 
release CO and water as products. The releasing agents commonly used are sulfuric acid 
(H2SO4), hydrochloric acid (HCl) and potassium ferricyanide (K3Fe(CN)6). Other acids such 
as lactic acid [48], citric acid [48, 49] or phosphoric acid [49] have also been tested.  
In the studies performed in earlier years (the 70s, 80s and 90s), potassium ferricyanide was 
introduced for the release of CO and became very popular due to the availability, since it was 
already used in spectrophotometric methods as a hemolytic agent. It was also found to be 
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efficient in liberating the CO and its extent of reaction was not influenced by the presence of 
O2 or O2Hb at a wide pH range, as compared to other acids tested [30, 46, 48, 50, 51]. However, 
in more recent studies, sulfuric acid has been preferred, mostly because, as compared to other 
acids of the same efficiency, it is more readily available, cheaper and allows the simultaneous 
liberation of CO and production of 13CO used as internal standard [4, 30, 31, 47, 49, 52–54]. 
After successful liberation, CO is into by GC and then detected with one of the above-
mentioned detectors.  
For the GC separation, a capillary column with a 5Å molecular sieve has been found to be 
specific for the separation of CO from other interfering gases such as nitrogen (N2), oxygen 
(O2) and methane (CH4) [51]. Various packed columns were used previously, but have been 
substituted by the capillary columns due to their significantly reduced size.   
To enhance sensitivity and accuracy and increase the range of analysis, GC methods were 
studied with various types of detection, such as thermal conductivity detection (TCD), flame 
ionization detection (FID), mass spectrometry (MS) and reduction gas analyzer (RGA) [55-
66]. The most commonly used and investigated detector was FID, firstly reported in relation to 
CO determination in 1968 [51]. After GC separation, the CO is chemically reduced to methane 
(CH4) with a methanizer and subsequently analyzed via FID.             
 
2.6.2 Sources of error  
 
The most important sources of error for GC techniques are found in the process of calibration 
before analysis and the methods of correlating measured CO concentrations to COHb levels 
that have previously been linked to the symptomatology. Generally, calibration of the 
instrument is performed either with pure CO gas, which was diluted to obtain the desired CO 
concentrations, or with fortification of blood with CO to reach different COHb% saturation 
levels. Additionally, excess CO was removed through the performing of a “flushing” step, in 
which the calibrators were flushed with a stream of inert gas (usually N2). This step enabled 
the removal of unbound CO from the sample, thus leaving only CO bound to Hb to be analyzed, 
but thereby deliberately neglecting the potential toxicity of free CO.  
First changes in the calibration method were made in 1993 when Cardeal et al. [49] firstly took 
advantage of the reaction of formic acid with sulfuric acid to form CO for calibration. However, 
no detail was given on how the analyzed blood was saturated with CO, nor was it explained 
how the formula used to back-calculate the measured CO concentration to a COHb level was 
created.  
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Czogala and Goniewicz [67] proposed a GC–FID based method which directly correlated the 
CO levels in air to COHb in blood through back-calculation and extrapolated it to the other 
factors assessed (exposure time, smoking frequency, number of smoked cigarettes and 
ventilation conditions). The technique was designed to ensure complete release of CO from the 
blood samples by performing the reaction and subsequent analysis in an airtight reactor. 
Similarly, the air samples were directly transferred from the room to the analysis instrument, 
which avoided time delays and possible losses of CO and allowed for direct correlation of the 
results to the other measurements. However, the details about the procedure to obtain 100% 
CO saturated blood used for calibration were not described, which is necessary to assess 
whether the method is reliable and reproducible. Furthermore, the formula used to back-
calculate the COHb saturation levels from the measured CO concentrations contained the 
Hüfner factor of 1.51, which differed from the factor reported by other studies [30, 46]. The 
Hüfner factor expresses the maximum amount of CO that can be bound to 1 g of Hb [68, 69]. 
A detailed list of additional pitfalls of GC methods is found in Table 2.1. 
2.7 Measurement of CO in blood: mass spectrometry, GC-MS and HS-
GC-MS 
 
2.7.1 Analytical techniques  
 
MS is the method of choice to detect CO because the identification is not only based on the 
retention time but also the mass spectrum. Middleberg et al. [31] developed a method, which 
combined GC–MS with flame atomic absorption spectroscopy (FAAS). Hereby CO was 
determined by GC–MS after release with sulfuric acid and heating, while FAAS was used to 
determine the total iron content of the blood, which is used to calculate a more precise total 
amount of available Hb. By using this assay, it was assumed that all the iron present in blood 
was part of the heme protein and was capable of binding CO, even though it needs to be taken 
into account that this is not completely true and depends on the state of the organs, tissues and 
possible present diseases. Therefore, the obtained values might not accurately reflect the real 
CO levels.   
 
2.7.2 Sources of error 
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Similarly to other GC methods, also in MS, main errors derive from the calibration of the 
methods, the subsequent back-calculation of COHb from CO and extrapolation of already 
existent COHb% saturation-symptom correlation (Table 2.1).  
Hao et al. [37] published an approach built on an HS-GC–MS method for analysis of CO in 
putrefied PM blood. Hereby, the standard curve was constructed from putrefied blood, which 
was saturated by CO-bubbling to reach 100% COHb and then flushed to remove excess CO. 
COHb% levels were then calculated from the ratio of saturated to untreated blood. In PM cases, 
to prevent the variation of Hb levels to affect the results, direct blood saturation was performed. 
It was stated that 30 min of pure CO exposure of the blood was necessary to fully saturate 
blood, even though the procedure applied to assess complete saturation, putrefied blood state 
and PMI were not described [37]. Furthermore, according to their results of the storage 
condition tests (possible loss of sealing parts of the HS vial, water bath temperature, stability, 
interval and temperature), the storage temperature did not affect the COHb% levels. However, 
this appears in contradiction with the majority of previously published studies, even though 
they were obtained with the use of other approaches, such as optical methods and other GC-
detectors.  
Varlet et al. [52] were able to develop and validate a new method, which used isotopically 
labelled formic acid (H13COOH) to produce 13CO as internal standard for an HS-GC–MS 
method. This is very advantageous since formic acid (HCOOH) was already used for the 
calibration, and sulfuric acid could be used to react with both types of formic acid, forming a 
mixture of CO and 13CO, from which the CO concentration could be derived mathematically 
and correlated to the COHb levels through the use of formulae previously published by other 
authors [46, 49]. However, these formulae describing back-calculation of COHb from CO 
concentrations measured by GC could be debatable due to the random finding of good 
correlation between the spectrophotometrically measured COHb levels and the CO levels 
measured by GC–MS  [52]. Varlet et al. [36] improved their method and compared it with 
results obtained through CO-oximeter. They were able to obtain cut-off values for different 
categories of back-calculated COHb% levels as compared to the ones directly measured by the 
CO-oximeter. However, even if this approach seems to show reliability for both clinical and 
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Table 2.1: Overview of analytical methods used for carboxyhaemoglobin/carbon monoxide analysis, their main properties and limitations and reference examples; CO: carbon 
monoxide, COHb: carboxyhemoglobin, PM: post-mortem, PMI: post-mortem interval, GC–RGA: gas chromatography–reduction gas analyser, GC-TCD: gas chromatography–
thermal conductivity detector, GC–FID: gas chromatography–flame ionization detection, GC–MS: gas chromatography-mass spectrometry. 
Specimen/method Technique Main characteristics Pitfalls References 
Breath  Electrochemical 
sensor 
 Easy to use 
 Non-invasive 
 Rapid (multiple determinations in short 
time period – useful in mass accidents) 
 Low cost 
 Portable 
 Alveolar breath CO correlated to COHb 
 Used in smoking cessation programs 
and to detect hemolytic diseases 
 Only fraction of CO exhaled is measured 
 Not able to determine total amount of CO in 
blood circulation 
 No correlation to CO in tissues  
 Not sufficiently sensitive for low-level CO 
exposures 
 Only approximate diagnosis can be made 
 Correlation between exhaled CO and COHb 
still debatable 
 Not suitable for all patients (elderly, 
diseased) – requires sufficient exhaled 
airflow 
Ogilvie et al. 1957 [6] 
Jarvis et al. 1980 [7] 
Jarvis et al. 1986 [8] 
Vreman et al. 1994 [14] 
Middleton et al. 2000 [9] 
Macintyre et al. 2005 [10] 









 Use of multiple wavelengths 
 Rapid 
 Easy to use 
 Fairly accurate 
 Small sample size 
 DW: not precise, accurate and specific 
 Sensitive to alteration of sample quality 
 Not optimal especially for PM samples with 
long/unknown PMI and/or storage 
conditions 
 Risk of misdiagnosis due to artefacts 
 Not able to determine total amount of CO in 
blood circulation 
 No correlation to CO in tissues  
 Focus only on COHb 
 Time-consuming sample preparation (COHb 
reduction) 
 Often observed inconsistency between 










Ramieri et al. 1974 [16] 
Winek et al. 1981 [17] 
Fukui et al. 1984 [19] 
Vreman et al. 1984 [46] 
Lewis et al. 2004 [55] 
Luchini et al. 2009 [56] 
Olson et al. 2010 [22] 
Varlet et al. 2012 [52] 
Hao et al. 2013 [37] 
Varlet et al. 2013 [36] 
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Specimen/method Technique Main characteristics Pitfalls References 
Blood CO-oximetry  Easy to use 
 Rapid 
 Low cost 
 Accurate 
 Precise 
 COHb saturation correlated to the 
severity of poisoning and symptoms 
reported by patients 
 Limit of accuracy: >5% COHb 
 Not applicable to low-level CO exposures 
 Invasive 
 Only CO bound to Hb taken into account 
 Often observed inconsistency between 
measured levels and reported symptoms 
 Susceptible to alterations due to sample 
quality 
 Difficult interpretation for PM samples with 
long/unknown PMI and/or storage 
conditions 
Dubowski and Lu 1973 [57] 
Costantino et al. 1986 [58] 
Mahoney et al.1993 [24] 
Oritani et al. 1996 [65] 
Levine et al. 1997 [59] 
Bailey et al. 1997 [21] 
Widdop 2002 [23] 
Lee et al. 2002 [60] 
Lee et al. 2003 [61] 
Brehmer and Iten 2003 [62] 
Boumba and Vougiouklakis 
2005 [18] 
Penney 2008 [11] 
Piatkowski et al. 2009 [5] 
Olson et al. 2010 [22] 




Pulse CO-oximetry  Measurement of COHb% saturation in 
circulation 




 Applicable in clinical setting 
 No laborious calibration needed 
 
 Not applicable in PM setting 
 Only CO bound to Hb taken into account 
 No correlation to CO in tissues 
 No blood sample available for 
confirmation/counter expertise  
 Low precision and accuracy for COHb 
>10% 
 Scarce information on device maintenance 
Piatkowski et al. 2009 [5] 
Zaouter and Zavorsky 2012 [39] 
Feiner et al. 2013 [40] 
Weaver et al. 2013 [41] 
Wilcox and Richards 2013 [42] 
Kulcke et al. 2016 [43]  
Blood, tissue GC–RGA  Measurement of CO in tissues 
 No dependency on blood quality 
 Automation possible 
 Use of highly toxic mercury vapours 
 Time-consuming sample preparation  
 Invasive 
Coburn et al. 1964 [44] 
Vreman et al. 1984 [46] 
Mahoney et al. 1993 [24] 
Marks et al. 2002 [63] 
Vreman et al. 2006 [30] 
Blood GC–TCD  Accuracy for low COHb% 
 Precise 
 Specificity 
 Measurement of CO released into HS of 
tube possible 
 No dependency on blood quality 
 Automation possible 
 Time-consuming sample preparation 
 High cost  
 Invasive 
Ayres 1966 [40] 
Dubowski and Lu 1973 [57] 
Fukui et al. 1984 [19] 
Van Dam and Daenens 1994 
[66] 
Oritani et al. 1996 [57] 
Lewis et al. 2002 [55] 
Brehmer and Iten 2003 [64] 
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Specimen/method Technique Main characteristics Pitfalls References 
Blood, tissue GC–FID  Rapid 
 Best sensitivity for CO 
 Specificity 
 Lowest LOD and LOQ  
 Assessment of different sample 
preparation and storage conditions 
(liberating agent, heating time, heating 
temperature, etc.) 
 Application to CO in tissues (PM) 
 Automation possible  
 Measurement of CO in tissues 
 No dependency on blood quality 
 Instrument specific for CO due to necessity 
of methanizer  
 Not applicable to analysis of other 
substances 
 Time-consuming sample preparation 
 Invasive 
 Back calculations of COHb from measured 
CO 
 Flushing of calibrators  removal of 
dissolved CO 
Collison et al. 1968 [51] 
Rodkey and Collison 1970 [48] 
Guillot et al. 1981 [58] 
Vreman et al. 1984 [46] 
Costantino et al. 1986 [60] 
Cardeal et al. 1993 [49] 
Levine et al. 1997 [61] 
Penney 2000 [69] 
Sundin and Larsson 2002 [53] 
Czogala and Goniewicz 2005 
[67] 
Boumba and Vougiouklakis 
2005 [18] 
Vreman et al. 2006 [30] 
Walch et al. 2010 [47] 





 High power of identification (retention 
time + mass spectrum) 
 Automation possible  
 Application to clinical and PM samples 
 No dependency on blood quality  
 Use of isotopically labelled formic acid 
for calibration and internal standard  
 Measurement of total amount of CO 
 Back calculations of COHb from measured 
CO 
 Debatable correlation between CO and 
COHb%  often inconsistency between 
COHb% and reported symptoms  
 Flushing of calibrators  removal of 
dissolved CO 
 Invasive  
 Time-consuming sample preparation 
Middleberg et al. 1993 [31] 
Oritani et al. 2000 [50] 
Marks et al. 2002 [63] 
Varlet et al. 2012 [52] 
Hao et al. 2013 [37] 
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2.8 Interpretation of results and choice of biomarker 
 
After analysis of the samples, an important and challenging aspect for CO determination is the 
interpretation of the results. There is not a consensual agreement on the cutoff values for the 
different levels of exposure and severity of poisonings. According to the World Health 
Organization (WHO), COHb levels in blood of the healthy non-smoking population should not 
exceed 2.5-3%, while for smokers, levels above 10% are considered to be abnormal [11, 71–
73]. Values of 30-35% COHb are the upper extreme values reportedly found in clinical 
poisoning cases. Above this limit, irreversible damages to the organs are expected, thus 
resulting in a cascade of events that eventually leads to death. 
However, these values are interpreted differently according to the cases. Various parameters 
can affect the perimortem COHb% levels and in the agonal period before death, which include 
the presence of oxidative smokes or other gases that can interfere and/or compete with the 
absorption mechanism of CO such as nitrogen dioxide (NO2) (increased MetHb), or the 
formation of other toxic gases like hydrogen cyanide (HCN) [74]. Pre-existing cardiovascular, 
hemolytic and respiratory diseases also can alter the mechanism and magnitude of CO 
absorption, with the potential to both decreases and increase the resulting COHb% levels [11, 
23]. Therefore, each case needs to be analyzed and interpreted individually, based on all the 
relevant information available. For example, a COHb level of 25% in a PM case may be 
considered as a contributing factor to the cause of death but should not be considered 
exclusively as the cause of death. Similarly, in clinical cases, 15% COHb can be considered as 
a poisoning case, but in heavy smokers, levels up to 18% have been found [72] in individuals 
that did not show any symptom of CO poisoning. Overall, there seem to be some significant 
discrepancies between COHb values and reported symptoms, which make the correct diagnosis 
of CO poisonings in clinical cases and the determination of the cause of death in forensic cases 
challenging.  
A possible explanation for these phenomena is that basing the diagnosis of a CO poisoning 
only on COHb% levels might actually underestimate the real CO burden. There might be an 
unknown amount of CO that on the one hand dissociates back from COHb, and on the other 
hand is dissolved in the blood without being bound to Hb, resulting in a higher total CO content 
than the one determined by CO-oximetry. The conventional assumption that the part of CO 
bound to Hb causes the most significant adverse health effects was repeatedly debated [3, 4, 
75–78]. Free CO in blood could constitute a toxic reservoir of CO for the organism and 
additionally fuel the major implications on the central nervous system (CNS) by the known 
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binding to other globins such as myoglobin, neuroglobin and cytoglobin [79, 80]. The ratio of 
COHb to CO dissolved and dissociated probably is also subject to interpersonal variability, 
which includes all factors such as e.g., metabolic rate and age [11] and needs to be taken into 
account when interpreting the results obtained by CO-oximetry.  
Another issue is that the majority of GC assays, with the exception of Varlet et al. [36, 52], 
includes the “flushing” step in their sample-preparation procedure. The CO in excess, which is 
not bound to Hb, is flushed away with inert gas, allowing the determination of only CO bound 
to Hb. This procedure is done under the assumption that only CO bound to Hb is relevant and 
responsible for the adverse effects of a CO poisoning. However, this assumption has been 
widely debated, leaving the possibility of additional CO found in blood and not bound to Hb 
to be able to have an effect on an intoxicated individual. Furthermore, in clinical routine COHb 
analyses, blood samples are not flushed, because it does not comply with the pathophysiology 
of CO poisoning. In general, the use of formulae to back-calculate CO measured with GC 
methods to COHb might be prone to additional errors and could lead to a misestimation of the 
true amount of CO present in the blood of an individual.  
All these issues raise the doubt whether the measurement of COHb is the most appropriate 
method for CO poisoning determinations. It seems plausible to propose a more accurate 
biomarker for CO poisonings. Several alternative biomarkers have been proposed in the past, 
such as lactate [81–83], bilirubin [84], S100β [85] and troponin concentrations in blood. Some 
of these gave positive and good correlations with COHb and were reported to be potentially 
helpful in diagnosing CO poisonings. However, none of these biomarkers are specific to CO 
poisonings but are rather indirect biomarkers derived from toxicity caused by CO in the 
cardiovascular, nervous system and cellular levels, which can be attributed also to other 
diseases.   
The development of an alternative biomarker specific to CO should be derived from the 
investigation of a novel measurement approach that does not only focus on the CO bound to 
Hb but also takes into consideration the role and toxicity of CO at cellular level, by measuring 
the total amount of CO present in the analyzed sample. Mainly due to the dependency of 
spectrophotometric methods from the good quality of the sample, which especially in forensic 
cases is not always available, it seems that GC methods are currently the most suitable 
techniques to be further explored. As detector, the mass spectrometer is the most versatile, 
accurate, user-friendly and nowadays routinely present in the majority of laboratories. Being 
able to determine the true CO exposure and correlating this to the symptoms reported by 
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patients would allow a more conclusive and comprehensive CO poisoning determination, 




Even though COHb is routinely measured by spectrophotometric methods, several issues 
concerning sample stability and the dependency of optical methods from the sample quality 
have led to the search for an alternative way for measuring CO, such as GC. In addition, there 
is raised discussion about a significant amount of CO present in blood in free form. Free CO 
has major toxic effects at a cellular level, affecting not only the respiratory system but also 
especially the CNS. However, it is not quantified with current methods focusing only on 
COHb; hence the back-calculation of COHb from CO leads to misestimations. Therefore, an 
alternative approach to quantifying the total amount of CO in blood directly instead of using 
CO in breath or COHb in blood should be used for CO poisoning determinations. Even though 
blood CO concentration cut-offs and their correlation with symptomatology are not yet 
available and GC–MS is more time-consuming, I recommend toxicologists especially for 
doubtful or very challenging cases to use GC–MS methods to verify the results obtained by 
CO-oximetry or spectrophotometry. This leads to results closer to the true CO burden, reducing 
the underestimation caused by COHb measurement and thus the risk and number of 
misdiagnoses. Especially if the analysis is delayed from sampling requiring storage, I further 
recommend toxicologists to document and indicate information about sampling time, analysis 
time and storage conditions because they can significantly influence the final interpretation.   
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Chapter 3 - Development and 
validation of a novel method for 
carbon monoxide poisoning 
determination 
 
3.1 Aims  
 
3.1.1 Postmortem (PM) range  
 
As thoroughly discussed in chapters 1 and 2, a main issue in the diagnosis of a CO poisoning 
involves the currently existing correlation between the COHb% levels and the symptoms 
developed by patients, which do not always agree: patients were found to have an elevated 
COHb% saturation level, but showed no signs of CO-intoxication, while other patients with a 
low COHb% -level lost consciousness or suffered severe delayed consequences.  There seems 
to be a great fallacy in the understanding of the true role played by CO in poisoning cases. This 
might be due to an underestimation of the CO measured with the current techniques, which is 
based on spectrophotometric determination of COHb, and the neglect of the possible presence 
of CO in dissolved state and not bound to Hb, which can have major implications in the role of 
CO in the pathophysiology of a CO-poisoning. Gas chromatography (GC) coupled to mass 
spectrometry (GC-MS) was shown to have the potential to measure CO with higher accuracy. 
Therefore, an improved approach for CO determination by airtight gas syringe (AGS) GC-MS 
is hereby presented, which not only shows improved sensitivity and lower costs but also takes 
into account the total amount of CO present in blood by analysing the CO in blood and in the 
headspace (HS) of the blood tube used to store the sample, with high importance from both an 
analytical and clinical point of view. This constitutes the first step to acknowledge the 
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3.1.2 Clinical range 
 
Another important issue that was also discussed in the previous chapter is the “flushing” of the 
calibrator with a stream of inert gas prior to GC-MS analysis in order to target only CO bound 
to Hb. This approach does not consider the amount of excess, free CO as relevant, which could 
lead to mis- or underestimation of the total load of CO in blood. For this reason, in the second 
part of this study, I aim to test the hypothesis of the presence of CO in free form in blood, by 
comparing analysis results of flushed and unflushed blood samples obtained at bedside from 
individuals that were exposed to CO. This represents the first step in expanding the knowledge 
of the true CO burden. Furthermore, I want to validate AGS-GC-MS technique for CO 
measurement in blood for a concentration range applicable also in clinical settings.   
 
3.2 Materials and Methods 
 
3.2.1 Chemicals and reagents 
 
Formic acid (reagent grade, purity ≥95%) was purchased from Sigma-Aldrich (St Louis, USA) 
and CO gas (99%) was from Multigas (Domdidier, Switzerland). To prevent degradation all 
formic acid solutions were prepared on a daily basis. The internal standard formic acid (13C, 
99%) was ordered from Cambridge Isotope Laboratories (Cambridge, UK). Sulfuric acid 
(≥97.5%) was purchased from Fluka (Buchs, Switzerland). For the validation in PM range and 
in vitro study of CO fortified blood, bovine blood was obtained freshly from a local butcher 
and collected in 1L polypropylene bottles, which were previously fixed with the four 
investigated preservatives to obtain concentrations equivalent to the respective concentrations 
in the blood collection tubes (Monovettes). Ethylenediaminetetraacetic acid (EDTA) salt 
dehydrate was purchased from Sigma-Aldrich (St Louis, USA), sodium fluoride (NaF) was 
provided by Fluka (Buchs, Switzerland), lithium heparin (LiH) was from Fresenius Medical 
Care (Bad Homburg, Germany) and sodium citrate (NaCit) was obtained from Merck 
(Darmstadt, Germany).  Human blood samples were obtained from volunteers participating in 
a study at the Department of Nephrology of the University Hospital of Geneva (HUG) in 
Switzerland. Blood of non-smokers before exposure to CO was used as blank blood for the 
validation in clinical range.   
 





The AVOXimeter 4000 Whole Blood CO-Oximeter and cuvettes were obtained from 
International Technidyne Corporation - ITC (Edison, USA). S-Monovettes of following types: 
2.6mL K3E (Ethylenediaminetetraaceticacid, EDTA), 3mL 9NC (sodium citrate, NaCit), 
2.7mL FE (sodium fluoride, NaF), 2.6mL KH (lithium heparin, LiH), were obtained from 
Sarstedt (Nürnbrecht, Germany). Precision sampling gas syringes equipped with a press button 
valve and with capacities of 500µL (for dilution) and 2mL (for injection) were purchased from 
VICI (Baton Rouge, LA, USA). Aluminium caps were from Milian (Vernier, Switzerland). All 
extractions were carried out in 20mL headspace vials from Agilent Technologies (Santa Clara, 
CA, USA).  
 
3.2.3 Instruments and GC-MS conditions   
 
For spectrophotometric analysis, AVOXimeter 4000 Whole Blood CO-Oximeter from ITC 
was used. The instrument uses five wavelengths for quantitative analysis, namely 520.1, 562.4, 
585.2, 597.5 and 671.7 nm. Following parameters can be measured: total haemoglobin (tHb), 
oxyhemoglobin (O2Hb), COHb and Methemoglobin (MetHb). Manufacturer guidelines were 
followed to obtain COHb analyses.   
For gas chromatographic analysis, Agilent 6890 N GC (Palo Alto, USA) equipped with an HP 
Molecular Sieve 5 Å PLOT capillary column (30 m x 0.32 mm x 30µm) obtained from Restek 
(Bellefonte, USA) was used. Following temperature programme was used: 50°C, held for 4 
minutes; the injector was set at 180°C, used in splitless mode, and the MS interface at 230°C. 
The employed carrier gas was helium at a flow rate of 40.0 mL/min. A solvent delay of 1.8 
minutes was used.  
For detection, Agilent 5973 mass spectrometer (Palo Alto, USA) was used, operating in 
electron ionization (EI) mode at 70eV. Selected Ion Monitoring (SIM) mode was used to 
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3.2.4 Sample preparation 
 
3.2.4.1 Method development (not in published paper) 
 
The method was developed on the basis of previous studies that showed the generation of CO 
through a combination of sulphuric acid and formic acid and the use of sulfuric acid as a 
releasing agent for CO bound to Hb. Sulfuric acid was hence employed not only as a liberating 
agent for CO bound to Hb but also to generate the internal standard 13CO from isotopically 
labelled formic acid (H13COOH) as well as CO from formic acid for the calibrators. During the 
method development phase, several parameters were investigated to optimize the sample 
preparation and analysis procedures compared to previous studies (mentioned in Chapter 2), 
including the following: 
 
 Amount of blood sample required: 25µL, 50µL, 100µL 
 Amount of reagent (H2SO4) required: 50µL, 100µL, 200µL 
 Size of sample preparation vial: 20mL GC-vial, 2mL GC-vial  
 Order of sample input in  vial: sample in aluminium cap/polypropylene (PP) pipette tip 
and sulfuric acid in the vial, sulfuric acid in aluminium cap/PP pipette tip and sample 
in the vial 
 Temperature of pre-heating: 50°C, 80°C, 100°C 
 Pre-heating time: 0 min, 30 min, 45 min, 60 min   
 Temperature of GC oven: 30°C, 40°C, 50°C 
 Injection volume: 500µL, 1000µL 
 
The different combinations tested are listed in Table 3.1. The detailed protocol for sample, 
calibration solution and reagent solution preparation and analysis can be found in Appendix 3, 
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Table 3.1: List of combinations of sample preparation and analysis parameters for the measurement of CO via 
Gas Chromatography-Mass Spectrometry (GC-MS) tested during the method development phase. 




























1 50 200 2 1 80 45 40 500 
2 50 200 2 1 0 0 40 500 
3 50 200 2 1 80 30 40 500 
4 25 50 2 1 50 30 30 500 
5 50 200 2 2 80 30 30 500 
6 50 200 2 2 80 45 40 500 
7 100 200 2 2 50 60 40 500 
8 100 200 20 2 50 45 50 1000 
9 100 100 20 2 80 45 40 1000 
10 100 100 20 2 100 45 40 1000 
11 100 100 20 2 80 60 50 1000 
12 200 200 20 2 80 60 50 1000 
13 200 200 20 2 80 45 50 1000 
14 200 200 20 2 80 30 50 1000 
15 100 100 20 2 100 60 50 1000 
16 100 100 20 2 100 45 50 1000 
17 100 100 20 2 80 60 50 500 
18 100 100 20 2 80 45 50 500 
 
Results of the different combinations are shown in Appendix 3, Figures A3.1-A3.18 as plots 
with linear regression lines (N.B. some plots have missing values, which are due to either 
instrument malfunction, sample preparation or injection error or being below the limit of 
detection). While nowadays studies aim at reducing the amounts of samples required for 
analysis, especially in forensic toxicology, where sample availability might be limited, in case 
of gas analyses, no reproducible results were obtained with the reduced sample and reagent 
sizes. This might be due to a non-completed reaction when using small volumes. Additionally, 
the volume of gas produced in a small 2mL GC-vial compared to the 20mL GC-vial is relatively 
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low and, thus, might not be sufficient to guarantee reproducibility. When adding the sample 
and reagents to the GC-vial, more accurate results were obtained when adding the sample, 
internal standard and calibration solutions into the vial first, followed by the sulfuric acid in 
the aluminium cap, which then reacted after sealing the vial and vortexing. Adding the sample 
into the aluminium cap lead to incomplete reactions. Similarly, no sufficient pre-heating, as 
well as a not sufficiently high GC oven temperature, did not guarantee a complete reaction of 
the reagents and release of CO. More reproducible results were obtained when injecting 1mL 
of gas volume rather than 0.5mL. The best results (best linearity/highest R2) were obtained in 
test 15 (Appendix A3.15). Therefore, the parameters employed in test 15 were selected as the 
parameters to be validated (Table 3.2):  
 
 
Table 3 2: Selected parameters for preparation of samples to be analysed and instrumental analysis. 
Parameters 
Amount of H2SO4 [µL] 100 
Amount of blood sample 
[µL] 
100 
Vial size [mL] 20 





Pre-heating time [min] 60 
GC oven temperature [°C] 50 
Injection volume [mL] 1 
 
 
The concentration range for validation was determined based on the analysis of some test 
samples (real postmortem blood samples of CO-poisoned individuals with known COHb 
concentrations) and their placement across the CO concentration range.  
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3.2.4.2 Fortification of blood  
 
To obtain CO-fortified blood samples to be used for the validation and in vitro storage study, 
pure CO gas was bubbled in blank bovine blood-containing tubes for a specified amount of 
time. The COHb% saturation levels were checked in 10-minute-intervals with the CO-oximeter 
until the desired initial COHb% level was reached (10-20% for low saturation, 30-40% for 
medium saturation and 50-70% for high saturation). To ensure homogenization, the bottles 
were agitated for 20 minutes after fortification and the final COHb%-concentration was 
subsequently determined by CO-oximetry.  
 
3.2.4.3 Calibration standards (PM range) 
 
An aliquot of freshly sampled bovine blood, which was previously analysed with CO-oximeter 
to guarantee the absence of CO before use, is used as matrix for calibration. Fresh solutions of 
the calibration standard formic acid (87 nmol/µL) and internal standard (IS) isotopically 
labelled formic acid (84 nmol/µL) were prepared daily with deionised water to prevent 
degradation. Calibration points were set in a working range between 0-208 nmol/mL HS, 
congruent with CO-saturation in a range relevant for postmortem samples (based on the results 
obtained from available real postmortem samples), with points at 6.5, 13, 26, 52, 104, 156 and 
208 nmol/mL HS (equivalent to 2.6, 5.2, 10.4, 20.8, 41.6, 62.4 and 83.2 µmol/mL in blood). 
Matrix effects were evaluated by preparing a blank sample with the matrix (i.e. blood) without 
any reagent. 10 µL of the IS solution were added to each calibration sample before extraction, 
leading to a final concentration of 42 nmol of 13CO/mL HS. All standards were stored at +4°C 
when not in use.   
 
3.2.4.4 Calibration standards (clinical range) 
 
An aliquot of human blood from non-smokers, which was previously controlled by CO-
oximetry and found at 0% COHb, is used as matrix for calibration. Calibration standard 
solutions of formic acid (43 µmol/mL) and IS solution of isotopically labelled formic acid (84 
µmol/mL) were prepared daily de novo in order to prevent degradation. Calibration points were 
set in a working range between 0-104 nmol/mL HS, with points at 1.63, 3.25, 6.5, 13, 26, 52 
and 104 nmol/mL HS (equivalent to 0.65, 1.3, 2.6, 5.2, 10.4, 20.8 and 41.6 µmol/mL in blood). 
Matrix effects were evaluated by preparing a blank sample with the matrix without any reagent.  
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3.2.4.5 Quality controls (QC) 
 
QC samples were prepared daily with formic acid obtained from a different lot than used for 
calibration solutions. For PM range, five QC solutions at concentrations of 10, 25, 80, 150 and 
200 nmol/mL HS (2, 5, 16, 30 and 40 µmol/mL blood), and for clinical range, five QC solutions 
at concentrations of 2, 5, 10, 30 and 60 nmol/mL HS (0.8, 2, 4, 12 and 24 µmol/mL blood) 
were prepared daily from formic acid diluted with deionised water. 
Additionally, the validity of the methods were tested with external controls, which were 
prepared by dilution of pure CO gas at two concentration levels, low and high, respectively 20 
and 150 nmol/mL HS for PM range and 5 and 60 nmol/mL HS for clinical range.    
 
3.2.4.6 Extraction procedure 
 
100µL of blood was introduced in a 20mL HS-vial, followed by aliquots of the various formic 
acid solutions for each respective calibrator and 10µL IS solution. Subsequently, an aluminium 
cap of 11mm (i.d.) was first filled with 100µL of sulphuric acid and then carefully introduced 
into the HS-vial. The vial was immediately hermetically sealed with magnetic PTFE/silicone 
septum caps of 20 mm (i.d.) and afterwards vigorously shaken and vortexed, in order to ensure 
complete mixing of the liquids contained in the vial. After preparation of all vials, extraction 
was completed by heating at 100°C for 60 minutes.  
Concerning real PM and clinical samples as well as in vitro storage study samples, two types 
of analysis were performed per tube: CO analysis in the HS before tube opening in order to 
measure an eventual CO release in tube HS during storage and CO analysis in blood after tube 
opening and blood sampling. For CO in HS-analysis, only IS and sulphuric acid were inserted 
into the HS-vial (no matrix).     
 




Approximately 50-100µL of blood were sampled from the tube and inserted into an 
Avoximeter 4000 Whole Blood CO-oximeter cuvette, which was then introduced in the 
Avoximeter 4000 Whole Blood CO-oximeter for analysis.  
 
Chapter 3 - Development and validation of a novel method for carbon monoxide poisoning determination 
 
 52 
3.2.5.2 CO in HS 
 
250µL HS were sampled from the closed blood tube and inserted into a previously prepared 20 
mL HS-vial with IS. Subsequently, 1mL was sampled and injected in the GC-MS for analysis.  
 
3.2.5.3 CO in blood 
 
1mL HS was sampled from the 20mL HS-vial containing the extract and injected in the GC-
MS for analysis.  
To ensure that no contamination from CO contained in the air affected the measurements, a 
sample of air in the analysis-room was also analysed. Air samples were collected with the AGS 
and analysed by GC-MS with the same conditions as the blood samples.         
 
3.2.6 Validation procedure  
 
The validation was performed according to the guidelines of the “French Society of 
Pharmaceutical Sciences and Techniques” (SFSTP) and included following validation 
parameters: response function (calibration curve), linearity, selectivity, trueness, precision 
(repeatability and intermediate precision), accuracy, limit of detection (LOD) and limit of 
quantification (LOQ). 
The response function, also defined as the calibration curve, is described as the relationship 
between the concentration of the analyte in the sample and the corresponding instrument 
response.  
The linearity of the method is assessed by fitting back calculated concentrations of control 
samples against the theoretical concentrations through the application of the linear regression 
model and evaluating the resulting regression coefficient.  
Trueness, also defined as bias, describes the closeness between the average of the experimental 
value and the calculated target value. It is expressed as percent deviation from the calculated 
target value.  
Precision is defined as the closeness of agreement (degree of scattering) between a 
measurement series obtained from multiple sampling of the same homogenous sample under 
the prescribed conditions and is determined by calculating the repeatability (intra-day 
precision) and intermediate precision (inter-day precision) for each control sample. The 
repeatability is determined by calculating the intra-day variance (S2r) and the intermediate 
precision through the sum of intra- and inter-day variances (S2IP).  
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Accuracy describes the closeness of agreement between the conventional true value or an 
accepted reference value and the value experimentally found. It is expressed as the sum of 
trueness (systematic error) and precision (random error).   
Calibrators and QCs were used for the validation experiments performed on three non-
consecutive days (p=3) not within the same week. The validation approach is based on the use 
of a β-expectation interval tolerance of 80%, indicating that the intervals for each experimental 
point include an average of 80% of the total values. The tolerance intervals (TI) were defined 




r is the standard deviation of repeatability and S
2
R is the 
standard deviation of reproducibility. In the β-expectation interval tolerance approach, k = tᵥ × 
√(1 + [1 / (I × J × B2)]), where I is the number of series, J is the number of repetitions, and B2 
is a coefficient. This coefficient is given as B2 = (R + 1) / [J × (R + 1)] with R = S2r / S
2
R. tᵥ is 
Student’s coefficient with degrees of freedom ν defined as ν = (R + 1)2 / {[(R + 1 / J)2 / (I – 1)] 
+ [(1 - 1/J) / (I × J)]}.    
 
3.2.7 PM samples 
 
A set of three samples of both cardiac and peripheral blood from CO positive cases were 
analysed (Table 3.3). The samples obtained during autopsy were all with a PM interval (PMI) 
of less than 40 hours and analysed immediately after collection at the toxicology lab. 
Measurement with CO-oximeter and GC-MS were performed with the above-mentioned 
conditions. The samples were then subdivided into sampling tubes with four different 
preservatives, namely ethylenediaminetetraacetic acid (EDTA), sodium fluoride (NaF), 
trisodium citrate (Cit) and lithium heparin (LiH), and stored at -20°C for a period between 4 to 
7 weeks. Subsequently, for all samples, the COHb and CO concentrations were determined 
with CO-oximetry and GC-MS respectively, where GC-MS was used to determine the CO in 
both the headspace and the blood of the sample. Additionally, the validity of the proposed 
approach was tested by comparison with approaches previously published by Cardeal et al. [1] 
and Sundin et al. [2] by back calculating the COHb%-levels from the obtained CO 
concentrations. These methods were found to give similar results to other methods found in the 
literature [3,4].  
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Table 3 3: Summary of relevant information on a set of real PM cases. 
Sample Sample type Age Sex Manner of Death 
1 Cardiac and Peripheral 
Blood 
22 F Fire victim 
2 Cardiac and Peripheral 
Blood 
67 M Fire victim 
3 Cardiac and Peripheral 
Blood 
44 M Suicide by CO 
intoxication  
 
3.2.8 Samples from volunteers  
 
3.2.8.1 CO-rebreathing method 
 
The CO-rebreathing method consists of a closed-circuit breathing system containing oxygen 
mixed with a certain amount of carbon monoxide. Patients breathe in and out through a 
mouthpiece linked to the circuit. In the study from which I acquired the blood samples, patients 
were lying in a horizontal position. After insertion of the mouthpiece, an adjustment period of 
2 minutes was used to deliver O2 only, before starting the delivery of the O2-CO mixture for a 
period of 10 minutes [62]. The volumes of CO delivered in O2 were between 57 and 105 mL, 
calculated according to the body mass index of each volunteer, in order to reach a target COHb 
value of approximately 10%.   
 
3.2.8.2 Blood collection and preparation 
 
Blood samples were obtained from a cohort of 13 former patients (9 men, 4 women) of the 
Nephrology Department of the University Hospital in Geneva (HUG), Switzerland.  
Three blood samples were taken from volunteers, one before and two directly after exposure 
to CO. Samples were immediately analysed by CO-oximetry. Half of the samples taken after 
exposure of the individual to CO were flushed with a nitrogen stream for 2 minutes, with a 
flow rate below 5 mL/min. Two needles were inserted in the rubber septum of the blood tube. 
One needle was plunged in blood and provided the nitrogen stream whereas the other was 
placed in the HS of the blood tube in order to relieve the pressure in the blood tube built with 
the release of CO and the nitrogen flush. After flushing, the samples were analysed by CO-
oximetry. Simultaneously, all samples (before exposure, flushed and not flushed after 
exposure) were prepared for analysis with AGS-GC-MS and analysed in triplicates. All 
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sampling and testing performed on volunteers were approved by an ethical committee under 
the study number CCER-2017-00421.        
 
3.2.9 Statistical analyses 
 
Mean, standard deviation and interquartile ranges were determined for all measured variables. 
Paired student t-test with an α-error of 0.05 was performed for comparison of the group means. 
All data treatment and statistical analyses were performed with R (version 3.3.1, 2016-06-21). 
   




The selectivity of the method was assessed with the measurement of samples obtained by the 
mixture of various intracadaveric gases with CO. These analyses were evaluated for co-eluting 
chromatographic peaks with possible interferences with either the CO or 13CO detection. No 
interference peaks for any of the other gases were observed at CO m/z ratio of 28 or 13CO m/z 
ratio of 29 (see Figure 3.1), which indicates that the method is sufficiently selective for 
determination of CO.  
m/z 28 (12CO) 
m/z 29 (13CO) 
Figure 3.1: Extracted ion chromatograms for m/z ratios 28 (upper) and 29 (lower), corresponding to CO and 
13CO respectively, for selectivity tests. 
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3.3.2 Response function (calibration curve) 
 
The response function, also known as the calibration curve, is defined as the relationship 
between the concentration of the analyte in the sample and the corresponding response. An 
assay of calibration curves was performed for CO determination by using bovine blood as blank 
matrix and each point of the curve was defined as the area ratio of CO to 13CO. The calibration 
curves were prepared on three non-consecutive days (p = 3), in triplicates (n = 3) and at seven 
concentration levels (k = 7): 6.5, 13, 26, 52, 104, 156 and 208 nmol/mL HS (equivalent to 1.3, 
2.6, 5.2, 10.4, 20.8, 31.2 and 41.6 µmol/mL in blood). The calculated concentrations for each 
calibration point were compared to the target values and found to be within ± 20%. A linear 
relationship between the CO concentration from samples spiked with formic acid and the 
measured response was determined. Table 3.4a shows the validation results for the calibration 




The linearity of the model was evaluated by fitting back-calculated concentrations of control 
samples against the theoretical concentrations through the application of the linear regression 
model. On each non-consecutive day (p = 3), control samples at five different concentrations 
(k = 5) , namely 10, 25, 80, 150 and 200 nmol/mL HS (2, 5, 16, 30 and 40 µmol/mL blood), 
were measured in triplicates (n = 3). The concentrations of the control samples were calculated 
by using the calibration curve determined for each analysis day. As represented in Table 3.4b, 
satisfactory linearity was obtained, with a slope of 0.9887 and a regression coefficient of 0.989 




The trueness, also known as bias, expresses the closeness between the experimental average 
value and the calculated target value and is expressed as the percent deviation from the 
calculated target value. Trueness was found to be lower than the acceptance criteria (within 
±15 of the accepted reference value and within 20% of the LOQ), as can be seen in Table 3.4c, 
and hence defined as satisfactory for CO determination.  
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Table 3.4: Validation results for CO determination in blood by AGS-GC-MS. (a) represents the mean coefficients 
of the response functions obtained from analysis of the calibrators; (b) represents the coefficients of the linear 
regression function obtained from analysis of the QCs against their theoretical value; (c) represents the trueness 
obtained from the QC analyses expressed in %; (d) represents the repeatability and intermediate precision obtained 
from QC analyses expressed in relative standard deviation % (RSD%). 
a) Response function [6.5-208 nmol/mL HS] (k = 7, n= 3, p = 3) 
 Day 1 Day 2 Day 3 
Slope 0.0252 0.0219 0.0214 
Intercept 0.4698 0.5803 0.4528 
r² 0.9892 0.9864 0.9920 
k: number of concentration levels; n: number of repetitions for each level; p: number of non-consecutive 





c) Trueness (relative bias %) ( k = 5, n = 3, p = 3) 
Levels [nmol/mL HS]  Trueness (%) 
10  -12 
25  0 
80  -2 
150  -3 
200  -5 
 
d) Precision (RSD%)  ( k = 5, n = 3, p = 3) 
Levels  [nmol/mL HS]   Repeatability Intermediate Precision 
10  0.951 0.952 
25  4.001 4.326 
80  5.980 5.980 
150  8.364 11.347 
200  4.046 8.630 
 
3.3.5 Precision: repeatability and intermediate precision 
 
Precision is designed to detect random errors and is defined as the closeness of agreement 
(degree of scattering) between a series of measurements obtained from multiple sampling of 
the same homogeneous sample under the prescribed conditions. It is assessed by calculating 
the repeatability (intra-day precision) and intermediate precision (inter-day precision) for each 
control sample. The repeatability variance was established by calculating the intra-day variance 
(S2r) and the intermediate precision was determined through the sum of intra- and inter-day 
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variances (S²IP). As can be seen in Table 3.4d, the RSD for repeatability and intermediate 
precision are in a range between 0.95% and 11.95%.    
 
3.3.6 Accuracy and limit of quantification 
 
Accuracy expresses the total error defined by the sum of trueness (systematic error) and 
precision (random error). It is defined as the closeness of agreement between the conventional 
true value or an accepted reference value and the value found. The accuracy profile for CO, 
depicted in Figure 3.2, expresses the method’s ability to provide analytical results by using 
both systematic and random errors, with a risk set at α = 5% for each concentration level. The 
mean bias (%) confidence interval limits for the control samples were within the acceptability 
limits of ±30%. Taking into consideration the acceptability limits of ±30%, the limit of 
quantification within validation criteria was found at below 10 nmol/mL HS (2 µmol/mL 
blood). Thus, the method is confirmed to be accurate within the range of 10 and 200 nmol/mL 
HS (2-40 µmol/mL blood), considered as the relevant range for postmortem analyses. The 
analytical LOQ was later determined at 0.9 nmol/mL HS (0.18 µmol/mL blood).   
 
 
Figure  3 2: Accuracy profile for CO determination using a simple linear regression model within the range of 
10-200 nmol/mL HS (2-40 µmol/mL blood). The continuous line represents the trueness (bias), the dashed lines 
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3.3.7 Limit of detection 
 
The LOD was determined by analysis of samples containing sulphuric acid and decreasing 
amounts of formic acid and assessed by using a signal-to-noise ratio of S/N >3. The noise was 
estimated by measuring 15 blank samples. The resulting LOD for CO quantification was found 
at 0.1 nmol/mL gas.  
 
3.3.8 Matrix effects 
 
The possible presence of matrix effects was evaluated by comparing the results obtained from 
the analyses of blank samples containing only bovine blood (Bl-IS) and sulphuric acid and 
samples containing bovine blood, sulphuric acid and internal standard (Bl+IS). The Bl-IS 
samples show the generation of low amounts of CO, which is most likely due to the acidic 
conditions the reaction takes place as well as heat, which lead to decomposition and 
degradation of proteins contained in blood. This confirms what was previously reported by 
Varlet et al. in 2012 [5].  
The Bl+IS samples allow for quantification of the matrix effects through interpolation of the 
calibration curves. The matrix effects were quantified as a mean concentration of 21,8 nmol/mL 
HS (4.5 µmol/mL blood), with a standard deviation (SD) of ± 4.3 nmol/mL HS (0.9 µmol/mL 
blood). With the use of an internal standard, this matrix effect is taken into account equally for 
all samples analysed.   
 
3.3.9 Analyses of postmortem samples 
 
Three postmortem blood samples were analysed in order to assess the performance of the 
method and its applicability on real human blood samples of people subjected to fatal CO 
intoxication. Changes due to storage were investigated by re-analysing each sample after a 
period of one month, in which the sample was stored at -20°C with different preservatives 
(EDTA, NaF, Heparinate, Citrate). The results are presented in Table 3.5. The results obtained 
for the three postmortem cases were also compared to the results obtained from the fortification 
of blank blood with CO in the range of 60%-80% COHb, as obtained by CO-oximetry analysis 
(Figure 3.3). 
 




Figure  3.3: Correlation plot between the total CO concentration in nmol/mL HS (measured by AGS-GC-MS) vs. 
the COHb saturation in % (measured through CO-oximetry), measured in blood for two groups of samples: real 
case samples (n=5) and samples fortified with CO stored in blood (n=18). Analyses were carried out in triplicates, 
but for illustration purposes, error bars are not displayed here.  
 
3.4. Discussion (PM range) 
 
3.4.1 Determination of CO through AGS-GC-MS 
 
CO content of three cardiac blood and three peripheral blood samples was determined through 
AGS-GC-MS, showing significant amounts of CO. Measurements by CO-oximetry, when 
possible, also result in high amounts of COHb determined (all >50%), indicating that CO 
intoxication was most likely the cause of death.   
For cardiac blood of case #3, no measurement was possible with the CO-oximeter due to the 
poor quality of the blood sample, leaving peripheral blood as the only available sample for 
COHb%-determination. It was, however, possible to determine the CO content of cardiac blood 
through AGS-GC-MS, which resulted in a concentration of 50.5 nmol/mL HS (10.1 µmol/mL 
blood). Cardiac blood of samples 1 and 2, which when analysed by CO-oximetry revealed a 
COHb concentration of >75%, resulted in CO concentrations of 142.5 nmol/mL HS (28.5 
µmol/mL blood) and 68.8 nmol/mL HS (13.2 µmol/mL blood) respectively. Therefore, if 
compared with the results from cardiac blood of samples 1 and 2, the cardiac blood 
concentration in sample 3, with a concentration of 50.5 nmol/mL HS (10.1 µmol/mL blood), 


















CO concentration [nmol/mL HS]
Total CO vs. COHb in blood
Real cases (n=5)
Fortified samples (n=18)
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peripheral blood sample, which showed a COHb% level of >75% and a CO concentration of 
113.1 nmol/mL HS (22.6 µmol/mL blood).  
Nevertheless, this case confirms the significant drawbacks of optical measurement methods. 
Without the peripheral blood sample, accurate determination of COHb levels would have not 
been possible, leaving the case unsolved, whereas total CO concentration by GC-MS was still 
possible, allowing interpretation. Furthermore, the importance of the development of an 
alternative method for CO determination, such as AGS-GC-MS, is highlighted, which might 
have the potential to also be of use in routine CO-poisoning determinations.  
However, it is not yet possible to fully interpret the results obtained through AGS-GC-MS 
measurements from a diagnostic point of view, since correlations between the symptoms and 
COHb% levels are the only associations available in the literature. Until now, no correlation 
between total blood CO and the symptoms has been developed. To obtain that, a complete 
assay to study the link between total CO in blood, independent of Hb, and the symptoms is 
required.  
Figure 3.3 illustrates that the CO concentration range associable to lethal doses (above 55% 
COHb) is hereby found to be above 45 nmol/mL HS (9 µmol/mL blood). This result is 
consistent with the CO concentration of 3 µmol/mL blood previously proposed to define CO 
as an actor in the cause of death [6].  
    
3.4.2 Back calculation of COHb% from CO 
 
To assess the validity of the proposed approach, the results obtained for CO concentrations 
were back calculated to COHb% saturation levels with formulae already published and 
compared to the values obtained through CO-oximetry. In fact, the correlation between the CO 
measured with GC and COHb% levels and the use of formulae to back calculate the CO to 
COHb% is still under discussion. Several formulae have been published to calculate the 
equivalent COHb% from the values obtained through the analyses with gas chromatographic 
methods [1–3,7,8]. The application of these formulae is mainly due to the apparent satisfactory 
correlation between the spectrophotometrically measured COHb% levels and CO levels 
obtained through the back calculation from the GC-analyses. However, these correlations were 
obtained with different experimental designs. While CO levels were measured with GC-MS or 
GC-FID, COHb ranges did not cover the full range of expected COHb saturations: for example, 
Cardeal et al. [1] obtained their correlation formula with a dataset that included a CO 
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concentration range of 0.005-16.85 nmol/mL HS (0.001-3.35 µmol/mL blood), which is equal 
to back calculated COHb% levels of 0.01%-16.1%, therefore being exclusively in a low level, 
clinical range; Sundin et al. [2] have a range that covers even lower levels, between 0.5% and 
5% COHb, which are within normal clinical levels for not intoxicated people.  
Another difference concerns the calibrators, which were artificially generated in situ, either 
diluted from pure gaseous CO or prepared after fortification of blood with CO followed by 
flushing with an inert gas, intended for the removal of residual dissolved CO. However, through 
this flushing step, the presence at the time of analysis of CO dissolved in blood and not bound 
to Hb is neglected, which is not in accordance with the pathophysiology of CO intoxications 
[4]. Nevertheless, despite these alterations, a majority of coherent results were confirmed with 
the use of several formulae by Varlet et al. [5].    
In the present study, the back calculated COHb% values obtained by applying the formulae by 
Cardeal et al. [1] and Sundin et al. [2] were found to be in a range between 83% and 274% and 
82% and 285% respectively, which is prevalently outside the physiologically relevant range 
and not consistent with the results obtained with the analyses by CO-oximetry. While the lower 
limits are in conformity with the expected high COHb amount, the highest back calculated 
COHb saturations are not relevant. Despite the fact that the number of samples analysed in this 
study is not statistically significant, the results cannot be disregarded and legitimate the 
investigation to identify the source of variation for  higher back calculated COHb results:   
(i) PM changes can lead to CO production through microbial metabolism and/or erythrocyte 
catabolism. However, all samples were obtained with minimal PMI, no PM changes could have 
occurred with our samples. Storage of the body and sampling was performed according to the 
regulations of Swiss forensic laboratories, therefore no degradation of the sample occurred due 
to poor storage conditions. However, no detailed information about the origin of the samples, 
PMI and storage conditions were given by Cardeal et al. [1], Sundin et al. [2] or Vreman et al. 
[3], even though these are important factors that need to be controlled to guarantee 
reproducibility and specificity of the results. Thus, this is a possible cause for the incongruence 
between approaches.  
(ii) A part of the blood CO burden is not bound to Hb in the tubes at the time of analysis. This 
might be explained by COHb dissociation during storage in tubes and/or during PMI in the 
body, or an existing, variable amount of CO dissolved at the time of sampling. The hypothesis 
of the presence in blood of CO dissolved during intoxications can be formulated because even 
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though CO dissolved in blood binds preferably to Hb, an unknown part can remain dissolved 
until binding with tissue proteins (Mb) and intracellular distribution (mitochondrial 
distribution) occurs. So far, it was assumed that once in the blood system, CO binds almost 
completely to Hb, resulting in COHb as the used biomarker for CO intoxications. But the 
results obtained here provide some doubts in whether there is more CO present in blood than 
just COHb and that the CO dissolved might play a more important role than expected [31]. 
This can result in a highly relevant role from a physiological perspective, with possible 
pathophysiological effects caused by the amount of CO dissolved in blood that have not yet 
been investigated, but might be relevant for both clinical and forensic cases. This could also 
help to find an explanation for the disagreement between the symptoms reported and COHb% 
levels measured in individuals. For this purpose, the correlation between total CO in blood and 
reported symptoms could be investigated. 
Furthermore, in PM blood samples, CO might also originate by dissociation from Hb, Mb or 
cytochromes, since binding of CO to these proteins is reversible with time. COHb measured 
optically in this type of sample would show only a part of CO present in blood and would not 
take into account this variable and unknown part of CO dissolved.            
(iii) Finally, a part of the CO in blood not bound to Hb in the tubes at the time of analysis can 
originate from COHb dissociation during storage. When blood showing an important COHb 
saturation is exposed to air for a significant time, the COHb measured at the end of exposure 
by optical methods was found to be lowered [10]. As time goes by during storage, CO 
dissociation from Hb can be hypothesized because the CO-Hb bond is reversible. Many studies 
have been led to investigate the influence of storage conditions on COHb measured by optical 
methods and an important diversity of results was obtained. However, to our knowledge, few 
data is available concerning the influence of storage conditions on CO measured by GC-MS. 
Moreover, the part of CO dissociated from COHb during storage could only partly explain the 
discrepancy between the results from the optical measurement methods and the back calculated 
results – for values as high as 75% COHb, even if completely dissociated, theoretically the CO 
dissolved could not reach values that back calculated are higher than 100%. Furthermore, 
COHb decreases did not exceed 20-25%.   
Preliminary tests for the evaluation of the role played by preservatives in the stability of the 
sample were performed with two sets of samples from two cases. The COHb and CO 
concentrations obtained for the measurements with different preservatives (Table 3.5) show 
the same trend for case 1 (decrease of CO in both cardiac and peripheral blood). For case 2, 
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increased CO concentrations were observed for two of the preservatives (EDTA and NaF) and 
decrease for the other two preservatives (LiH and NaCit), while COHb generally decreases 
slightly. Case 3 shows a fairly stable cardiac blood sample, while CO in peripheral blood 
decreases.   
 
Table 3.5: Summary of data from the analyses of three real PM cases with suspicion of CO intoxication, analysed 
by CO-oximetry and AGS-GC-MS on day of sample collection and after storage in the freezer for 30 days. *for 
Sample 3, second analyses were carried out after 52 days; Samples: cardiac blood (CB), peripheral blood (PB); 
preservatives: ethylenediaminetetraacetic acid (EDTA), sodium fluoride (NaF), lithium heparin (LiH), trisodium 
citrate (Cit).  
Sample Preservative COHb [%] 
CO-oximetry 
CO in Blood [nmol/mL HS] 
(µmol/mL blood) AGS-GC-MS 









NaF >75 78.04 (15.61) 
LiH >75 93.15 (18.63) 




EDTA 57,1 49.7 89.92 
(17.98) 
68.80 (13.76) 
NaF 44.9 87.33 (17.47) 
LiH 61.8 62.38 (12.48) 
Cit 55.3 47.57 (9.51) 
2 
CB 
EDTA >75 70.7 68.77 
(13.75) 
95.55 (19.11) 
NaF 64.8 108.10 (21.62) 
LiH 70.5 79.75 (15.95) 




EDTA 69.5 65.1 100.62 
(20.12) 
119.50 (23.90) 
NaF 47.5 136.21 (27.24) 
LiH 64.7 81.94 (16.39) 
Cit 64.8 52.15 (10.43) 
3* 
CB 









Previous studies suggested that no significant effects or differences were observed when using 
EDTA or NaF tubes [11], which contradicts our results for case 2, where increases are observed 
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in both cardiac and peripheral blood. No antecedent research was found on the other two 
preservatives LiH and NaCit. Therefore, our results do not give clear indications on whether 
preservatives play a relevant role in the stability of samples and given the limited number of 
samples, no significant conclusions can currently be drawn from our data. The role of 
preservatives might be of relevance, but further investigation is required.  In order to be able 
to determine the significance of the influence with a strong statistical relevance, a higher 
number of samples need to be tested and evaluated.  
Additionally to the preservatives, there are several other factors that could influence the 
measurement of total CO in blood and have not yet been investigated. Storage conditions, such 
as temperature and volume of air in sampling container, are known to be of relevance in the 
measurement of samples in forensic and clinical cases and have specifically been studied for 
the measurement of COHb through spectrophotometric methods and gas chromatographic 
methods, which used calibrators with flushing of CO in excess prior to the analysis [10–13]. 
However, no data is available on storage conditions for the measurement of total CO in blood.   
In general, the increased CO of PM samples can be due to enzymatic or bacterial action that 
occur when a sample is not analysed immediately after death (long PM interval). It is possible 
that after the first analysis on the day of sampling, bacteria or enzymes still present in the blood 
lead to increased CO concentrations, even though storage in the freezer should significantly 
reduce their activity. Therefore, it is very important to minimize PMI, whenever possible, and 
perform all analysis in a timely manner, to avoid the effects of PM-induced concentration 
changes.  
Decreased CO concentrations could be derived from the fact that the aliquots of blood 
transferred to the tubes with different preservatives came from the same blood tube sampled 
during autopsy and that homogenization of CO within that blood tube had not yet occurred, 
thus resulting in higher CO levels during the first measurement than in the aliquots after 
storage. This could have been avoided by aliquoting the blood and then measuring CO levels 
at day 0, rather than using only one blood tube to determine baseline CO at the time after 
sampling. Another potential reason for reduced CO concentrations during storage can be the 
transfer of CO from the blood into the HS. In the present study, a measurement of the amount 
of CO in the HS of the samples was thus also performed. However, the amounts detected were 
as low as 0.001% of total CO, indicating that no significant amounts of CO are released into 
the HS during frozen storage over one month. This implies that CO would remain under 
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dissolved form in blood during storage. But given the limited number of samples, this 
assumption is not definitive and needs to be analysed further for confirmation.  
Nevertheless, in the present study, the discrepancy between optical measurements of COHb% 
by CO-oximetry and back calculated COHb% from total CO measured by GC-MS is noticeable 
even in samples immediately analysed without any storage. As a result, the important back 
calculated COHb saturations might, in fact, derive from a variable amount of CO dissolved in 
blood, not bound to Hb at time of sampling. The CO-oximeter is only capable of quantifying 
the amount of CO bound to Hb. With this AGS-GC-MS approach, the total amount of CO 
present in the blood sample is analysed, which is a sum of COHb and dissolved CO. 
 
3.5 Conclusion (PM range) 
 
An AGS-GC-MS method for the quantification of the total amount of CO in blood from CO-
poisoning cases, validated according to the ‘β-expectation tolerance interval’ accuracy profile 
as recommended by the SFSTP, was hereby exposed. The method presents improved 
sensitivity (lower LOD and LOQ) and lower costs due to reduced quantities of reagents 
compared to the previously published study by Varlet et al. from 2012 [5]. Moreover, the 
method is accurate and reliable (±30%) for measurements of CO concentrations in a range from 
10-200 nmol/mL HS (2-40 µmol/mL blood).  
The main novelty of this study is the consideration of the totality of CO present in the blood, 
which includes CO bound to Hb as well as CO dissolved in blood and the CO released into the 
HS of the sampling tube. No flushing of the calibrators is hereby performed, which is in 
accordance with physiological principles. The results reported show a significant difference of 
the CO concentrations if compared to results from previously published works, suggesting that 
the AGS-GC-MS method might be a valid alternative to the use of COHb as a biomarker for 
CO exposures, with the latter possibly underestimating the true role played by CO in such an 
intoxication.      
Additionally, this method could be of high importance in explaining numerous cases in which 
the reported COHb% levels did not correlate to the symptoms shown by intoxicated patients, 
with applications in both the clinical and forensic field, even though further research into this 
approach needs to be performed for confirmation. Furthermore, for applicability and validity 
in clinical cases, the validation of this method with a lower calibration range and with real 
clinical samples also needs to be completed.     




3.6 Results (clinical range)  
 
3.6.1 Validation of the method in a clinical range 
 
Results of the validation for all criteria are summarized in Table 3.6.  
Calibration curves for CO determination were obtained by using CO negative human blood as 
blank matrix. Calibration curves, which represent the response function, were acquired on three 
non-consecutive days (p = 3), in triplicates (n = 3) and at seven concentration levels (k = 7): 
1.63, 3.25, 6.5, 13, 26, 52 and 104 nmol/mL HS (equivalent to 0.65, 1.3, 2.6, 5.2, 10.4, 20.8 
and 41.6 µmol/mL blood). For each calibration point, calculated concentrations were compared 
to the target values and found to be within ± 20%. The relationship between the CO 
concentration from samples spiked with formic acid and the measured response was found to 
be linear. Validation coefficients for the calibration curves are shown in Table 3.6a.    
On each non-consecutive day (p = 3), control samples at five different concentrations (k = 5), 
namely 2, 5, 10, 30 and 60 nmol/mL HS (0.8, 2, 4, 12 and 24 µmol/mL blood), were measured 
in triplicates (n = 3). The concentrations of the control samples were calculated by using the 
calibration curve determined for each analysis day. As shown in Table 3.6b, satisfactory 
linearity was obtained, with a slope of 1.05 and a regression coefficient of 0.99 in the range of 
2 to 60 nmol/mL HS (0.8-24 µmol/mL blood).    
The selectivity of the AGS-GC-MS method was previously confirmed in section 3.3.1.     
Trueness was found to be lower than the acceptance criteria (within ±20% of the accepted 
reference value and within 20% at the LOQ), as is shown in Table 3.6c, which is satisfactory 
for validation according to SFSTP guidelines [14].   
Table 3.6d shows that the relative standard deviation (RSD) for repeatability and intermediate 
precision are in a range between 0.50% and 3.55%.    
Figure 3.4 represents the accuracy profile for CO. The mean bias (%) confidence interval limits 
for the control samples were within the acceptability limits of ±30%. Taking into consideration 
the acceptability limits of ±30%, the limit of quantification within validation criteria was found 
between 2 and 5 nmol/mL HS (0,8 and 2 µmol/mL blood). Thus, the method is confirmed to 
be accurate within the range of 5 and 60 nmol/mL HS (2-24 µmol/mL blood) according to the 
β-interval tolerance accuracy profile.   
In addition, the external controls gave excellent accuracy, with an RSD below 15% (Table 
3.6e). 




Table 3.6: Validation results for CO determination in blood by AGS-GC-MS - (a) represents the mean coefficients 
of the calibration functions obtained from analysis of the calibrators; (b) represents the coefficients of the linear 
regression function obtained from analysis of the QCs against their theoretical value; (c) represents the trueness 
obtained from the QC analyses expressed in %; (d) represents the precision obtained from QC analyses expressed 
in relative standard deviation % (RSD%); (e) shows mean and RSD% of the external controls.   
a) Response function [1.63-104 nmol/mL HS] (k = 7, n= 3, p = 3) 
 Day 1 Day 2 Day 3 
Slope 0.03 0.02 0.03 
Intercept 0.59 0.63 0.61 
r² 0.98 0.99 0.98 
k: number of concentration levels; n: number of repetitions for each level; p: number of non-consecutive days     





c) Trueness (relative bias) ( k = 5, n = 3, p = 3) 







d) Precision (RSD%)  ( k = 5, n = 3, p = 3) 






*Inter-series variance (s2g) is negligible for all levels, resulting in same values for repeatability and intermediate precision 
e) External controls ( k = 2, n = 3, p = 1) 
Levels [nmol/mL HS] Mean 
(Confidence Interval) 
RSD [%] 
5 4.49 (3.93, 5.06) 12.0 
60 65.5 (60.0, 73.9) 6.57 
 
 




Figure  3.4: Accuracy profile for CO determination using a simple linear regression model within the range of 2-
60 nmol/mL HS (0.8-24 µmol/mL blood). The continuous line represents the trueness (bias), the dashed lines 
represent the acceptance limits set at ± 30% and the dotted lines are the relative lower and upper accuracy limits.  
 
3.6.2 Analyses of flushed samples 
 
Blood samples of 13 patients were analysed before and after exposure to CO as well as with 
and without a flushing step. Triplicates were acquired for analyses with CO-oximetry and 
AGS-GC-MS. Results of all analyses are found in Table 3.7 and represented in Figure 3.5.  
For all samples analysed, a relative increase of both TBCO and COHb can be observed when 
comparing the values before and after CO exposure (Figure 3.5 and Table 3.7). Increases were 
confirmed and found to be significant by comparing the means with Student t-Test (Table 3.8). 
Important observations can be made when comparing the COHb and TBCO levels before and 
after a flushing step (Table 3.7 and 3.8). For the levels of COHb, there is no consistent trend 
that can be observed, with a COHb increase in some patients and a decrease in others. The 25th 
and 75th interquartile range (Table 3.8) for COHb before and after flushing (range includes 0), 
as well as the results of the t-Test (p-Value > 0.05), confirm this result. This behaviour could 
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Table 3.7: Differences for before and after CO exposure and before and after flushing, measurement results for 
























1 M 84.3 1.90 -2.20 0.11 0.11 
2 M 89.0 7.30 -1.50 1.95 0.81 
3 F 87.9 7.30 -1.30 2.20 0.30 
4 M 59.3 6.80 -0.90 1.84 0.75 
5 F 48.3 5.20 0.60 0.75 0.34 
6 M 104 6.10 -0.90 0.93 0.67 
7 M 86.7 7.70 -2.60 0.74 0.33 
8 M 89.1 8.10 -0.90 1.06 0.31 
9 F 71.2 10.90 1.20 1.99 0.30 
10 M 57.4 6.80 1.50 0.78 0.66 
11 F 99.5 6.90 2.50 1.51 0.49 
12 M 60.8 6.20 2.10 1.63 0.23 
13 M 65.3 8.70 0.10 3.05 0.57 
 
Conversely, TBCO shows a consistent trend: for all samples analysed, TBCO before flushing 
is higher than after flushing. Statistical significance was confirmed by performing a paired 
Student t-Test of the means (p-Value = 8.955e-06). Mean and interquartile range for TBCO 
differences before and after flushing additionally confirm the positive relationship (Table 3.8).    
 
Table 3.8: Summary statistics and results of paired t-Test with 95% confidence interval (CI) for the differences 
for COHb and TBCO before (B) and after (A) exposure and before (NF) and after flushing (F); p-Values in bold 
are significant (below 0.05).   




TBCO Diff A/B 
[µmol/mL] 
TBCO Diff NF/F 
[µmol/mL] 
Mean 6.92 -0.18 1.43 0.45 
SD 2.06 1.64 0.79 0.22 
1st Quartile 6.20 -1.30 0.78 0.30 
3rd Quartile 7.70 1.20 1.95 0.66 
p-Value 6.02*e-07 0.71 2.93*e-05 8.96*e-06 
95% CI 5.98; 9.53 -1.17; 0.81 0.95; 1.90 0.32; 0.58 
 
 




Figure  3.5: Results for the total CO concentration in blood (TBCO) in µmol/mL (bars, left axis) measured by 
AGS-GC-MS and the COHb saturation in % (dots, right axis) measured through CO-oximetry in blood for 13 
patients before (green) and after (blue) CO exposure and after a flushing step (orange).    
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3.7 Discussion (clinical range) 
 
An improved AGS-GC-MS method for CO determination in blood was validated for a clinical 
concentration range (1.63-104 nmol/mL HS / 0.65-41.6 µmol/mL blood) and was successfully 
applied to the analysis of blood samples coming from individuals with controlled CO 
exposures. The observed increase of both COHb and TBCO before and after CO exposure was 
to be expected, since all individuals were breathing in a mixture of O2 and CO. Patients with a 
CO burden before exposure, namely patients with ID number 3, 4, 9, 11, 12 and 13, admitted 
to being smokers. Smokers are known to have a higher baseline CO level, which varies 
depending on the frequency [17–19], hence it explains the presence of CO in several patients 
before exposure.  
Significant variability of CO burden after exposure is found between individuals. Even though 
the volumes of CO administered were adapted to the weight and height of the patients, other 
factors involving the respiratory system and blood circulation, such as ventilation rate, tidal 
volume, inspiratory and expiratory reserve volume, alveolar ventilation, cardiac rhythm and 
cardiac output, influence the net amount of CO that enters the circulation [20]. In addition, 
malfunctioning of the rebreathing system can lead to altered amounts of CO effectively being 
administered, resulting in the observed inter-patient variations.  
The samples were all subject to the same storage and sample treatment conditions (immediately 
after blood collection) and analysed with the same parameters and measurement method 
(within 48 hours after blood samplings). It is therefore not very likely that the differences in 
detected concentrations are due to any error in the measurement technique or used parameters, 
but mainly to the removal of CO through a constant nitrogen stream. This legitimizes the 
hypothesis that there is a significant amount of CO present in free form in blood from an 
individual, who was subject to CO exposure. The amount of free CO on average ranges 
between 10 and 60% compared to the initial TBCO burden.    
Additionally, when plotting the results of the 13 clinical samples with the results obtained from 
in vitro CO-fortified samples (Figure 3.6), it can be seen that the clinical samples all comply 
with the in vitro measurements, further diminishing the probability of errors in the 
measurement and strengthening the assumption of CO being eliminated through flushing.  




Figure  3.6: Correlation plot between TBCO in µmol/mL measured by AGS-GC-MS vs. the COHb saturation in 
% measured through CO-oximetry for two groups of samples: stored blood samples fortified with CO (squares 
for high fortification level 60-70%, lines for medium fortification level 30-40% and triangles for low fortification 
level 10-20%, n=54) and real case samples (circles for flushed and diamonds for not flushed samples, n=26). 
Analyses were carried out in triplicates, but for illustrative purposes, error bars were not displayed.  
This suggests that with the execution of a flushing step a significant amount of CO is removed 
from the analysed sample. Thus, the result is biased not only from an analytical but also from 
a clinical point of view: the excess amount of CO may have a more significant 
pathophysiological activity than previously suspected. The direct cellular toxicity of molecular 
CO through impairment of cellular respiration and generation of free radicals, which are known 
to be tumour-cells promoters, was reported in previous studies [21–27]. Yet, the importance 
given to its implications in the direct adverse effects in CO poisonings was held to a minimum. 
Most likely this was because the presence of CO dissolved in blood in free form was never 
clearly demonstrated before.   
Furthermore, the acknowledgement of dissolved CO represents one possible argument for 
explaining the discrepancy between reported symptoms and measured COHb. Considering 
only the amount of CO bound to Hb when determining a CO poisoning may lead to 
underestimation of the true burden CO poses, explaining why in many cases the measurements 
are inconsistent with the symptoms a patient is showing and also why several patients show 



















Correlation plot: COHb in %  vs TBCO in µmol/mL
Low fortification (n=18) Medium fortification (n=18) High fortification (n=18)
Clinical cases (not flushed, n=13) Clinical cases (flushed, n=13)
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may be the missing quantity that gets closer to the true CO concentration in blood and burden 
on the body of an exposed individual. CO toxicity at cellular level may not only explain some 
of the symptoms of acute CO poisonings but, due to the slow dissociation rate from cellular 
proteins, it may also elucidate the reasons behind the delayed neurological effects reported 
hours or days after COHb was removed from the system through oxygen therapy and after low-




This study constitutes a preliminary study that aims to demonstrate the existence of CO 
dissolved not bound to Hb. This hypothesis has been tested with a cohort of 13 individuals 
through bedside blood collection. However, these findings have to be verified on a higher 
number of volunteers, even if the experimental design is complex to perform due to time-
dependent analysis. Moreover, there is no clear evidence about a constant amount of CO 
dissolved, since in each patient the difference between TBCO before and after flushing varies. 
These variations are most likely due to interindividual variability: several factors such as pre-
existing cardiovascular or respiratory conditions, metabolic rate, ventilation rate and volumes, 
sex and age can play a role in the behaviour and amount of CO in blood. Additional 
measurements with more individuals will lead to higher statistical significance and will reduce 
the interindividual variability. In addition, analytical parameters affecting the storage as well 
as biological phenomena taking place after sampling of blood are known to potentially alter 
the measurement results, even if I reduced them to a minimum in this study. Further 
investigations into these TBCO pharmacodynamics and pharmacokinetics are needed to 
account for this behaviour.   
 
3.9 Conclusion (clinical range) 
 
This study presents the validation of an improved carbon monoxide analysis method in human 
blood, based on AGS-GC-MS, for a range of 1.63 to 104 nmol/mL HS (0.65-41.6 µmol/mL 
blood), which is applicable to clinical CO exposure cases. The method was applied to a cohort 
of 13 patients, who were exposed to controlled amounts of CO, and results compared to 
measurements by CO-oximetry. Furthermore, a flushing step was performed on samples after 
CO administration. Results seem to support the hypothesis that TBCO may be an alternative to 
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COHb as biomarker for determination of CO poisoning, since consideration of only CO bound 
to Hb may underestimate the total burden of CO in blood. By comparing flushed and unflushed 
samples, it was determined that there is a significant amount of CO present in blood in free 
form (10-60%) at the sampling time post-exposure.  
This represents an important finding for the understanding of the true role played by CO in 
poisoning cases and for the explanation of the discrepancy often encountered by clinicians 
between symptoms and results and the onset of delayed neurological sequelae, even after 
complete removal of COHb from the system after normo- or hyperbaric oxygen therapy, 
possibly leading to a decrease in the number of misdiagnoses. Nevertheless, before the 
application of the method in clinical settings, this hypothesis needs to be verified by more 
numerous cohorts and in-depth statistical analyses, to increase statistical power. Additionally, 
further investigation into the biochemical mechanisms behind the distribution and behaviour 





[1] Z.L. Cardeal, D. Pradeau, M. Hamon, I. Abdoulaye, F.M. Pailler, B. Lejeune, New 
Calibration Method for Gas Chromatographic Assay of Carbon Monoxide in Blood, J. 
Anal. Toxicol. 17 (1993) 193–195. 
[2] A.M. Sundin, J.E. Larsson, Rapid and sensitive method for the analysis of carbon 
monoxide in blood using gas chromatography with flame ionisation detection, J. 
Chromatogr. B Anal. Technol. Biomed. Life Sci. 766 (2002) 115–121. 
https://doi.org/10.1016/S0378-4347(01)00460-1. 
[3] H.J. Vreman, R.J. Wong, D.K. Stevenson, J.E. Smialek, D.R. Fowler, L. Li, R.D. 
Vigorito, H.R. Zielke, Concentration of carbon monoxide (CO) in postmortem human 
tissues: Effect of environmental CO exposure, J. Forensic Sci. 51 (2006) 1182–1190. 
https://doi.org/10.1111/j.1556-4029.2006.00212.x. 
[4] H.J. Vreman, D.K. Stevenson, A. Zwart, Analysis for carboxyhemoglobin by gas 
chromatography and multicomponent spectrophotometry compared., Clin. Chem. 33 
(1987) 694–697. https://doi.org/10.1093/clinchem/33.5.694. 
[5] V. Varlet, E. Lagroy De Croutte, M. Augsburger, P. Mangin, Accuracy profile 
validation of a new method for carbon monoxide measurement in the human blood 
Chapter 3 - Development and validation of a novel method for carbon monoxide poisoning determination 
 
 76 
using headspace-gas chromatography-mass spectrometry (HS-GC-MS), J. 
Chromatogr. B Anal. Technol. Biomed. Life Sci. 880 (2012) 125–131. 
https://doi.org/10.1016/j.jchromb.2011.11.028. 
[6] V. Varlet, E.L. De Croutte, M. Augsburger, P. Mangin, A new approach for the carbon 
monoxide (CO) exposure diagnosis: Measurement of total co in human blood versus 
carboxyhemoglobin (HbCO), J. Forensic Sci. 58 (2013) 1041–1046. 
https://doi.org/10.1111/1556-4029.12130. 
[7] H. H, Z. H, Z. L, Z. Z, Y. Z, Headspace GC-MS Detection of Carbon Monoxide in 
Decomposed Blood and Hepatic Tissues, J. Forensic Sci. Criminol. 1 (2013) 1–6. 
https://doi.org/10.15744/2348-9804.1.302. 
[8] H.J. Vreman, L.K. Kwong, D.K. Stevenson, Carbon monoxide in blood: An improved 
microliter blood-sample collection system, with rapid analysis by gas chromatography, 
Clin. Chem. 30 (1984) 1382–1386. 
[9] Y. Ouahmane, J. Mounach, A. Satte, A. Bourazza, A. Soulaymani, N. Elomari, Severe 
poisoning with carbon monoxide (CO) with neurological impairment, study of 19 
cases, Toxicol. Anal. Clin. 30 (2018) 50–60. 
https://doi.org/10.1016/j.toxac.2017.10.003. 
[10] A. Ocak, J.C. Valentour, R. V Blanke, The effects of storage conditions on the stability 
of carbon monoxide in postmortem blood, J. Anal. Toxicol. 9 (1985) 202–206. 
https://doi.org/10.1093/jat/9.5.202. 
[11] G.W. Kunsman, C.L. Presses, P. Rodriguez, Carbon monoxide stability in stored 
postmortem blood samples, J. Anal. Toxicol. 24 (2000) 572–578. 
https://doi.org/10.1093/jat/24.7.572. 
[12] R.F. Coburn, G.K. Danielson, W.S. Blakemore, R.E. Forster, Carbon monoxide in 
blood: analytical method and sources of error, J. Appl. Physiol. 19 (1964) 510–515. 
https://doi.org/10.1152/jappl.1964.19.3.510. 
[13] D.H. Chace, L.R. Goldbaum, N.T. Lappas, Factors affecting the loss of carbon 
monoxide from stored blood samples, J. Anal. Toxicol. 10 (1986) 181–189. 
https://doi.org/10.1093/jat/10.5.181. 
[14] P. Hubert, J.J. Nguyen-Huu, B. Boulanger, E. Chapuzet, N. Cohen, P.A. Compagnon, 
W. Dewé, M. Feinberg, M. Laurentie, N. Mercier, G. Muzard, L. Valat, E. Rozet, 
Harmonization of strategies for the validation of quantitative analytical procedures: A 
SFSTP proposal. Part IV. Examples of application, J. Pharm. Biomed. Anal. 48 (2008) 
760–771. https://doi.org/10.1016/j.jpba.2008.07.018. 
Chapter 3 - Development and validation of a novel method for carbon monoxide poisoning determination 
 
 77 
[15] C. Brehmer, P.X. Iten, Rapid determination of carboxyhemoglobin in blood by 
Oximeter, Forensic Sci. Int. 133 (2003) 179–181. https://doi.org/10.1016/S0379-
0738(03)00066-5. 
[16] J.J. Mahoney, H.J. Vreman, D.K. Stevenson, A.L. Van Kessel, Measurement of 
carboxyhemoglobin and total hemoglobin by five specialized spectrophotometers (CO-
oximeters) in comparison with reference methods, Clin. Chem. 39 (1993) 1693–1700. 
[17] J. Czogala, M.L. Goniewicz, The complex analytical method for assessment of passive 
smokers’ exposure to carbon monoxide, J. Anal. Toxicol. 29 (2005) 830–834. 
https://doi.org/10.1093/jat/29.8.830. 
[18] J. Schimmel, N. George, J. Schwarz, S. Yousif, S. Suner, J.B. Hack, 
Carboxyhemoglobin Levels Induced by Cigarette Smoking Outdoors in Smokers, J. 
Med. Toxicol. 14 (2018) 68–73. https://doi.org/10.1007/s13181-017-0645-1. 
[19] R.D. Stewart, Carboxyhemoglobin Levels in American Blood Donors, JAMA J. Am. 
Med. Assoc. 229 (1974) 1187. https://doi.org/10.1001/jama.1974.03230470029019. 
[20] L.K. Weaver, Carbon Monoxide Poisoning, N. Engl. J. Med. (2009). 
https://doi.org/10.1056/NEJMcp0808891. 
[21] K.R. Hardy, S.R. Thom, Pathophysiology and Treatment of Carbon Monoxide 
Poisoning, Clin. Toxicol. 32 (1994) 613–629. 
https://doi.org/10.1016/j.ncl.2009.04.002. 
[22] K.R. Olson, Carbon monoxide poisoning: Mechanisms, presentation, and controversies 
in management, J. Emerg. Med. 1 (1984) 233–243. https://doi.org/10.1016/0736-
4679(84)90078-7. 
[23] B.C. Hill, The pathway of CO binding to cytochrome c oxidase Can the gateway be 
closed?, FEBS Lett. 354 (1994) 284–288. https://doi.org/10.1016/0014-
5793(94)01140-0. 
[24] B. Chance, M. Erecinska, M. Wagner, MITOCHONDRIAL RESPONSES TO 
CARBON MONOXIDE TOXICITY, Ann. N. Y. Acad. Sci. 174 (1970) 193–204. 
https://doi.org/10.1111/j.1749-6632.1970.tb49786.x. 
[25] J. Zhang, C.A. Piantadosi, Mitochondrial oxidative stress after carbon monoxide 
hypoxia in the rat brain, J. Clin. Invest. 90 (1992) 1193–1199. 
https://doi.org/10.1172/JCI115980. 
[26]  a Verma, D.J. Hirsch, C.E. Glatt, G. V Ronnett, S.H. Snyder, COMMENT on Maines 
Carbon monoxide: a putative neural messenger., Science. 259 (1993) 381–4. 
http://www.ncbi.nlm.nih.gov/pubmed/9431545. 
Chapter 3 - Development and validation of a novel method for carbon monoxide poisoning determination 
 
 78 
[27] M. Barinaga, Carbon monoxide: killer to brain messenger in one step., Science. 259 




































A3.1 Protocol for sample preparation and analysis of blood samples for CO 
determination via CO-oximetry and GC-MS 
 
A3.1.1 Preparation of blank matrix (i.e. unfortified bovine blood) 
 
1) Prepare a 1 L polyethylene (PE) 
2) Retrieve 1 L of bovine blood per preservative for fortification and 250mL of blood per 
preservative to use for the calibration curve.  
3) Analyse a sample of the fresh blood via CO-oximetry to determine the baseline COHb% 
content – only use for subsequent analyses if at <1% COHb. 
 
A3.1.2 Preparation of calibration standards, internal standard (IS) solution and quality 
controls 
 
Calibration standard: formic acid (MHCOOH = 46 g/mol, ρ = 1.22 g/mL) solution at 87 
µmol/mL (for post-mortem (PM) range) 
1) Insert 10 mL of distilled water in a 20mL headspace (HS)-vial. 
2) Pipette 32.8 µL of formic acid into the HS-vial. 
3) Seal vial with a septum and vortex upside down for several seconds to allow 
homogenization. 
4) When not in use, store refrigerated at 4°C for a maximum of one week.  
 
Calibration standard: formic acid (MHCOOH = 46 g/mol, ρ = 1.22 g/mL) solution at 43 
µmol/mL (for clinical range) 
1) Insert 10 mL of distilled water in a 20mL HS-vial. 
2) Pipette 16.4 µL of formic acid into the HS-vial. 
3) Seal vial with a septum and vortex upside down for several seconds to allow 
homogenization. 
4) When not in use, store refrigerated at 4°C for a maximum of one week.  
 
IS solution: isotopically labelled formic acid (MH13COOH =47 g/mol, ρ = 1.246 g/mL) 
solution at 84 µmol/mL) 
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1) Insert 10mL of distilled water in a 20mL HS-vial. 
2) Pipette 32.0 µL of isotopically labelled formic acid into the HS-vial. 
3) Seal with a septum and vortex upside down for several seconds to allow homogenization.  
4) When not in use, store refrigerated at 4°C for a maximum of one week.   
 
Quality control: pure CO gas 
1) Fill one 20mL HS-vial completely with distilled water and seal it with a septum. 
2) Turn the vial upside down. 
3) Insert one needle for injection. 
4) Insert another needle for release of excess water.  
5) Transfer pure CO (99%) gas into the HS-vial through the injection needle until the vial is 
half-filled with gas.  
6) Depending on the concentration of the quality control (QC) required, transfer the required 
amount of CO gas into another 10mL HS-vial that was previously sealed.  
7) Dilute into another sealed HS-vial if necessary (for low QC concentrations).  
 
A3.1.3 Preparation of calibration curve for PM range 
 
1) Insert 100µL of blank blood into a 20mL HS-vial.  
2) For each calibration solution, insert the volumes of the calibration and IS solutions into the 
HS-vial according to the following table: 
Table A3 1: List of amounts of calibration and internal standard solutions required for each calibration point in 















10 10 10 10 10 10 10 10 
Chapter 3 - Development and validation of a novel method for carbon monoxide poisoning determination 
 
 81 
3) Insert 100µL of sulphuric acid in an aluminium cap that is then carefully inserted into the 
vial.    
4) Seal the vial immediately and vortex upside down for several seconds. 
 
A3.1.4 Preparation of calibration curve for clinical range 
 
1) Insert 100µL of blank blood into a 20mL HS-vial.  
2) For each calibration solution, insert the volumes of the formic acid and isotopically labelled 
formic acid solutions into the HS-vial according to the following table: 
Table A3.2: List of amounts of calibration and internal standard solutions required for each calibration point in 















10 10 10 10 10 10 10 10 
 
3) Insert 100µL of sulphuric acid in an aluminium cap that is then carefully inserted into the 
vial.    
4) Seal the vial immediately and vortex upside down for several seconds. 
 
A3.1.5 Preparation of blood samples for analysis 
 
1) Insert 100µL of blood sample into a 20mL HS-vial.  
2) Add 10µL of isotopically labelled formic acid solution. 
3) Insert 100µL of sulphuric acid in an aluminium cap that is then carefully inserted into the 
vial.    
4) Seal the vial immediately and vortex upside down for several seconds. 
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A3.1.6 Analysis of samples via GC-MS 
 
1) Insert prepared samples into an oven at 100°C for 60 minutes.  
2) Take samples out of the oven and let it cool down to room temperature.  
3) With an airtight gas syringe (AGS), sample 1mL of the samples’ HS. 
4) Inject it into the GC-MS instrument.  
5) To perform triplicate analyses, perform the sample preparation and analysis steps again.  
A3.1.7 Analysis of samples via CO-oximetry 
 
1) Calibrate instrument prior to analysis with calibrators provided by the manufacturer.  
2) With a syringe provided by the CO-oximeter manufacturer, samples approximately 50-
100µL of blood from the sample. 
3) Insert blood into cuvettes provided by the manufacturer.  
4) Insert cuvette with blood sample into CO-oximeter for analysis.  
5) Once the sample is analysed, discard of the cuvettes and syringe.  
 
A3.1.8 Protocol for flushing of samples 
 
1) Sample 2 blood tubes per patient, which have been administered CO through the CO-re-
breathing-system, into EDTA tubes (2.3 mL).  
2) Analysis: 
NO FLUSHING 
a. Prepare and analyse samples according to the protocol for blood samples 
      FLUSHING 
a. Adjust nitrogen (N2) flow rate to reach the required maximum of 5mL/min.  
b. Once blood sample is obtained, insert one needle into septum to release excess 
pressure. 
c. Insert the needle with N2 flow into the blood tube, making sure it is at the bottom 
of the tube. 
d. Flush sample for 3 minutes, then remove N2 flow and additional needle. 
e. Vortex (slowly) for 30 sec to ensure homogenization, then let rest for 1 min   
f. Prepare and analyse samples according to the protocol for blood samples.  
g. If analysis not possible immediately, storage in the fridge (4°C) – record time 
between sampling and analysis. 




Figure A3.1: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 




Figure A3.2: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition 
of linear trendline, linear regression equation and regression coefficient (R2) for Test 2.  
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Figure A3.3: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 
linear trendline, linear regression equation and regression coefficient (R2) for Test 3.  
 
 
Figure A3.4: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 
linear trendline, linear regression equation and regression coefficient (R2) for Test 4.  
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Figure A3.5: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 




Figure A3.6: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 
linear trendline, linear regression equation and regression coefficient (R2) for Test 6.  
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Figure A3.7: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 




Figure A3.8: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 
linear trendline, linear regression equation and regression coefficient (R2) for Test 8.  
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Figure A3.9: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 




Figure A3.10: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 
linear trendline, linear regression equation and regression coefficient (R2) for Test 10.  
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Figure A3.11: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 




Figure A3.12: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 
linear trendline, linear regression equation and regression coefficient (R2) for Test 12.  
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Figure A3.13: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 




Figure A3.14: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 
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Figure A3.15: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 




Figure A3.16: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 
linear trendline, linear regression equation and regression coefficient (R2) for Test 16.  
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Figure A3.17: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 




Figure A3.18: Peak Area Ratio of carbon monoxide (CO) from the blood sample over 13CO from the 
internal standard (IS) plotted against the CO concentration in the calibration standards, with addition of 
linear trendline, linear regression equation and regression coefficient (R2) for Test 18.  
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Chapter 4 - New strategy for carbon 
monoxide poisoning diagnosis: 
Carboxyhemoglobin (COHb) vs 




Procedures for sample collection and storage are one of the main aspects in the practice of 
clinical and forensic analyses of biological specimens. Given the medical and legal 
implications of these types of analyses, it is crucial that standardized protocols are in place to 
allow for correct and accurate interpretation of the results obtained, which help to provide 
adequate diagnoses and treatment strategies in clinical cases and hold up in court in forensic 
cases  [13–15]. The fundamentals of these protocols are driven by the biochemical, physical 
and toxicological processes that occur when a substance of interest in a biological matrix is 
extracted, transported and stored prior to analysis. Storage after analysis is also of interest since 
in many cases, especially forensic, reanalysis of a sample after several days or weeks is a 
necessary step in the investigation [14].  
A common practice is to store blood samples possibly frozen or at least refrigerated, with the 
addition of an anticoagulant and in a place not exposed to light [13]. Samples are usually 
obtained by laboratories in standard volume tubes, therefore the volume of the headspace (HS) 
or air volume above the sample is determined based on the volume of the sample, not the 
selected sampling tube. Furthermore, in a laboratory routine, a blood sample is often employed 
for multiple analyses, including drug screenings and alcohol testing [21,22].       
Since CO is a gaseous compound, samples obtained from individuals suspected of CO 
poisoning have the potential of additionally being very susceptible to exposure to air and 
frequent reopening. Even though the bond between CO and Hb is very strong, it is also a 
reversible reaction, which, over long periods, can lead to dissociation, releasing CO into the 
HS of the sampling tube [10,23]. Frequent reopening can hence lead to analyte loss. Another 
consequence of COHb dissociation includes the potential influence of the ratio of sample 
Chapter 4 - New strategy for carbon monoxide poisoning diagnosis: Carboxyhemoglobin (COHb) vs Total 
Blood Carbon Monoxide (TBCO) 
 
 94 
volume to HS in the sampling tube on the amount of CO dissociating into the HS. The 
formation of an equilibrium between CO in blood and HS was proposed by the study group of 
Kunsman et al. [24], who observed a loss of COHb in samples with a higher volume of air in 
the sampling tube. They also showed a decrease in COHb levels over time for samples that had 
a higher initial saturation level [24]. Other storage parameters that were investigated in 
previous studies include different temperatures and preservatives, which often were 
contradictory: some studies showed no or little change with storage over long periods of time 
and at elevated temperatures  [25–27], while others showed decreased COHb levels for 
different preservatives [24,28].  
These differences can be explained by the fact that the majority of these studies were mainly 
performed using spectrophotometric methods for analysis, which are known to be susceptible 
to optical changes in the blood quality [29]. 
To be able to avoid erroneous results derived from poor sample quality due to inadequate 
sample collection and storage conditions, gas chromatographic (GC) methods can be 
alternatively employed. GC methods lead to results that are independent of optical changes to 
the specimen and enable the measurement of the total amount of CO in blood (TBCO) and in 
the HS of the sampling tube, as an alternative to COHb [19,30,31]. In addition, the 
measurement of TBCO is in conformity with the pathophysiological mechanisms of a CO 
poisoning, which recent developments have shown to be related not only to COHb but also free 
CO [32–34].   
Therefore, with this study, I aim to evaluate the effects of storage parameters such as 
temperature, preservative, HS volume, reopening cycles, freeze- and thaw-cycles and the level 
of initial COHb saturation over a storage period of one month on the quantification of both 
COHb and TBCO, in order to determine the most appropriate practices for sample collection 
and storage in CO poisoning cases with delayed analyses or storage in non-optimal conditions. 
Furthermore, I compare the spectrophotometric technique of CO-oximetry to a gas 
chromatography-mass spectrometry-based one, introducing the concept of TBCO 
measurements as a necessary addition to COHb measurements, which are more sensitive to the 
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4.2 Materials and Methods 
 
 
4.2.1 In vitro storage study 
 
The in vitro study to evaluate several storage parameters was carried out over a period of one 
month, with samples analyzed on days 0, 1, 2, 4, 7, 14, 21 and 28.  
Blood specimens were generated on day 0 to investigate the following parameters at various 
levels (Detailed protocol is found in Appendix 4.1): 
 Temperature: room temperature (RT), refrigeration at +4°C, freezing at -20°C 
 Preservative: EDTA, NaF, LiH, NaCit  
 HS volume: <25%, 25-50%, >50% of the total tube volume 
 Saturation levels: 10-20%, 30-40%, 50-70% 
 Reopening cycles 
 Freeze- and thaw-cycles 
One set of samples used to investigate the reopening cycles were reanalyzed on each day of 
analysis, while another set of samples used to investigate all other parameters were analyzed 
once on the day of analysis. To assess the freeze- and thaw-cycles, the samples for investigating 
the reopening cycles stored in the freezer were used. A total of 2376 blood samples were 
analyzed, which were distributed for each parameter and day of analysis as follows: 108 
samples for each saturation level per day, of which 27 per preservative, 36 per temperature and 
36 per HS volume. Analyses were carried out in triplicates.   
 
4.2.2 Back calculation of COHb from CO 
 
Various research groups have previously proposed formulae to back calculate COHb from CO 
measured through GC approaches [35–38]. I compare the CO concentrations measured with 
the AGS-GC-MS method and back calculated to COHb through the formula proposed by 
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4.2.3 Statistical analyses 
 
Since saturation level is expected to have the most significant effect on the data and to simplify 
the data analysis, the dataset was split into the three categories (high, medium and low 
saturation level) and used for modelling. Data was then checked for normal distribution and 
transformed accordingly (Table 4.1). Due to the upper detection limit of the employed CO-
oximeter of 75%, a large portion of the samples analyzed with high saturation level was found 
at 75%, despite potentially being higher. This is not an issue from a pathophysiological point 
of view since the value is clearly in the toxic range of COHb concentrations. However, from a 
statistical perspective, this generated a severely left-skewed distribution, which could not be 
corrected through transformations. Therefore, censored regression was considered for 
statistical analyses of the data. “censReg” is a package in the statistical software R, which can 
be useful when faced with censored data. The way the software deals with the values in case 
of a right-sided censoring is that it estimates the values above the censored limit based on 
maximum likelihood with the data available [39]. This might be, however, problematic, since 
the software returns estimated values that can exceed 100, which is the physiological limit for 
COHb saturation.  
 
Table 4.1: List of transformations employed for data according to the analyte of interest and saturation 
level, *: for high saturation level COHb, no normal distribution was obtained, thus non-parametric tests 
were employed.  









- Cube root 
 
Non-parametric tests were used for assessment of single storage parameters in high saturation 
levels, but no assessment was possible with multiple storage parameters. Missing values in 
cases of instrument malfunctioning or due to the advanced stage of sample degradation were 
completely excluded for statistical analyses. Kruskal-Wallis test for high saturation COHb 
levels, multiway analysis of variance (ANOVA) for the other saturation and response variables 
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(COHb and TBCO) as well as multiple linear regression (MLR) and comparisons via Student 
t-test were used to assess the effect of the investigated parameters and generate correction and 
prediction models. All statistical analyses were performed with R (version 3.3.1, 2016-06-21).     
 
See Materials and Methods section 3.2 for description of all other relevant details.  
 
4.3 Results  
 
4.3.1 Correlation between COHb and TBCO 
 
Figure 4.1 shows the plot of results obtained for COHb vs results of the same samples for 
TBCO. Linear regression was applied to the data and the obtained linear regression line is 
depicted in red. A correlation factor (R2) of 0.68 with a p-value well below the significance 
limit of 0.05 (p-value <2.22e-16) represents a moderate positive correlation between the two 
measures.  
To determine whether the formula proposed by the study group of Cardeal et al. [37] is 
applicable to our method, I have used it to back calculate the values obtained from the AGS-
GC-MS measurements and compared the measured COHb with calculated COHb from TBCO 
values. A paired Student t-test was performed to statistically compare the two groups. With a 
p-value of <0.05 (p-value <2.2e-16), it was determined that the groups are significantly 
different.   
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Figure 4.1: Correlation plot for COHb [%] vs TBCO [µmol/mL] from the storage study results, with correlation 
formula, correlation factor (R²) and p-value. 
 
4.3.2 Influence of storage parameters 
 
 
4.3.2.1 Relevance of CO in HS 
 
To determine whether there was a significant amount of CO released into the HS of the 
sampling tube, the results for CO in blood were added to the results of CO in HS and compared 
to the results of CO in blood with a paired Student t-test. With a p-value of <2.2e-16, the two 
groups were found to be significantly different. Average relative differences in values were 
found to be between ±0.01% (histogram of relative differences distribution in Figure 4.2).  
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Figure 4.2: Histogram of relative differences in % of CO concentrations with and without taking into account the 
CO in the headspace (HS). 
 




To determine the influence of reopening the sampling tubes on the results obtained from the 
measurements of COHb and TBCO, the unpaired Student t-test was used to compare the 
samples that were reopened during the study period to samples that were not reopened. Results 
for both COHb and TBCO gave p-values >0.05, thus indicating that there is no statistically 
significant difference in results for samples that were reopened for reanalysis.  
 
Freeze- and thaw-cycles 
 
The effect of freezing and thawing a sample multiple times on the obtained measurement 
results for COHb and TBCO was determined by comparing results obtained from samples, 
which underwent multiple freeze- and thaw-cycles, to samples, which underwent only one 
freeze- and thaw cycle. The unpaired Student t-tests for both COHb and TBCO lead to p-values 
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>0.05, resulting in no statistically significant difference between the comparison groups. To 
further test whether the first freezing cycle had a major effect on the concentrations, I compared 
the results of samples that underwent one freeze- and thaw-cycle with the samples that did not. 
The Student t-test for both COHb and TBCO gave p-values >0.05, thus affirming no statistical 




To determine which and if any of the investigated parameters has a significant effect on the 
measures COHb and TBCO, an ANOVA was first carried out for each parameter and saturation 
level in relation to COHb and TBCO, respectively, with exception of high saturation COHb 
levels. Due to the inability of the data to reach normal distribution despite transformation 
attempts, the non–parametric Kruskal-Wallis test was employed to assess the different storage 
parameters one by one. Subsequently, an additive model selection process was performed, 
which consisted in the generation of several models through addition of one parameter in each 
new model, which were, in order, temperature, preservative, time (day of analysis) and HS 
volume. I was not able to investigate interactions between the parameters since the number of 
outputs remaining after cleaning of data was not sufficient to the number required to obtain 
enough study power. ANOVA was then used to determine the significance of the parameters 
in the models (significance was obtained with a p-value < 0.05). Results are summarized in 
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Table 4.2: Results of ANOVA for single parameters and combination of parameters for high, medium and low 
saturation level; COHb: carboxyhaemoglobin, TBCO: total blood carbon monoxide; **: p < 0.01, *:0.05 ≤ p ≤ 
0.01, –: not significant parameter (p >0.05), #: for high saturation COHb levels, non parametric Kruskal-Wallis 











Variables COHb# TBCO COHb TBCO COHb TBCO 
1 Temperature ** ** – ** – * 
2 Preservative ** ** ** ** ** ** 
3 Time – – * – – – 
4 HS volume – – – – – – 
5 Temperature # ** ** ** ** ** 
  Preservative # ** ** ** ** ** 
6 Temperature # ** ** ** ** ** 
  Preservative # ** ** ** ** ** 
  Time # – ** * * * 
7 Temperature # ** ** ** ** ** 
  Preservative # ** ** ** ** ** 
  Time # – ** – * * 
  HS volume # – ** – – – 
 
4.3.3 Correction model 
 
To be able to generate a correction model applicable to COHb or TBCO measurements based 
on this dataset, first, the behaviour of the response variables over time for each saturation level 
needed to be identified. Therefore, time plots for COHb and TBCO were produced (Figures 
4.3a-f), with a black line going through the means of the COHb/TBCO concentrations for each 
day of analysis. The graphs show a general weak linear trend for all saturation levels and 
response variable. For high and medium COHb levels (Figures 4.3a and 4.3b), a weakly 
decreasing trend can be observed, whereas for low COHb saturation (Figure 4.3c) there is a 
slight decrease in the initial phase, followed by a plateauing towards the second half of the 
month. For high TBCO levels (Figure 4.3d), there is a sudden drop after the first day, followed 
by a stabilization and weak decrease along the monitoring period. A similar drop can be seen 
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for medium TBCO concentrations (Figure 4.3e) on day 7, which is again followed by a 
stabilization and generally a weak decrease towards the end of the storage period. TBCO in 
low concentrations (Figure 4.3f) shows a slightly increasing tendency. Generally, increasing 
variation can be observed the higher the saturation level and the higher the number of storage 
days from t0.  
Due to the general linear behaviour, MLR analysis was selected and used for each response 
variable and each saturation level to determine the coefficient estimate for each parameter and 
their significance, based on the following equation: 
 𝑐 =  𝑐𝑀 − 𝑥𝑡𝛽𝑡 − 𝛽𝑃 − 𝛽𝑇 −  𝛽𝑉             (1) 
with c: corrected concentration of analyte of interest (here COHb in % or TBCO in 
µmol/mL), cM: measured concentration of analyte of interest; xt: number of days since 
sampling of specimen, βt: coefficient estimate for time, βP: coefficient estimate for selected 
preservative, βT: coefficient estimate for selected storage temperature, βV: coefficient 
estimate for selected HS volume.     
Reference level for each parameter was selected based on common guidelines for sample 
collection and storage in toxicological analyses (if specified), with EDTA as reference for 
preservative, freezing as reference temperature, low HS volume (<25%) and day 0 as reference 
for time. Results of the MLR are summarized in Table 4.3. To be noted here that all results for 
TBCO are based on normalized data and, thus, coefficients need to be transformed back to be 
able to obtain the actual TBCO concentrations (e.g., for high saturation TBCO, log 
transformation was applied, therefore the back transformation involves application of the 
exponential function to the coefficient estimates).   
 
 








a b c 
d e f 
Figure  4.3a-f: Boxplots with error bars for COHb concentrations in % (a-c) and TBCO concentrations in µmol/mL (normalized) (d-f) over time for high, medium and low saturation levels, black 
dot: mean COHb/TBCO concentration for the day of analysis, line in box: median. 
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Table 4.3: Coefficient estimates (β) and 95% confidence intervals (CI) from Multiple Linear Regression (MLR) with storage parameters preservative, temperature, time and 
HS volume for measurement of COHb and TBCO for high, medium and low saturation levels. In bold the significant parameters (p<0.05). MLR was performed with normalized 
data for TBCO (see Table 4.1). 
SATURATION 
LEVEL 
HIGH (60-70%) MEDIUM (30-40%) LOW (10-20%) 
 COHb  
(R2 = 0.67) 
TBCO  
(R2 = 0.39) 
COHb 
(R2 = 0.81) 
TBCO 
(R2 = 0.22) 
COHb 
(R2 = 0.76) 
TBCO 


























-0.34 (-0.41, -0.26) -7.01 (-7.54, -6.48) -0.20 (-0.26, -0.13) 
LiH 2.39 (1.25, 3.53) 0.27 (0.21, 0.32) -13.49 (-14.14, -
12.83) 
-0.51 (-0.59, -0.44) 5.30 (4.83, 5.77) -0.10 (-0.15, -0.04) 
NaCit -5.96 (-7.20, -4.72) 0.18 (0.12, 0.23) -17.63 (-18.30, -
16.96) 
-0.27 (-0.35, -0.19) 3.00 (2.53, 3.47) 0.21 (0.16, 0.27) 
Temperature (-20°C) 
+ 20°C 5.63 (4.63, 6.64) 0.06 (0.01, 0.10) -0.71 (-1.28, -0.13) -0.20 (-0.26, -0.13) 0.07 (-0.37, 0.51) -0.09 (-0.14, -0.04) 
+ 4°C 2.60 (1.57, 3.64) -0.02 (-0.07, 0.02) 0.12 (-0.46, 0.69) -0.04 (-0.10, 0.03) 0.75 (0.33, 1.17) 0.02 (-0.03, 0.07) 
Time (Day 0) 
Day x -0.83 (-1.02, -0.63) 0.01 (0.00, 0.02) -0.44 (-0.55, -0.33) 0.00 (-0.01, 0.01) -0.16 (-0.24, -0.08) 0.00 (-0.01, 0.01) 
HS volume (<25%) 
25%-50% -0.23 (-1.25, 0.78) 0.00 (-0.05, 0.04) -0.72 (-1.30, -0.14) 0.05 (-0.02, 0.12) 0.04 (-0.39, 0.46) 0.00 (-0.05, 0.05) 
>50% -1.32 (-2.33, -0.31) -0.03 (-0.07, 0.02) -1.14 (-1.72, -0.57) -0.04 (-0.11, 0.03) -0.35 (-0.78, 0.07) -0.03 (-0.08,0.02) 
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4.3.3.1 Saturation level 
 
For COHb, all parameters show statistical significance except HS volume 25-50% for high 
saturation levels, while all parameters are significant except storage in the fridge (+4°C) for 
medium saturation levels and storage in the fridge, preservatives NaF, LiH and NaCit and time 
are significant for low saturation levels.  
For TBCO, across all saturation levels, all preservatives are significant as well as storage at 
room temperature (+20°C), while no statistical significance was found for the other 
investigated parameters. 
 
4.3.4 Prediction Model 
 
To be able to predict the COHb concentrations based on a measured TBCO value and the given 
storage conditions, the dataset was split into a modelling set and a testing set. The testing set 
was obtained by extracting the data of one repetition for each analysis. The modelling set was 
then employed to generate a prediction model based on the linear function of  
𝑐𝐶𝑂𝐻𝑏 =  𝑐𝑇𝐵𝐶𝑂 −  𝑥𝑡𝛽𝑡 −  𝛽𝑃 −  𝛽𝑇 −  𝛽𝑉             (2) 
with cCOHb: concentration of COHb in [%], cTBCO: concentration of TBCO in µmol/mL, xt: 
number of days since sampling of specimen, βt: coefficient estimate for time, βP: coefficient 
estimate for selected preservative, βT: coefficient estimate for selected storage temperature, βV: 
coefficient estimate for selected HS volume.  
Coefficients and standard errors of the model are found in Table 4.4. This model was then used 
to predict the COHb concentrations based on the TBCO values and storage parameters form 
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Table 4.4: Coefficient estimates (β) and standard error (SE) from Multiple Linear Regression (MLR) for 
prediction model (R² = 0.94), with storage parameters preservative, temperature, time and HS volume for 
measurement. In bold the significant parameters. To evaluate the efficiency of the prediction model predicted 
values were compared with measured values with a Student t-test, which resulted in a p-value above 0.05, thus 
indicating that the measured and predicted values are not statistically different. Prediction efficiency was further 
confirmed by linear regression of predicted and measured COHb concentrations, which resulted in a good 





Coefficient estimate (β) Standard error (SE) 
Saturation level (Low, 10-20%) 
Medium (30-40%) 13.75 0.57 
High (60-70%) 48.79 0.87 
Preservative (EDTA) 
NaF -12.00 0.63 
LiH -2.04 0.59 
NaCit -7.53 0.62 
Temperature (-20°C) 
+ 4°C 2.16 0.53 
+ 20°C 2.87 0.53 
Time (Day 0) 
Day x -0.10 0.02 
HS volume (<25%) 
25%-50% -0.43 0.53 
>50% -0.71 0.53 
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Figure 4.4: Correlation plot for measured COHb vs predicted COHb concentrations in %. Complete dataset was 
subdivided in training (2/3) and test (1/3) set, prediction model was generated based on training set and applied 




4.4.1 Correlation between COHb and TBCO 
 
Before assessing each storage parameter and their potential impact on the measurement results, 
I first needed to determine the direction and magnitude of the correlation between the employed 
methods, namely CO-oximetry and GC-MS. Previous studies have determined a strong 
positive correlation between COHb determined via CO-oximetry and CO measured by GC, 
with R2 found generally above 0.9 for detection via flame ionization detector (FID) or reduction 
gas analyser (RGA) [36,37,40,41] and 0.85 for detection via MS [31,38,42,43]. Additionally, 
Cardeal, Vreman and others have proposed formulae to back calculate COHb from the CO 
measured through these GC methods, which are based on the correlation they obtained by 
comparing the two measurement methods [36–38,44].          
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Results from this study, however, do not confirm the results of these research groups. A weaker 
correlation between COHb measured by CO-oximetry and CO measured by GC-MS (R2 = 
0.68, see Figure 4.1) was determined. Furthermore, the statistically significant difference 
found between the measured values and the ones back calculated through the applied formula 
from Cardeal et al. (see section 3.2.1) does not confirm results previously obtained [43]. 
Therefore, the formula seems to be unsuitable. One possible explanation for this discrepancy 
in results can be found in the different analytical approaches used by each research group. 
While Vreman uses GC-RGA for detection [35,36], Cardeal uses GC-FID [37] and Hao [38] 
and Varlet [43] GC-MS. The advantages and disadvantages of each detection method have 
been discussed thoroughly in the past [17,45,46]. Generally, it is determined that GC-FID is 
the most sensitive method for CO analysis, but time-consuming and impractical due to the 
additional need of a methanizer, which makes the instrument limited to only a specific analysis, 
while GC-MS is the most versatile, accurate, rapid and reproducible method for CO 
determination in blood [17,45]. In addition to a different detection method, the research groups 
also use different calibration and sample preparation approaches. Various acids and oxidizing 
agents have been employed as ‘liberating agents’ to release CO for analysis via GC, which can 
result in different recoveries and efficiencies in CO release, hence altering the final CO 
concentrations obtained [19,31]. Furthermore, the calibration solutions were prepared 
differently. All previous studies have performed a flushing step of the calibrators prepared from 
CO-bubbled blood, with the aim of removing the ‘excess’ CO and, thus, recover only the CO 
bound to Hb. However, this does not comply with the pathophysiology of CO poisonings: both 
bound and free CO are responsible for the toxicity mechanisms of CO in the human body 
[1,7,16,34]. Consequently, removing and not analyzing free CO can underestimate the true CO 
burden, potentially resulting in fatal misdiagnoses. Therefore, in this study, I do not determine 
only the bound CO fraction, but the TBCO, which includes both free and bound CO. The 
amount of free CO was already found to be significant and may be one of the reasons for the 
discrepancy between our results and those from previous researchers regarding both the 
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4.4.2 Influence of storage parameters 
 
4.4.2.1 CO in HS 
 
The bond between CO and Hb is very strong, due to the high affinity of CO for the hemoprotein, 
which leads to COHb as being considered the sole biomarker of CO exposure. It is often 
reported as constituting the major form CO acquires when crossing the lung-blood barrier, 
making up more than 90% of inspired CO [47]. However, recent studies have also 
acknowledged the incongruence between symptoms and measured COHb and the possibility 
of a higher percentage of CO not bound to Hb than previously assumed [7,8,16,30,34,48]. This 
can partially be explained by the reversible reaction between CO and Hb: despite the high 
affinity, there is still a part of CO that can go back to its unbound form, even though it most 
likely constitutes only a small fraction. This equilibrium can, however, be shifted towards free 
CO by an increased HS volume: since CO is a gas, it behaves according to the ideal gas law, 
and according to Le Chatelier’s principle and the entropy laws, an increase in volume drives 
the gas molecules to shift and distribute towards the additional space, where the gas 
concentration is lower. An increased HS volume can, thus, increase the concentrations of CO 
in the HS significantly.  
Based on the results of the measurements of CO in the HS of the blood tubes after statistical 
analysis, CO in HS is determined to be significant. However, statistical significance does not 
always reflect a significance from a biochemical point of view, and, thus, needs to be put into 
the right context. As represented in the histogram in Figure 4.2, relative differences are 
generally below 0.01% COHb, which from a pathophysiological perspective do not have an 
impact on the severity of the poisoning. Therefore, I conclude that there is not a significant 
amount of CO that is released into the HS of the blood tube during storage.   
 
4.4.2.2 Reopening and freeze- and thaw-cycles 
 
Exposure to air through repeated reopenings of the samples was reported to decrease COHb 
values, which is mainly due to a loss of CO through an increase in the available volume. This 
can cause a shift in the equilibrium of free CO driven by entropy [49]. Similarly, blood samples 
stored below freezing temperature that had to undergo multiple freezing and thawing cycles 
due to repeated measurements required showed reduced COHb values, even though at a lesser 
extent [28,38]. In this study, however, results showed that both reopening and freeze- and thaw-
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cycles did not have a significant impact on the measurement values for neither COHb nor 
TBCO. Previous research into alterations to COHb values due to storage of blood samples 
showed mild reductions when observed for periods varying between 45 days and 2 years 
[24,28,38]. Considering that in the current study the observation period was of 28 days, this 
could explain the lack of significant alterations observed, reopening and freeze- and thaw-
cycles may affect the COHb and TBCO values only at a later storage period. Furthermore, in 
the study performed by Chace et al. [28], samples were allowed free air exchange during the 
whole period of storage, whereas the samples in this study were reopened only on the days of 
analysis. Kunsman et al. stored the samples for a period of 2 years and reopened the tubes only 
for the second analysis, thus only accounting for one reopening and one freezing- and thawing-
cycle [24]. Therefore, no substantial loss of CO could have occurred due to exposure to air or 
the freezing- and thawing-cycle, which is in accordance with the observed results. Hao et al. 
describe a substantial loss of COHb during storage over 45 days when measured with UV-
spectrophotometry, while COHb back calculated from CO measured by HS-GC-MS is shown 
to be stable over the course of the storage period [38]. A similar behaviour is confirmed in this 
study.          
 
4.4.2.3 Storage parameters: temperature, preservative, time and HS volume     
 
Various storage conditions have previously been investigated by multiple research groups, with 
results usually showing either increased or decreased COHb concentrations based on the 
storage temperature chosen, the preservative used to prevent blood clotting or exposure to 
different amounts of air over the course of prolonged storage time. However, there is also the 
possibility that these parameters affect the alteration of measurement differently based on 
whether the CO level in blood is high or low. While a parameter might have significant effects 
when low CO levels are present in the blood specimen, the variation in higher saturation levels 
might not be as significant, thus making that parameter to be considered for certain types of 
poisoning cases. Therefore, the different storage parameters were evaluated for each saturation 
level separately, which was not investigated previously by other research groups.      
The Multiway-ANOVA (Table 4.2, model 7) shows that all investigated parameters 
significantly affect the COHb concentrations for all saturation levels (except HS volume for 
low COHb concentrations), which is in congruence with previous studies reporting CO changes 
due to these parameters [24,25,28,38]. This behaviour is, however, different for TBCO, where 
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HS volume does not influence the measurement results in any saturation level and time only 
affects these at low concentrations. Hence, TBCO seems to be less affected by storage 
conditions compared to COHb, especially at medium to high ranges, which are of particular 
relevance for forensic cases.  
This is further confirmed by the MLR analysis results (Table 4.3), where a higher number of 
parameters are found to be significant for COHb than TBCO. A closer look at the variables 
shows that all preservatives are influential for both COHb and TBCO measurements (the higher 
the magnitude of the coefficient estimates (in either positive or negative direction), the more 
significant their effect). 
For TBCO the effects of the different preservatives are of similar magnitude and direction in 
each saturation level, except for NaF in high saturations, which shows a decrease in TBCO (-
0.24), as opposed to the other two preservatives showing an increase (0.27 for LiH, 0.18 for 
NaCit). Additionally, TBCO in low saturation levels shows a decreasing trend (-0.20 for NaF, 
-0.10 for LiH), with only NaCit resulting in increased levels (0.21).  
For COHb, a clear trend can be observed with NaF, where a decrease is observed in all 
saturation levels and the magnitude decreasing from higher to lower saturation (-16.35, -13.92, 
-7.01). Since NaF is a weak anticoagulant, its effect might diminish during prolonged storage, 
therefore increasing the chance of blood clotting, which reduces the blood quality. Therefore, 
it is not surprising that a decrease in COHb is observed and that the effect is more evident with 
higher COHb concentrations. However, for LiH and NaCit, no consistency can be observed 
between saturation levels and the effect of the preservative. With LiH as a preservative, the 
highest effect shows at medium COHb levels, with an average decrease of 13.49, whereas for 
the other saturation levels, increased COHb concentrations are observed (2.39 in high COHb 
levels, 5.30 in low COHb levels). Heparin is a widely used anticoagulant, especially in clinical 
toxicology and biochemistry, despite its high cost and short-lasting action. It belongs to the 
family of glycosaminoglycans. The anticoagulant feature of this complex chemical structure is 
the sulfated pentasaccharide units, which have a high binding affinity for antithrombin III, a 
plasma protein that inhibits blood clotting [50,51]. Considering that Hb has a relatively high 
binding affinity for oxygen and that the CO-Hb bond is reversible, it is possible that at certain 
concentrations the sulfated pentasaccharide units of heparin interact with Hb, thus altering the 
measured COHb concentrations. Furthermore, LiH is employed as a liquid solution, rather than 
a salt as all other preservatives. This increases the potential for blood dilution, therefore leading 
to decreased COHb measurement results [52]. These explanations for the observed behaviour 
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are all hypothetical, no specific study was conducted in the past assessing the effect of storage 
with heparin for blood samples used in CO poisoning determinations.   
When using NaCit as a preservative, the highest decrease in COHb is shown, similarly to LiH, 
in medium COHb ranges (-17.63), while a less significant decrease is reported in high 
saturations (-5.96) and an increase in low saturations (3.00). NaCit is, similarly to NaF, a weak 
anticoagulant, used primarily in blood transfusions and generally clinical blood samples, 
mainly due to its low cost and reversibility of the anticoagulant mechanism (chelation of 
calcium ions) [53,54]. Therefore, it is possible that at certain COHb concentrations, driven by 
a concentration gradient or chemical interactions, either the chelation of calcium or the bond 
between Hb and CO is reversed (which is a coordinated bond and not a covalent bond), leading 
to decreases in COHb. In addition, it has been previously reported in several studies that citrate 
alters the measurements of other compounds, such as gamma-hydroxybutyrate (GHB), leading 
to false positives. While the mechanism has not yet been elucidated, it was recommended that 
citrate as a preservative should not be used for forensic drug analyses [55–57]. Therefore, I 
hypothesize that a similar reaction might take place for COHb measurements, even though 
further investigation is needed to confirm this.       
Regarding HS volume and temperature, these are shown to be more influential at higher 
saturation levels for COHb concentrations, which is in accordance with results reported by Hao 
et al. [38], who also showed a more marked change in COHb concentrations with increased 
COHb saturation level. Storage at room temperature, as opposed to storage in the fridge or 
freezer, shows more prominent increases of high COHb concentrations. This is in accordance 
with biochemically- and bacterially-induced blood degradation, which is increased with higher 
temperatures. Results reported by Kunsman et al. [24] showing reduced COHb levels with 
increased exposure to air is also confirmed by the MLR results, with a negative and more 
significant coefficient estimate (β) reported for COHb levels (Table 4.3). However, this 
behaviour is not shown with TBCO, for which HS volume, time and storage in the fridge or 
freezer do not play an influential role. Only the choice of the preservative and storage at RT 
has a significant impact on TBCO measurements.   
This supports the hypothesis that TBCO appears as more stable and less prone to significant 
changes due to temperature, time and air exposure, as opposed to COHb. COHb measurement 
by spectrophotometry is affected by changes to the optical blood quality, which are mainly due 
to blood constituents catabolism occurring with time and also temperature changes, making the 
measurement more challenging and in some cases even impossible (the instrument returns an 
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error message). Furthermore, measurement by CO-oximetry is also affected by the amount of 
Hb present in the blood sample, with a range of 5-25 g/L limiting the measurements, which is 
especially relevant for forensic cases, where with long PMI, the blood quality is often altered, 
potentially leading Hb levels higher or lower to the instrument’s limits [29]. The majority of 
these factors are, however, not relevant for TBCO measurements. Optical blood changes, blood 
component catabolism, shifts of CO from bound to free, redistribution or increases of Hb in 
the blood compartments – neither of these factors influence measurement of CO via GC-MS. 
The pre-analytical reaction that takes place does not differentiate free or bound CO, all CO is 
transferred to the gas phase and then analyzed with a GC-column specific for gaseous 
molecules, thus reducing the potential interference of compounds present in the sample. 
However, TBCO measurements are impacted by PM generation of CO, similarly to COHb 
measurements, which is more likely to occur when samples are stored at higher temperatures. 
This explains why TBCO is shown to be influenced by storage at room temperature. 
Nevertheless, TBCO measurement may constitute a more reliable method for quantification of 
CO in non-optimal sampling and storage circumstances.        
 
4.4.3 Correction model 
 
In this study, several storage conditions have been investigated over a prolonged period, with 
parameters influencing the measurement results differently based on the chosen conditions and 
saturation level. Therefore, the selection of appropriate storage conditions is essential in 
guaranteeing accurate and reliable results, which can determine whether a case is attributed to 
CO poisoning as the cause of death, contributing factor or unrelated to death, with significant 
legal consequences. However, optimal conditions cannot always be guaranteed. Based on the 
laboratory equipment, resources, location and collaboration with local law enforcement and 
emergency departments, conditions of sampling and storage may vary. To be able to obtain 
consistent and accurate results across laboratories, I have used our data and MLR analysis to 
generate a correction model for both COHb and TBCO with parameters temperature, time, 
preservative and HS volume as input variables.  
Equation (1) can be adapted to the case at hand: depending on whether COHb or TBCO is 
being measured, the coefficient estimates for the selected storage conditions (if they vary from 
the reference conditions, otherwise the variable is equal to 0) that are significant for the relevant 
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saturation level are back-transformed (if necessary), input into equation (1) and the corrected 
concentration is obtained.  
As an example, if there is a blood sample that was stored with NaCit and >50% HS volume in 
the freezer for 28 days and obtained a COHb concentration of 35%, the corrected concentration 
would be: 
𝑐𝐶𝑂𝐻𝑏 =  35.00% − 28 ∗ (−0.08) − (−17.37) −  0 − (−1.24) = 55.85% 
For a sample stored with the same conditions and with a measured TBCO concentration of 5.00 
µmol/mL, the coefficients need to be back transformed for use with the correction formula. In 
this case (medium saturation level), log transformation was performed, therefore the 
exponential function needs to be applied to the coefficients, giving us following corrected 
concentration: 
 𝑐𝑇𝐵𝐶𝑂 =  5.00 µ𝑚𝑜𝑙/𝑚𝐿 − 0 − (𝑒
(−0.21)) −  0 − 0 = 4.19 µmol/mL 
This provides an important tool to be employed by laboratories and emergency departments 
that do not have the financial or logistical capacity to guarantee the best conditions for sampling 
and storage of specimens, such as in less developed countries where samples might need to be 
mailed to a laboratory with the appropriate equipment. It will enable them to obtain accurate 
and reliable determinations in CO poisoning cases, despite non-optimal storage conditions. 
However, this formula cannot be applied if temperatures during transport exceed 20°C, as 
temperatures above were not investigated here. Generally, laboratory guidelines and best 
practice regulations may vary across countries, even though a lot of effort is being put into 
reaching a global consensus on clinical and forensic laboratory standards. However, differences 
in storage and sampling practice are still common and therefore a consensus should at least be 
reached regarding the accuracy of results, which is the main goal and, finally, the achievement 
of this study. With this model, not only can correct diagnoses in suspected CO poisonings be 
obtained regardless of the sampling and storage conditions, but results can also be compared 
across laboratories and countries, allowing the creation and expansion of a collaboration 
network, which can be fruitful under other aspects as well. 
 
4.4.4 Prediction model  
 
Going a step further to obtain the most accurate and reliable CO poisoning determinations 
possible, I have integrated the storage conditions with the proposed alternative biomarker 
TBCO to be able to obtain COHb values that reflect with higher accuracy the levels present in 
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blood specimen, even in cases where COHb cannot be measured due to degradation. By 
measuring TBCO and inputting the coefficient estimates (Table 4.4) into equation (2), COHb 
concentrations can be predicted. The efficiency of the prediction model was confirmed by 
testing it on a set of data with known COHb and TBCO concentrations and storage conditions, 
which gave a satisfactory correlation coefficient of 0.87. Therefore, this prediction model 
together with TBCO measurement can be employed by laboratories for cases where 
measurement with CO-oximetry is not possible, allowing CO poisoning determinations in all 
possible conditions. However, a limitation of this prediction model is that it can only be applied 
to samples with a short postmortem interval (PMI). PM degradation affects the concentrations 
of CO in ways that go beyond storage, such as PM CO production through bacterial activity in 
the body. This was not a factor investigated in this study but would be an important aspect to 
research in order to further expand the potential application range of the proposed prediction 




In forensic cases, samples are usually stored for periods longer than 1 month, often for more 
than 1 year, since the timeline of court cases is very long and samples might be reanalyzed for 
cross-examination. Therefore, it is reasonable that the effects of time on COHb and TBCO are 
not very significant. Even though they are arithmetically significant for COHb, the differences 
over one month of less than 1% COHb will not affect the interpretation of toxicological 
findings. Studies with prolonged storage time should be carried out to examine the long-term 
effects. Another aspect that needs to be taken into consideration is that these tests were 
performed on non-human blood. Despite the similarities in blood density and Hb 
concentrations between bovine and human blood, it is possible that results might differ when 
using human blood. Nevertheless, I believe that these differences would not be very significant. 
Furthermore, this study focused on investigating storage parameters, not considering PM 
changes occurring when dealing with forensic cases. Therefore, the models generated here are 
applicable to clinical cases, but when dealing with forensic cases, PM changes need to be taken 
into consideration for interpretation of the results. Nevertheless, I believe that the models can 
be used to assess the storage conditions and are to be added to the interpretation of potential 
PM changes. An additional aspect that might limit this study is the instrument’s limit of 75% 
on COHb measurements. However, considering that from a toxicological perspective, the 
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findings will not change based on whether the COHb concentration is at 75% or above (CO at 




In this study, I have not only compared two biomarkers and detection methods (COHb 
measured via CO-oximetry and TBCO measured via GC-MS) for the application in CO 
poisoning determinations but also investigated the nature and magnitude of effects caused by 
different storage conditions on the accuracy of the obtained measurement results by both 
biomarkers. 
The significant discrepancy between TBCO and COHb is shown by the weaker correlation 
found between the two measures, as opposed to correlations of previously reported studies, 
who used to flush the calibrators prior to analysis. This affirms the importance of the 
measurement of free CO in addition to bound CO to obtain results that more closely correspond 
to the true pathophysiological levels.  
Furthermore, TBCO appears to be more stable during storage for prolonged time intervals, with 
no significant alterations observed due to different HS volumes, storage in the fridge or freezer 
and several preservatives during this period. On the contrary, COHb is affected by all 
investigated parameters, even though at different extents. This confirms that optical 
measurement methods are more prone to deliver inaccurate results due to storage conditions. 
Conversely, TBCO measurement should be promoted, especially in forensic investigations, 
where trials can be delayed and last for long periods and often require a reanalysis of supportive 
evidence. Therefore, I recommend the use of TBCO as an alternative biomarker to COHb for 
CO poisoning determinations. Moreover, unlike general storage guidelines for clinical and 
forensic toxicology (e.g. TIAFT, UKIAFT, etc.), who suggest NaF as the preservative of choice 
[15,22,58], based on our results, I generally recommend collection of samples for CO analysis 
in EDTA tubes for short storage periods (up to one month), stored possibly in the freezer or 
fridge. When COHb is analysed, it is also important to fill the collection tube at more than 50% 
of its volume and to analyse the sample as soon as possible.      
However, in laboratories or institutions where optimal storage is not possible, the use of the 
proposed correction formula provides an important tool to obtain more accurate measurements, 
even in non-optimal conditions. Additionally, in cases where spectrophotometric 
measurements are not possible due to the degradation of the sample during storage, the 
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1) Prepare polyethylene (PE) containers for blood retrieval by adding the required amount of 
preservative – 1.6g/L of Ethylenediaminetetraacetic acid (EDTA), 1g/L of sodium fluoride 
(NaF) (+ 1.2 g/L of EDTA), 4 vials of lithium heparin (20,000 IU/L), 29.98g/L of trisodium 
citrate (NaCit).  
2) Retrieve 1 L of bovine blood per preservative for fortification and ~250mL of blood per 
preservative to use for calibration curve into the PE containers.  
3) Put containers on a shaker for homogenization for 30 minutes.  
4) Analyse blood from each container via CO-oximetry to determine baseline COHb% 
content.  
5) Fortify blood with pure CO gas (various amounts, based on desired initial COHb% 
saturation, which is determined with analysis of a sample with CO-Oximeter at regular 
intervals of 10 minutes), 
6) Waiting for homogenization of blood (sample is put on a shaker for 30 minutes).  
7) Filling of the previously labelled and stacked blood tubes (monovettes).   
8) Analyse samples of Day 0 via CO-oximetry and GC-MS. 
9) Storage of the remaining samples according to their intended storage condition.  
Day X 
 
1) Retrieve samples from storage location – for frozen samples, make sure that samples are 
thawed at least 30 minutes prior to analysis to allow complete thawing.  
2) Prepare samples and analyse them according to protocol. 
3) After analysis, store samples that need to continue storage into its allocated storage place, 
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Chapter 5 - Improvement of 
measurement error in carbon 
monoxide exposure assessments: 




Recently there have been significant developments in methods to measure CO and determine 
individual CO exposure estimates [29–32], which can consequently have repercussions on the 
health risk estimates and on the strength and direction of association between CO exposure and 
certain health outcomes for different exposure groups. This association is described 
numerically by the relative risk (RR) (often also reported as odds ratio or risk ratio) and can be 
significantly affected by errors in the exposure estimation especially in low-level CO 
exposures, where changes in lower concentration ranges can make a difference in the 
classification of the case into either exposed or non-exposed group [33].          
An aspect that all exposure assessment studies in environmental epidemiology have in common 
is the unavoidable disposition for uncertainty. According to Blair et al. [34], the two main 
methodological issues in epidemiological studies are confounding and exposure 
misclassification, of which the second is of greater concern than the first. In the case of a 
continuous or measured variable, exposure misclassification is called measurement error and 
can cause substantial bias in exposure estimates [35,36]. Measurement error in the assessment 
of individual exposure levels often leads to bias towards the null in estimates of health effects 
and to an underestimation of the variability of the estimates, which can have severe 
consequences [37,38]. It is, therefore, crucial to determine exposure measurement error and 
correct for it. Generally, methods to correct for measurement error are available, but a specific 
model for the assessed exposure is required and often different results are obtained based on a 
different type of error [35]. In case of CO exposure, it is of particular interest to assess the 
effects new methodological developments have on the individual measurement of CO, quantify 
the resulting differences and errors and use these to evaluate the magnitude of their effect on 
exposure estimates and health risks in a population.  




Therefore, the aim of this study is to critically explore current trends in CO exposure 
assessments and identify potential methodological gaps, with special focus on low-level indoor 
CO exposures, as well as determine their sources of error and quantify measurement errors 
arising from recent methodological and toxicological advances. For this purpose, a conceptual 
map based on the human exposure assessment graph proposed by Mark Nieuwenhuijsen in his 
book “Exposure assessment in Environmental Epidemiology” (Figure 1.6) [24], but adapted to 
indoor CO exposure and extended according to information found in the investigated literature 
will be created. The final goal is to create an updated and clear overview of the type and 
magnitude of errors in CO exposure measurements and assessments, which is then employed 
to correct exposure estimates and relative risks. This will help get closer to the true global 
burden of CO exposure and ideally will be used by public health institutes, occupational and 
environmental authorities when evaluating health risks from indoor CO levels and creating new 




5.2.1 Literature Search 
 
To be able to determine and characterize measurement errors in CO exposure assessments, a 
thorough literature search to identify studies that performed CO exposure assessments through 
measurement of CO exposures was necessary. A literature search was conducted from 
November 2018 to May 2019 in databases PubMed, Web of Science and Scopus (Table 5.1). 
A first search with the keywords ("carbon monoxide" AND (exposure OR measurement OR 
assessment)) gave 9088, 15695 and 26577 hits. I narrowed down the search by changing the 
search string to (“carbon monoxide” AND exposure AND (assessment OR measurement)) in 
order to include all studies investigating carbon monoxide and exposures related to either 
assessments or measurements. This resulted, however, in a higher number of hits for all 
databases. Therefore, I further modified the search term by using ("carbon monoxide" AND 
("exposure assessment" OR "exposure measurement")). This gave us 78 hits in PubMed, 148 
in Web of Science and 234 in Scopus. A title and abstract search of these studies was then 
carried out to include all relevant studies. Since the scope of this review is to focus on indoor 
CO levels, all studies investigating outdoor air pollution and outdoor CO levels were excluded. 
Conference papers were also excluded due to insufficient methodological details. Studies 
focusing on the biological and physiological mechanisms of CO exposures or not with CO as 




the primary scope and using animal- or cell-based approaches were also excluded since the 
main scope of this study is to evaluate human CO exposure (Table 5.2). After removal of 
duplicates, a total of 92 papers were selected.  
 
Table 5.1: Search strings used in the literature search for CO exposure assessment studies. 










"carbon monoxide" AND (exposure 
OR measurement OR assessment)  
9097 15727 26578 Nd 
“carbon monoxide” AND exposure 
AND (assessment OR measurement) 
675 1423 2572 Nd 
"carbon monoxide" AND 
("exposure assessment" OR 
"exposure measurement") 
78 148 234 Nd 
"carbon monoxide" AND 
("exposure assessment" OR 
"exposure measurement") WITH 
EXCLUSION CRITERIA 
44 59 42 92 
 
 
Table 5.2: Inclusion and exclusion criteria for literature search. 
Inclusion criteria Exclusion criteria 
Indoor CO exposure assessment studies Outdoor air pollution papers 
Human CO exposure measurement studies Outdoor CO exposure assessment papers 
Biological monitoring, personal monitoring 
and microenvironment monitoring and 






Studies with animal-/cell-based approaches   
Number of study subjects <50 
 
These were categorized according to the type of study: observational (Table A5.1a), 
experimental (Table A5.1b) and review articles (Table A5.1c). To be able to evaluate low-
level CO exposures over time, longitudinal studies provide the required detailed 
methodological information and time data, as opposed to cross-sectional studies, which 
generally focus on time point measurements [39]. Therefore, the observational studies were 




further divided into longitudinal and cross-sectional studies and only the 48 longitudinal studies 
were further evaluated. Another important parameter that defines a high-quality 
epidemiological study is study power and the related sample size. Identifying the sample size 
needed to be able to determine the smallest clinically important effects and also reduce costs 
and resources is an essential step of every epidemiological study. Sample size mainly depends 
on the accepted significance level, the statistical power, the expected effect size and variability 
of the sample [23]. Significance level (α) and statistical power (1-β) are conventionally at 0.05 
and 0.80, respectively [40]. Effect size and variability are usually determined specifically for 
each type of exposure based on previously reported studies, but generally, in order for 2-group 
comparisons to obtain statistically valid results for exposure estimates, a sample size greater 
than 50 was proven necessary. Consequently, studies with >50 study subjects were retained, 
while studies that had between 40 and 50 subjects were individually evaluated. Furthermore, 
for an exposure measure to be considered valid and accurate, especially when involving the 
use of a biomarker, measurements should be obtained with a minimum of two different 
measurement techniques [41,42]. The remaining 22 studies were thus scanned for the number 
of measures used for the exposure assessment, which left 7 studies using 2 or more exposure 
measures (Figure 5.1).          
 




5.2.2 Classification of CO exposure assessment and exposure measurement methods 
 
Classification of the methods used for CO exposure assessment in these papers revealed that 
the most employed methods are the direct ones, with 35.9% of the total studies, including only 
biological monitoring (19.6%), only personal monitoring (13%), and a combination of both 




(3.3%). Indirect methods were only used in 19.7% of the studies. However, the main method 
for CO exposure assessment was a combination of direct and indirect methods, which made 
out 44.4% of the total studies under investigation (Figure A5.1).  
 
 
Figure  5.2: Summary of frequencies for exposure assessment methods in observational CO exposure studies 
based on literature review; BM: biological monitoring, MON: environmental monitoring, PM: personal 
monitoring, Q: questionnaire, MOD: environmental modelling. 
 
Figure 5.2 shows the frequencies for each combination of exposure assessment method for the 
selected observational studies, which reflects the results when including all types of studies. 
Detailed information about the type of exposure assessment method, the measure of exposure, 
the measurement devices, the number of study subjects, measurements over time and replicates 
and the length of the observation period were extracted for the 7 selected studies and are 
summarized in Table 5.3. 
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Table 5.3: Detailed study information on selected CO exposure assessment studies; BM: biomonitoring; PM: personal monitoring; MON: environmental monitoring; MOD: environmental modelling. 







Measurement device Number of subjects Number of measurements 
in time (pi) 
Number of repetitions per 
measurement 
Number of total 
measurements 




[43] cohort BM, PM and Q ExCO and 
pCO 
MicroCO monitor and 
HOBO CO data logger 
288 subjects in 72 homes ExCO: 2 per individual 
(before and after temazcal 
use); pCO: 1 per individual 
during use 
ExCO: duplicates; pCO: 
continuous at 10s 
intervals 
288 4 weeks  Y* 
 
[44]   




CO-oximetry, breath CO 
analyser and ambient 
monitors 
36 adults, 30 children 2 measurement rounds 
(before and after temezcal 
use, not applicable to all 
participants) 
airCO: continuous during 
temezcal use at 2s logging 
interval; SpCO: 2-4 min 
intervals (central 40s 
averaged); exCO: 
triplicates with 1-2 min 
breaks in between trials 
34 before and 51 
after exposure 
measurements 
3-4 hour prior to 
temazcal use and 
within 1 h after 
 N 
 
[45]   





USB-CO Logger and CO 
monitors 
104 households (48 
traditional stove: 56 RMS) 
2 simultaneous 
measurements per stove 
type 
Continuous 104 48h  N 
 
[46]   




HOBO CO logger 60 homes pCO: 2 per household 
(before and 1 month after 
stove installation); airCO: 8 
per household (4 locations 
in house (close to stove, 
center of kitchen, just 
outside of kitchen and 
bedroom) and before and 
after stove installation) 
pCO: semicontinuous 
(1min averages); airCO: 
continuous real-time; 
repeated on 5 days for 
25% of homes 




[47]   






monitor and fixed-site 
monitors 
401 1 per participants Continuous 359 pCO:48h; airCO 
from fixed-site 




[48]   
cohort PM and MON pCO and 
airCO 
Passive electrochemical 
CO monitor and non-
dispersive infrared 
monitors (CO 10-M and 
11-M) 
194 1-4 times per child Continuous 449 20-24h  N 
 





PM and MON pCO and 
airCO 
Draeger diffusion tubes  182 intervention,  197 
control households; 161 
intervention, 154 control; CO 
personal tubes: 43 
intervention and 50 controls)  
1 per individual and 3 per 
household 
2-3 for 13 intervention 
and 12 control households  








To give an overview of the type and frequency of exposure measurement methods selected in 
CO exposure assessment studies, cohort and cross-sectional studies with enough study power 
and one or more methods for exposure measurement (n=26) were assigned to each assessment 
method and device used for CO exposure measurement (Table 5.4). Details of exposure 
assessment and measurement methods are described in the following paragraphs and displayed 
in Figure A5.2.     
 
Table 5.4: Overview of exposure assessment methods and associated exposure measurement devices 
identified in the literature review with respective references for observational and cross-sectional 

































Only studies with <50 study 










5.2.2.1 Personal monitoring 
 
The measure of exposure in personal monitoring is CO in parts per million (ppm) or milligrams 
per cubic meter (mg/m3) and was mainly determined by four types of devices: 
1) Personal CO monitors, which were fixed on the individual for the whole observation period 
and readings were taken on the selected measurement times [69]; 




2) Handheld/portable CO monitors, which are similar to personal CO monitors but carried by 
the individual in the observation location and for the whole duration of the measurement 
[70]; 
3) CO passive diffusion tubes, which were attached to the individual or the immediate 
environment of the individual for the observation period; readings were taken by measuring 
the length of the tube where a colour change can be observed [49];  
4) Real-time gas monitors, which measure the concentration in continuous mode, data was 
directly saved or sent to a computer for analysis [71].   
Measurements were generally performed over a set monitoring interval, which ranged from 
24h to 72h, with either continuous measurements or repeated measurements in intervals 
ranging from 30 minutes to full working shifts of 8h. The complete monitoring period was 
found to range between a few days or weeks to months or several seasons during a year (See 
Table 5.3).      
     
5.2.2.2 Biological monitoring 
 
For biological monitoring, measurement methods for COHb include:  
1) Pulse CO-oximetry, a non-invasive method to measure the peripheral blood CO 
concentration [75];  
2) Blood Gas Analyser (BGA) or CO-oximetry (which is part of a BGA), a 
multiwavelength photometer that measures the concentrations of blood gases based on 
their spectral absorbance when exposed to light, including CO, which is reported in 
COHb% [76]; 
3) Breath CO monitors, a CO detector with an electrochemical sensor where the CO levels 
in the end-tidal volume of expired air are measured; COHb levels are then obtained 
through calculation with a reported empirical relationship formula [73,74].     
4) Gas chromatography (GC) in combination with different detectors (Flame-Ionization 
Detector, Mass Spectrometer, etc.), which measures the CO released from a blood 
sample after having undergone sample treatment; CO concentrations are then correlated 
to COHb levels through formulae published in the literature [77];   
While personal monitors were used for prolonged monitoring intervals, biomonitoring usually 
occurred on specific time points, but included several replicates (duplicates or triplicates) on 
each analysis day as well as repeated measurements on several times of the day or different 




days after exposure. Methods 1-3 were all used in observational studies, while GC methods 
were only used in studies with a limited sample size (<50) and usually of experimental nature. 
                       
5.2.2.3 Environmental monitoring and modelling 
 
CO in environmental settings is measured as ambient air CO in either ppm or µg/m3, similarly 
to personal monitoring. The difference hereby is that while personal monitors measure the 
individual CO exposure, with environmental monitoring/modelling an average CO 
concentration is determined for a defined time period (e.g. daily, monthly, annually) in a 
specific (micro)environment (urban/rural area of delimited surface) for a specific population 
group and assigned equally to all individuals in the exposure group [78]. Outdoor CO 
monitoring mainly occurs through fixed/site monitors (passive sampling), which are positioned 
throughout a country with usually a population-based distribution (higher density in urban 
areas than rural areas) [6,79]. Averages are reported for daily, weekly, monthly or annual 
intervals and used to estimate the population exposure to CO [80,81]. For indoor CO 
monitoring, ambient CO monitors and CO alarms but also active sampling through CO gas 
analysers are used to obtain CO concentrations in specific microenvironments, such as 
households [17,45,46,49,81–83], motor vehicles [51,84,85] or occupational settings 
[12,51,56,57,86–88].  
Exposure modelling is often used in combination with personal or environmental monitoring 
(hybrid models) to validate the developed models and consequently allow these models to 
reflect the true human exposure to air pollutants over time in order to assess the health outcomes 
of air pollution exposure in the population [78]. Main categories of exposure models include 
proximity models, dispersion models, land use regression (LUR) models, human inhalation 
models (HIM) and hybrid models [89]. While these models are generally employed and more 
suitable for the assessment of outdoor CO levels, a few have been found to be employed also 
for indoor CO, such as the HIM (see Appendix A5.2).  
HIM are a type of probabilistic model that estimate the individual exposure level by taking into 
account the time spent in a microenvironment as well as the human activity (e.g. inhalation 
rates, microenvironments, etc.), physiological parameters (e.g. sex, age, height, etc.) and 
chemical and environmental conditions [90,91]. By incorporating environmental and human 
activity and physiology data, human inhalation models can provide more accurate exposure 
estimates than other types of models and have the potential to better support associations 




between air pollution and adverse health outcomes. Examples of such models for CO exposure 
include the probabilistic National Ambient Air Quality Standard (NAAQS) Exposure Model 
(pNEM) for CO (pNEM/CO) developed by the EPA in 1992 and revised in 2000 [92], the 
Simulation of Human Activity and Pollutant Exposure (SHAPE) model [16] and the Air 
Pollutants Exposure Model (APEX) [93], the latter being derived from pNEM/CO. Predictions 
from the pNEM/CO model were evaluated against observed data for subjects from two study 
areas, Denver, Colorado, and Washington, D.C. CO measurements were performed with CO 
data loggers, personal diaries and data from fixed-site monitors. The model resulted in 
overestimating the 8h exposure of people with low-level exposures and underestimating the 8h 
exposure of people with high-level exposures. Furthermore, over 10% of the daily maximum 
exposures in Denver and 4% in Washington exceeded the NAAQS of 9ppm. Additionally, 
estimates of breath CO levels from fixed-site monitors were in excess of 10 ppm, which is 
equivalent to around 2% COHb [16,92,94]. Considering that the NAAQS for CO were 
designed to guarantee blood COHb levels of the population and especially high-risk groups 
below 2%, this study confirmed the doubts of the inability of fixed-site monitors alone to 
represent the total CO exposure.  
 
5.2.3 Errors in CO exposure assessments 
 
In epidemiologic studies, there are three main classes of errors that can cause bias in the 
exposure-outcome associations and need to be considered when assessing the validity of a 
study: random errors, systematic errors and confounding (Figure A5.3). Random errors 
represent the variability in estimates due to unknown or uncontrollable causes. These can 
normally be adjusted for through repeated readings, adjusted surroundings and adequate 
sample size. Systematic errors arise when some aspect in the study design, execution or 
interpretation phase has not been performed or selected correctly. Confounding occurs when 
an observed association between an exposure and a health outcome is due to a third factor that 
was not considered but is associated with the exposure and independently affects the risk for 
the health outcome [95]. According to Sackett [96], there are 35 biases that can arise in an 
epidemiologic research study that involves the measurement of exposure, the two main ones 
being selection bias and information/misclassification bias.  
Selection bias can alter the study results through an incorrect selection of the study participants, 
which can falsely direct the study course towards the desired outcome since the study sample 
selected might not represent the general population [95].  




Information/misclassification bias includes for example recall bias, which occurs when 
individuals with a particular health outcome or characteristic remember and report their 
previous experiences incorrectly. Observer bias arises when the researcher performing the 
study has knowledge of the disease status and, as a consequence, asks more specific questions 
[96]. This can usually be avoided by performing a blinded study. Thus, the most significant 




5.3.1 Measurement error in CO exposure assessment 
 
Even though CO exposure studies all are subject to random errors, systematic errors such as 
selection bias and confounding, given that the majority of CO exposure assessment studies 
involve personal or biomonitoring, the focus is on the evaluation of errors in measurement of 
CO estimates in epidemiologic studies. Based on the investigated literature, an overview of the 
identified sources of measurement error in CO exposure assessments is presented in Figure 
5.3 and described in more detail in the following section.  
 
5.3.1.1 Biological monitoring 
 
For CO exposures, the main biomarker of exposure is COHb concentrations in blood, even 
though alternative biomarkers have been investigated, such as total blood CO (TBCO) [97], 
lactate [98], bilirubin [99], S100β [100] and troponin [101]. To obtain an accurate estimate, a 
reliable and valid biomarker is necessary [41]. Therefore, an important part of exposure 
assessment is the choice of the biomarker (Figure 5.3). The aim is to achieve the most accurate 
relationship between in vivo concentrations of the selected biomarker, the health outcome and 
the true exposure levels, which is evidently affected by the biomarker selection.  
CO in breath is being used to estimate CO exposure levels, which are obtained from the 
correlation of CO measured in exhaled breath to COHb blood concentrations [102]. However, 
measurement of CO in breath cannot account for the total CO concentration present in an 
exposed individual at the time of exposure, since it is a method that is very susceptible to intra-
subject and inter-subject variability [42]. Main sources of variability include the subject’s 
breath-holding abilities, pulmonary capacity, ventilation rate and comorbidities as well as 
random instrumental errors [102–104]. These can lead to variability between subjects, but also 




intra-subject variability that can occur due to measurements performed on different times of 
the day, with biological variation in the body due to sleeping, eating, exercise and general 
lifestyle changes within the measurement period. Repeated measurements are usually 
performed to account for the intra-subject variability [42].              
Apart from TBCO, all other alternative biomarkers are not specific for CO, but rather indirectly 
related to the toxicodynamic process of CO in a human body, hence have been found unsuitable 
for CO exposure determination due to potential confounding from other types of exposure or 
health status [21,99,105]. Estimates can be significantly over- or underestimated and 
misclassification can occur, with potentially fatal consequences.   
For specific biomarkers such as COHb and TBCO, errors can arise from various sources within 
the analytical process, including the origin of the sample, storage conditions, sample extraction 
procedures, instrumental analysis, data analysis and interpretation of the results [35,41,42,106] 
(Figure 5.3).   
   
 




Figure  5.3: Overview for conceptual map of sources of measurement error in CO exposure assessments, based on investigated literature. 
 




5.3.1.2 Origin of the sample 
 
The choice of the tissue for biomarker extraction and analysis is of relevance. Blood is the most 
commonly selected tissue for CO analysis, but breath and, in post-mortem cases, solid tissues 
such as skeletal muscle or spleen have also been tested [107,108]. However, representativeness 
of the biomarker in the selected tissue must be evaluated: distribution of a gaseous substance 
like CO is heterogeneous in solid compared to liquid specimens, therefore significant inter-
specimen variability can occur, leading to systematic errors in their estimation.    
One major contributing aspect to measurement error is time. Once xenobiotics enter the body, 
they undergo several metabolic steps (absorption, distribution, metabolism, elimination – 
ADME), which take different amounts of time. An important measure that needs to be known 
is the ‘half-life’ of a substance, which is the time needed for the concentration of the substance 
to be reduced to half the initial concentration. The shorter the half-life, the more difficult it is 
to detect a substance in human tissues and the more important it is to time the sampling 
appropriately [109]. The half-life of COHb is stated to be between 2-4 hours, depending on 
individual characteristics (e.g. ventilation rate, metabolic rate, etc.), exposure duration and 
concentration [110,111]. For clinical samples, where exposure most likely occurred within the 
last hours or days, variations can be due to time differences down to minutes between 
samplings. These differences are due to the toxicokinetic processes (blood flow can cause 
concentration differences between arterial and venous blood samples) as well as the 
biochemical behaviour of CO, such as dissociation over time (CO binding to Hb is a reversible 
reaction) or equilibration (steady-state). A small part of CO is also produced endogenously 
during enzymatic activity causing haem-degradation. [72,112,113]. For post-mortem samples, 
where most likely an acute and fatal exposure occurred, timing is significant due to several 
phenomena that occur after death during decomposition. Thermo-coagulation, putrefaction and 




Biological specimen storage is another known and major source of error when using 
biomarkers [106]. Factors that can alter CO concentrations during storage include time, type 
of preservative, temperature, freeze- and thaw-cycles, volume of air in sampling container, tube 
reopening and initial saturation [115,119–121]. Over time, degradation of the sample can occur 
due to biochemical phenomena (e.g. bacterial degradation), which can cause both CO 




generation and CO loss through chemical transformation to other substances [119,122]. 
Different preservatives and temperatures have been reported to cause both increased and 
decreased CO levels. A higher temperature can speed-up the degradation process or catalyse 
enzymatic reactions that chemically modify CO [115,120,123]. Also oxygenation of the sample 
and repeated opening of the sampling tube can cause significant CO loss [120].  
 
5.3.1.4 Pre-treatment and extraction 
 
Errors in biomarker monitoring can arise also due to specimen processing [106]. Selection of 
the extraction method is important to be able to guarantee complete recovery. For COHb, 
analysis via CO-oximetry is specific for CO and does not require extraction of the analyte, 
since it is measured directly in the blood sample, thus no error is introduced, while UV-
spectrophotometry requires the additional analysis of a matrix to obtain the full spectrum and, 
thus, introduces additional potential error sources. For TBCO, the full release of CO from the 
blood sample was established and validated through the use of a strong acid (sulphuric acid). 
Other releasing agents have been tested, however with less recovery. Another aspect important 
during the processing and analytical phase is the operator performing the steps. If multiple 
people are handling the sample, random errors may be introduced due to variations between 
laboratory technicians following the protocol differently. Therefore, it is suggested that either 
the same operator performs all the steps or that the protocol is described in specific detail [42].  
 
5.3.1.5 Instrumental analysis 
 
After proper collection, storage and processing, the sample is ready to be analysed. For 
analysis, there are several choices that need to be made to optimize the outcome, such as the 
measurement method, the instrument for analysis and instrumental setup [41,106,113,124]. 
Random errors can be introduced by instrumental or methodological errors. These are not 
known but can be controlled and accounted for through repeated measurements, daily 
calibration of the instrument and regular quality controls (QCs). Calculation of the coefficient 
of variation (CV) and interclass correlation (ICC) are some examples of how to describe and 
quantify laboratory errors. The CV can be used to determine intra- and inter-assay variability. 
ICC is an alternative to CV and measures the stability or reliability within groups or 
individuals, with the advantage of considering the impact of the intra-assay variation compared 
to the total variation [106].  




Another aspect to consider is that to make sure that no selection bias occurs, the timing of 
analysis between cases and controls needs to be the same.    
The analysis method selected is required to have the capability, reliability and validity of 
measuring the biomarker concentration with optimal accuracy and precision [41]. COHb is 
measured spectrophotometrically with a CO-oximeter, either as a separate instrument or as part 
of a blood gas analyser (BGA) [58,125,126], TBCO is measured gas chromatographically via 
GC-MS [29,127]. While COHb measures only the quantity of CO bound to Hb, TBCO is able 
to measure the total amount of CO in blood, including CO bound to Hb and free CO. Tests on 
clinical samples have shown that the amount of free CO can vary from 10 to 80% between 
subjects [127], which can have a significant impact on individual exposure estimates. However, 
these analyses were performed on a limited number of subjects, therefore further tests are 
needed to confirm the magnitude of these variations.  
 
5.3.1.6 Data treatment and interpretation of results 
 
A final, but nonetheless important potential source of errors is the data treatment and 
interpretation of results part. Analysing and interpreting the results correctly can have a crucial 
impact on the subsequent use of these results for group estimates or risk or incidence rates, 
which are then employed by public health and environmental institutions to set-up strategies 
for disease prevention and control. The choice of the software, as well as the statistical methods 
and protocols for data treatment, can cause substantial misclassification bias. A simple error as 
choosing a paired instead of an unpaired Student t test can cause a change in the significance 
of the p-value or confidence interval (CI), thus classifying the measured concentrations into 
the wrong group (disease vs control). Therefore, it is very important that the laboratory 
personnel performing the data analysis is well trained, with sufficient and appropriate 
experience and background in the topic. Another aspect that might influence the interpretation 
of the results is observer bias. If the person performing the analyses is aware of the subject’s 
health status and the study aim, he might direct the data treatment towards the desired outcome, 
thus biasing the results [96]. This can be minimized by blinding a study.  
 
5.3.1.7 Personal monitoring 
 
As opposed to biomonitoring, in personal monitoring, exposure to CO is not measured as a 
dose in the body, but as concentrations of CO in the immediate environment of an individual, 




which should represent the closest estimates of the true personal exposure. Therefore, it is 
important that the relationship between personal CO (pCO), the effective in vivo concentration 
and the true exposure are accurately determined. These then are correlated to the true exposure 
and can be extrapolated to the general population through probabilistic modelling techniques. 
The errors introduced during the estimation and extrapolation process cannot be completely 
removed, but it can be minimized through appropriate exposure assessment and error correction 
methods [5,38]. The first step is the relationship between personal exposure and biological dose 
measurements. Correlation between pCO and COHb in blood has been determined by 
performing studies that simultaneously employed CO monitors and blood COHb 
measurements [128,129]. The first study investigating an empirical relationship between CO 
exposure and COHb levels was by Coburn, Foster and Kane (CFK), who are known to have 
developed the CFK-model describing the physiologically-based pharmacokinetic (PBPK) 
model for CO [130]. The model has since been expanded by other study groups [131–134] but 
the CFK-model remains the preferred mathematical PBPK model for pCO/COHb calculations 
and predictions. However, this model not only relies on a study cohort with a low number of 
participants, but it also does not take into consideration the magnitude and effects of free CO 
in blood and extravascular tissues, which has been the focus of extensive debates recently 
[14,29,127,135,136]. Changes in the effective amounts of CO in blood (total CO, not only 
COHb) can invalidate the equations and models used so far for CO estimations and predictions 
if the changes are too significant.  
Another aspect to consider is the differences in short-term vs long-term and low-level vs high-
level CO exposures. CO monitors usually are employed by measuring the CO exposure for 
limited amounts of time and for only limited repeated measurements, which are then averaged, 
therefore potentially being unable to register sudden, short-term increased exposures. Also, 
averaged measurements tend to attenuate the results, not reflecting extreme increases or 
decreases in the CO concentrations, which are however important for diagnostic purposes. The 
number of repeated measurements is also important since a single or a low number of 
measurements are a poor indicator of usual exposure [55,137,138].   
The distance of the monitor to the person is an additional factor to be considered. To be accurate 
and truly reflect the exposure of the individual to CO, the monitor should be located right next 
to the nose or mouth, however, due to practical infeasibility, they are usually carried in a 
backpack or suitcase or, especially for children, allocated beneath an individual’s face, such as 




on the back or chest [45,48,57,87]. This could potentially lead to underestimated measurements 
since CO is a gas lighter than air and tends to rise [139].  
Regarding the analytical process and the instrumental characteristics, measurement error can 
arise similarly to biomonitors due to random instrumental errors, instrumental or 
methodological inadequacy and due to different personnel performing the analyses as well as 
the data treatment and interpretation. Inter- and intra-assay variation can occur also due to day-
to-day variability or sampling times that differ between runs or cases and controls [38,42].  
Furthermore, some CO monitors are temperature-dependent, resulting in differences in results 
based on the time of the year or the location the measurements were performed [140]. Spatial 
variability of CO can potentially bias the measurements, both increasing and decreasing CO 
concentrations, if a monitor is not placed on the individual, but rather in an indoor environment 
and used as a surrogate for personal CO exposure (e.g. kitchen) [6,80].      
 
5.3.1.8 Environmental monitoring/modelling  
 
Following the correlation of pCO and blood COHb levels, which results in estimates for 
individual CO exposure, correlations between pCO and environmental CO concentrations lead 
to group estimates, which can be used to obtain population CO exposure and risk levels. pCO 
and environmental CO levels have been linked by application of models such as pNEM/CO 
and APEX to environmental or personal exposure studies, such as in the Denver and 
Washington population [92,94,141]. Issues with these studies have been highlighted 
previously, where exposures were both over- and underestimated, based on the levels of 
exposure (high vs low) [94,135]. Alterations to the correlation of measures of exposure and 
individual estimates can consequently also significantly affect this type of environmental 
modelling in population studies. Measurement error in environmental CO studies have been 
investigated and thoroughly discussed by various research groups, however, the impact of 
individual exposure measurement error was never directly related to the group estimates 
[33,35–38,55,80,142–145].   
 
5.3.1.9 Combination of methods 
 
The findings of the model prediction evaluations (e.g. from the pNEM/CO study) indicate that 
models alone cannot accurately determine personal exposure to a pollutant such as CO. A 
problem associated with indirect exposure assessment methods is that they generally result in 




exposure estimates for outdoor sources and/or (micro)environments since this is where most 
monitoring sites and satellites are located. However, for the association with health outcomes, 
it is important to take into account the total/cumulative human exposure that represents not 
only the outdoor sources of exposure but most of all the indoor sources of exposure. Indoor 
exposure accounts for the major exposure pathway since people generally spend more time 
indoors than outdoors. Personal exposure/ambient exposure concentration ratios tend to vary 
substantially by location and microenvironment. Even though ambient exposure estimates 
might have been validated, personal exposure errors, which are difficult to eliminate, can still 
exist and thus affect the overall relationship between exposure and health outcome. Therefore, 
it is reasonable that the majority of studies assessing CO exposure use a combination of direct 
and indirect methods to obtain their results. Relevant studies in our review showed that the 
most common approach is to use a combination of three methods: personal or biological 
monitoring together with environmental monitoring or modelling and questionnaires (17.2%, 
Figure 5.1) are used to determine duration and frequency of exposure to different types of CO 
sources, the number of cooking and heating appliances as well as typical living and working 
patterns. Some studies employed a combination of personal monitoring with environmental 
monitoring/modelling (8.6%). Other common combinations include biological monitoring 
aided by the use of questionnaires, which make up 8.6% of the total studies under investigation. 
The majority of the studies in Figure 5.1 were usually limited to a low number of study subjects 
(<50), resulting in a lower power for epidemiologic studies. Only seven studies were identified 
that met the criteria for high-quality CO exposure assessments with a sufficient study power 
and that used a minimum of two methods to measure CO [43–46,49–51,53].  
Out of these seven studies, only the study by Thompson et al. [43] performed a validation study 
(see Table 5.3). Validation is, however, a crucial step in an epidemiologic study to guarantee 
an accurate estimate of the exposure-outcome association. With a validation study (or, in 
absence of the true exposure, a reliability study) an important part of the error burden on 
exposure assessments relying on exposure measurement is taken into account and corrected 
for. This is particularly important for exposures that rely on biomarkers, such as in the case of 
CO [37,41,42].  
 
5.3.2 Calculation of measurement error improvement based on an example 
 
Every individual is exposed to CO from background levels present in the atmosphere. These 
are usually not toxic, but create a baseline CO level that is above zero [146]. The baseline level 




changes from person to person, not only due to inter-person variability but also to confounders 
such as smoking. Smokers have a CO baseline level that is significantly higher than for non-
smokers in the population. As already mentioned in a chapter 2 (section 2.5.2), baseline COHb 
levels for smokers can range from 3-8% for normal smokers (15-25 ppm), while for heavy 
smokers levels of 10-15% are reached (30-40 ppm) [107,147]. To measure whether population 
groups are exposed to indoor CO levels, biomarker cut-offs are common to differentiate 
between exposed and non-exposed individuals, taking into account their CO baseline level 
[10].  
When improving the measurement method for CO exposure, the measurement error affected is 
non-differential, since samples and the measurement device do not vary between exposed and 
non-exposed groups and, thus, neither do bias and error variance [148]. Since individual 
measurements are improved, which are part of a population sample that is then averaged to 
represent the population, we are improving classical measurement error [37].  
Improvement of the method for CO measurement involves a biomarker that not only measures 
CO bound to Hb but also the amount of free/dissolved CO in blood. This means that the method 
gives more accurate results, with values approximating the true value better. Therefore, the 
sensitivity of the method is improved by reducing the systematic bias coming from an 
inaccurate biomarker.  
Precision of the measurement is defined as the measure of variation in the measurement error 
in the population, which is independent of the measurement accuracy, and described by the 
variance (square of standard deviation) [148]. By having an improved biomarker and 
measurement method, not only is accuracy increased, but also precision, since we decrease 
measurement error in the measure, which is reflected in the population estimate as well.     
The range of detection of the biomarker is also expanded, thus potentially increasing the 
variability of the exposure estimate in the population. Nevertheless, better accuracy should also 
lead to a narrower confidence interval.  
Furthermore, from an exposure group perspective, this also means that sensitivity (probability 
of correctly classifying a truly exposed subject as exposed) and specificity (probability of 
correctly classifying a non-exposed subject as non-exposed) of the exposure were improved, 
since more accurate results lead to reduced misclassification in exposed/non-exposed groups. 
Therefore, this should change the proportion of the exposure in the population and affect the 
relative risk.      




These improvements result in more accurate CO estimates when comparing the improved 
biomarker total blood carbon monoxide (TBCO) to COHb measurements, thus decreasing 
classical measurement error [97]. The general aim is to determine the potential impact that 
measurement error for CO exposure measurement has on the RR of CO exposures.  
 
5.3.2.1 Study protocol 
 
For continuous measures, a simple model of measurement error is described by the following 
equation[42]: 
𝑋𝑖 = 𝑇𝑖 + 𝑏 + 𝐸𝑖 (1) 
With X: observed/measured exposure; T: true exposure; b: bias (systematic error that occurs for all subjects in 
population); E: inter-subject error (from sources of error such as choice of measurement method, omissions or 
variations in execution of protocol, etc.) differs in each subject i.  
To be able to quantify the impact, an observational study based on the results of the critical 
review of the relevant literature, which identified the most valid CO exposure assessment 
studies available so far, was selected.  
Out of these, the study by Thompson et al. [43], who reports results of the comparison between 
personal CO monitor (pCO) and exhaled breath CO (exCO) measurements (which were back 
calculated to COHb with the use of formulae), was selected and the data reported in the study 
employed to quantify the effect improved COHb levels would have on the RR.  
 
5.3.2.2 Calculation steps 
 
1. To perform the calculations, two main scenarios are taken into consideration, one for each 
exposure measurement (EM) method. In this study, the first scenario is COHb measured 
via pCO, scenario two is COHb measured via exCO. Each scenario differs from each other 
by their observed standard deviation (SD), which is inherent to the EM method and 
obtained by the data reported in the study [43].  
 
2. Furthermore, each scenario has a different set of parameters, with variables tested over a 
certain range (see descriptions below).  
 
3. σT is the true standard deviation (SD – square root of true variance) of the exposure 
estimate, which is unknown; however, it is known that the variance of the observed measure 




X is greater than the variance of the true measure T in the population since the observed 
measure is affected by measurement error [2]. Mathematically, this is also true for the SD, 
which justifies the assumption of σT being smaller than σX. As in the study at hand we have 
observed SDs of between 7 and 9 for the two proxy methods, we have selected a “dummy” 
true SD that is smaller than the observed ones. For mathematical simplicity, we have set σT 
was at 5. It is, however, possible indeed that the true SD is even smaller than that, which 
would make the results of the calculations more substantial, or also the other way around. 
This assumption can be changed numerically based on the case under investigation. 
 
4. σX (the observed SD) is calculated from the data in the selected study [43] from the given 
data of minimum, maximum, median, sample size and 25th and 95th percentile (with 
assumption of normal distribution), based on the equation (13) given in the study by Wan 
et al. [149] for estimation of the standard deviation when it is not given in the original 
study.  
 
5. The difference between true and observed measure and, thus, true and observed variance, 
is the amount of variance that is due to measurement error [37]. σ2E is the variance of the 
error and is calculated by subtracting the variance of the true exposure (square of true SD) 
from the observed exposure (square of observed SD). The SD of the error is then calculated 
as the square root of the error variance.  
 
6. There are several sources of error that contribute differently to the total error (see critical 
review for details). The relative error contribution represents the relative amount of the 
observed error that can be attributed to a source of error; different scenarios are tested, 
which are based on error estimates either mentioned in the study or obtained from other 
studies using the same method/device/parameters. This range is variable and adaptable to 
different studies.   
 
7. The next step involves assumptions to be made on the relative improvement made on the 
error contribution of the error by improving certain sources of errors. I hereby selected an 
improvement range of 20%-80%, based on the results obtained from the clinical study with 
comparison of COHb and TBCO as biomarkers for CO poisoning determination [97].  
 




8. To calculate the amount of improvement on the observed exposure that these improved 
errors would have, first, the net remaining fraction of error SD in the improved exposure 
estimate is determined, which is calculated by multiplying the relative error contribution 
with the relative improvement of the error contribution and subtracting that from 1. 
 
𝜎𝐸𝑁𝑒𝑡𝐼𝑚𝑝 = 1 − (𝜎𝐸𝐶𝑅 ∗  𝜎𝐸𝐶𝑅𝐼𝑚𝑝)  (2) 
 
9. To obtain the variance of this net fraction, σENetImp is squared.   
 
10. The absolute improved error variance can be calculated by multiplying the net fraction 
σ2ENetImp with the original error variance.  
 
11. From this, the improved exposure estimate is calculated by adding the true variance with 
the improved error variance.  
 
12. The average magnitude of errors (both classical or Berkson type) for continuous measures 
is described by the standard deviations (σX) or variances (𝜎𝑋
2). Classical measurement error 
is described by the coefficient of reliability ρXX, which is equal to the square of the validity 
coefficient, which is the correlation between the true and observed/measured exposure 
variance, ρXT [37,42]. In linear regression, the reliability coefficient is represented by the 
attenuation of the slope [150].  
𝜌𝑋𝑋 =  𝜌𝑋𝑇




2    (3) 
 
13. An improved reliability coefficient ρXXImp is calculated by using the improved σ2XImp 
compared to the true variance. The validity coefficient ρXT can range between zero and one, 
with a value of one meaning that X is a perfectly precise measure of T.  It can be estimated 
in a validity study by the Pearson correlation coefficient of X with T (for linear regressions). 
Thus, the square of the validity coefficient, which is equal to the reliability coefficient ρXX, 
represents the proportion of X explained by T, with the remaining part being variance due 
to error [42].  
 




14. Since the RR was not reported in the selected study, a literature search for a study with 
similar study area, population and parameters was performed, resulting in a study by 
Hubbell et al. to be the most suitable in providing RRX [151].  
 
15. The improved RR is calculated by using the observed RR and taking the fraction of 







  (4) 
 






)  − 1  (5) 
 
 
5.3.2.3 Calculation output 
 
It is clear from the review of the literature that there is a substantial gap in indoor CO exposure 
assessments, with a lack of sufficiently high-quality CO exposure assessment studies fully 
considering and correcting for measurement error. Therefore, out of the seven studies that were 
identified as performing high quality indoor CO exposure assessments, the one by Thompson 
et al. [43] was selected as an example, since it was the only one that performed a validation 
study. Having in mind the sources of measurement error overview (Figure 5.3), the sources of 
error in the study were determined and summarized in Table 5.5. Measurement error 
improvement calculations were then carried out and used to calculate the effect on relative 
risks. Table 5.6 summarizes the results of the calculations of measurement error improvements 
and the effect on the relative risks for two different exposure measurement methods (EMM), 
COHb measured with a personal monitor and COHb measured through an exhaled breath 
device. Detailed results of the calculations are found in Table A5.2. Table A5.3 provides a 
description of the abbreviations and acronyms used in the calculation process.  
It can be observed that for sources of error that contribute from 5 to 70% to the total 
measurement error, by using an improved measurement method that improves the 
measurement from 20-80%, the RR is increased by <1% to a maximum of 18.28% for exCO 




and from <1% up to 28.96% for pCO. The higher the error contribution, the more influential 
the exposure measurement improvements, and, thus, the closer we get to the true RR. These 
results also show that for pCO the improved RR is higher than for exCO.  
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Table 5.5: Identified sources of measurement error in the study by Thompson et al. based on the measurement errors in CO exposures overview (Figure 5.3) with references; 
BM: biological monitoring, PM: personal monitoring; B1: Error resulting from the endogenous CO levels, B2: error deriving from the choice of a less accurate biomarker such 
as exhaled CO (exCO), B3: error deriving from the analytical process, which in this case is the use of the exhaled breath CO monitor and is given in the study, P1: error deriving 
from the use of the CFK equation to relate pCO to the true CO exposure estimate, P2: error deriving from the use of averages for short-term and long-term exposures, P3: error 
deriving from the position of the monitor, in this case, non is present since the monitor is located in the optimal position, P4: instrument accuracy is reported in the study for 
the personal CO monitor, P5: there is no error deriving from an insufficient number of readings since continuous measurements are performed, P6: there is no inter-reader 
variability since the data is logged automatically, P7: error deriving from temperature dependence, P8: no error from the daily or time of day variability since monitoring is 
performed for 24h intervals over 4 weeks, P9: no error deriving from location or space variability since the spaces are on average the same size 
Error class Error type Error description Error estimate [%] Reference 
BM B1 Endogenous exposome 1.0 [151] 
B2 Choice of biomarker – ExCO 8.5 [109] 
B3 Analytical Process – Instrumental Analysis 1.0 [61] 
PM P1 pCO-total CO relationship (use of CFK equation) 8.5 [139] 
P2 Short-term vs long-term exposure – use of averages 1.2 [152] 
P3 Position of CO monitor 0 [61] 
P4 Instrument accuracy/sensitivity 7.0 [61] 
P5 Number of measurements – continuous readings 0 [61] 
P6 Inter-reader variability – automated data-logging 0 [61] 
P7 Temperature dependence 5.0 [61] 
P8 Daily variability/time of day variability – 24h 
measurements over 4 weeks 
0 [61] 
P9 Location/space variability – same size for ovens 0 [61] 




Table 5.6: Summarized results of measurement error improvement calculations on data from the study by Thompson et al. [127]; ]; σT: standard deviation of true estimate; σ
X
: 
standard deviation of observed estimates; σ
2
X
: variance of observed estimate; σ
2
E
: variance of error; σ
ECR
c modifiable fraction of relative contribution to standard deviation of 
error; σ
ECRImp
: Fraction of σ
ECR
 reduced in improved x; σ
2
ENetImp
: Net remaining fraction of error standard deviation in improved x; σ
2
EImp




improved variance of x; RR
X
: observed relative risk; RR
XImp
: improved relative risk; %RR
Imp
: Relative improvement of RR. 
 
   
 
EMM σT σX σ2X σ
2
E σECR σECRImp σ
2
ENetImp σ²Eimp σ²Ximp RRX RRXImp %ImpRR 
COHb 
via pCO 






1.22 1.22-1.36 0.28%-8.63% 
COHb 
via exCO 






1.22 1.22-1.30 0.23%-6.47% 




5.4 Discussion  
 
This study aimed at critically evaluating current CO exposure assessment studies, in order to 
determine their advantages, identify potential pitfalls and create a better understanding of how 
different sources of error can affect exposure estimates and relative risks, with a special focus 
on low-level indoor CO exposures, which were identified as an undervalued exposure risk. 
After a thorough examination of the relevant literature, a conceptual map of sources of error 
and measurement error in CO exposure assessment studies, which was based on the model 
described by Mark Nieuwenhuijsen [24], was developed. This was then applied to a selected 
study to help determine and quantify the sources of measurement error and employed to 
calculate how alterations in the error contributions influence exposure and risk estimates.   
Exposure measurement error, or misclassification of exposure, is a significant limitation of 
epidemiologic studies, due to the fact that exposures occur in different locations over varying 
periods of time and due to feasibility, cost and efficiency matters of obtaining accurate 
individual exposure estimations [5,34]. Large uncertainty in exposure measurement leads to a 
large error in relative risk estimates, thus it is paramount to have valid and reliable 
measurements of exposure, which includes the correct determination and interpretation of 
measurement errors.  
Based on this critical review, the exposure assessment method selected (e.g. biological 
monitoring, personal monitoring), there are different types and amounts of error sources that 
can affect the exposure measurement and, thus, the exposure estimate. For an exposure 
assessment to achieve robustness and validity, it is important to take all the relevant potential 
sources of error into account when designing the study. Clearly, not all listed errors are relevant 
for every CO exposure study. It depends on the type of exposure investigated (e.g. occupational 
vs recreational), the exposure group that is investigated (e.g. pregnant women vs. bus drivers), 
the area of interest (e.g. school vs kitchen) as well as the main aim of the study (e.g. association 
to certain health outcomes vs comparison between exposure groups) [24]. The choice of these 
parameters in a study delineates the types and amounts of potential errors arising, there is no 
fixed rule generally applicable to all epidemiological exposure studies, but for an exposure 
assessment to be valid, measurement error needs to be minimized, in order to get closer to the 
true exposure estimate [154]. Classical measurement error usually biases effect measures 
towards the null value (indicating no association). This can have serious adverse effects [37], 




for example in cases where potentially harmful levels of CO are not correctly detected and, as 
a consequence, proper treatment is not administered, leading to adverse health effects. 
The ideal situation is where a method can estimate the true exposure. This is, however, usually 
not the case in epidemiological studies. As an alternative, proxies are used in combination with 
measurement error correction methods that have been proposed, such as regression calibration 
[36], simulation extrapolation, bootstrapping [47] or moment reconstruction [155]. In all these 
measurement error correction methods, the assumption is that there is a validity or reliability 
study available. A validity study is a study in which the exposure is measured for a subset of 
individuals with two methods, one giving high accuracy, a “golden standard”, and one “proxy”. 
This is why often a combination of biomonitoring and personal monitoring or personal 
monitoring and environmental monitoring are used. The alternative to a validity study is a 
reliability study, where in the subset of individuals the exposure is measured with the same 
method, but repeatedly and independently [148,155].       
In the selected example study by Thompson and colleagues [43], two methods are used to 
estimate CO exposure, biological monitoring (exhaled breath CO monitor) and personal 
monitoring (personal CO monitor). However, neither of these methods measure the true 
exposure. Therefore, in a previous study, a more accurate biomarker that could improve the 
measurement of CO and get closer to the true value of CO exposure was developed. The 
developed biomarker is called TBCO and measures the total amount of CO present in blood, 
both the free fraction and the one bound to Hb. Results showed that for clinical cases, 
differences between 10 to 80% were found between COHb and TBCO measurements [97]. I 
then wanted to use this new method to see the effects that improving the measurement method 
could have on measurement error and, as a consequence, on the relative risk of CO exposure 
in the given example. As a general trend, it is observed that with reduced measurement error 
variance, an improved reliability coefficient and consequently a higher RR are obtained. 
Depending on the size of the error contribution (σECR) and the relative improvement of that 
error source (σECRImp), the improvements on the RR vary from very small (<1%) to relatively 
substantial (29%). Similar relative improvements are obtained in other studies looking at 
measurement error correction in outdoor CO exposures [156] as well as other air pollutants 
[47,142]. Even though these studies look at outdoor and not indoor air pollution, it is reassuring 
to know that the values obtained in our simulation are in the same range as reported by other 
research groups. From an epidemiological point of view, improving the RR from 1.22 to 1.57 
is relatively moderate, especially considering that a source of error is unlikely to have a 




contribution of 70% (such as in the most extreme case displayed), but more in the range of 5-
30%, thus having an improved RR of ~1.32. However, if we consider that CO exposure 
generally has a rather small RR and in light of the fact that measurement error contributes one 
part of the total error sources in epidemiological studies, it can be seen as a significant 
achievement to improve the RR by approximately 1-30%, solely by improving the 
measurement method. Additionally, when looking at other types of exposures investigated in 
epidemiologic studies, for example, where one group might be exposed to a certain chemical 
due to an occupational hazard and another group is not, the RRs in these cases vary 
substantially from group to group, due to the absence of the evaluated exposure in one of the 
groups. In the case of CO exposure, it is important to bear in mind that CO is ubiquitous and 
everyone is exposed to it, even if at different levels. The RRs obtained in these cases do not 
differ greatly from one group to another, making a difference from 1.22 to 1.32 a significant 
improvement.   
Having a closer look at the improvements for the different methods, it can be seen that the 
highest relative improvements are obtained for the method with the higher observed SD (here 
pCO). This is in congruence with what was reported by Armstrong in his 1998 study [37] as 
well as his more recent chapter with Basagaña [155], where they showed that measurement 
error will have less effect if the true exposures are more spread out. They stated that 
measurement error needs to be relatively important to cause significant bias, which is obviously 
very reassuring but should not be underestimated.            
Another aspect that is affected by classical measurement error is study power. Increased 
measurement error reduces study power. According to a study by Lagakos [157], measurement 
error in a study should be reduced by improving accuracy, but only when the proportional 
increase of the reliability coefficient is less than the proportional increase in the total study cost 
per individual that is needed to achieve it. As an example, if the reliability coefficient is 
increased by 50% with spending 40% more money per individual, it is worth it, but if the cost 
in this example would be 70%, the increased accuracy would not be worth the additional cost 
[155,157]. In our study example, the increases in reliability coefficient for error contributions 
of 5-30% range from 1-30%. The additional cost per study subject is unknown since no data is 
available on the cost for the measurement devices used in the study under investigation. 
Assumptions can be made on the cost of using a portable electrochemical sensor (the principle 
behind personal monitors and exhaled breath CO monitors) compared to a GC-MS instrument, 
with portable electrochemical sensors known to be cheaper than GC-MS. Based on the size of 




the error contribution, the probability is higher for higher contributions that the cost might be 
worth it, whereas for only small error contributions, it is more recommendable to keep 
employing the less accurate method. Nevertheless, study power is also achieved with an 
increased sample size. With an increased coefficient of reliability, study power increases and 
lower sample size is required to be able to find the same statistically significant association, 
thus reducing the cost of the study [149,155]. This should also be taken into account when 
deciding whether improving the accuracy of a measurement method is worth the cost. 
An additional element to consider in our improvement calculations is the portability of the 
coefficients, such as the reliability coefficient or the RR, from one study to another. In our 
example, data for the SD and variances from one study (Thompson et al. [43]) were used, the 
RR from a similar, but slightly distinct study (Hubbell et al. [151]), with a different study 
country (Guatemala vs Haiti) and measurement device (pCO/exCO vs CO-oximetry). The 
reliability coefficient depends not only on the distribution of the error variance but also on the 
variance of the true exposures [155]. In our example, equal true variances were assumed, 
therefore the reliability coefficient is applicable to both exposure measurement methods. 
However, the ‘real’ observed RR might be different for the Thompson [43] study compared to 
the Hubbell  [151] study. The study countries are different but located in a geographically and 
socio-economically very similar area, hence it is plausible that the RRs are similar. When 
looking at the measurement devices, all three methods were compared by using COHb as 
biomarker. With CO-oximetry known to be more accurate then exCO, but pCO being a more 
complete marker for the true exposure, it is possible that the RR for the Thomson study might 
be higher [158]. A higher initially observed RR might result in a more substantial increase in 
the relative improvements of the RR, which increases their importance from a public health 
perspective, potentially shifting the decision of using the improved measurement method vs 




What beomes clear in this study is the complexity but also the importance of exposure 
assessments for CO exposures. There are numerous factors to consider when designing a study 
aimed at assessing the exposure to a pollutant, of which a major part is played by the assessment 
and reduction of potential error sources (e.g. bias, confounding, etc.). Out of these, an important 
one in exposure assessments in environmental epidemiology is measurement error. Each 
exposure type can have a variety of errors arising from different parameters inherent to the 




exposure itself, the measurement method, the instrument used, the study group as well as the 
general aim of the study, which is what makes the study design phase of an exposure 
assessment such as complex but crucial step. To help identify the sources of measurement error 
for CO exposures, I have generated a conceptual map for sources of measurement error in CO 
exposures, which represents a very useful tool helpful in simplifying CO exposure assessments 
and creating more robust, valid and accurate studies. The importance of these assessments is 
not only in identifying the sources of error but also in minimizing them. This can be done in 
several ways, including the selection of appropriate study size and study population as well as 
a suitable exposure measurement method, which combined need to give satisfactory study 
power to be able to detect an exposure that is the closest to the true exposure. In the example 
given in this study, the effect of improving the exposure measurement method on varying 
amounts of measurement error contributions was determined in a selected study and found that 
relatively moderate increases of the RR were obtained. Despite this being a single example, it 
can be used as a model applicable to other studies, showing that even small improvements in 
the study design of an exposure assessment can have a significant impact on exposure estimates 
and relative risks. Therefore, I recommend researchers wanting to perform exposure 
assessment studies for CO exposures to make use of the conceptual map and calculation model 
as part of their study design phase. I also want to highlight the importance not only of accurate 
and valid exposure assessments but also of their crucial role in providing public health institutes 
with the epidemiologic evidence for the generation of prevention, treatment and training plans, 





[1] R. Burnett, H. Chen, M. Szyszkowicz, N. Fann, B. Hubbell, C.A. Pope, J.S. Apte, M. 
Brauer, A. Cohen, S. Weichenthal, J. Coggins, Q. Di, B. Brunekreef, J. Frostad, S.S. 
Lim, H. Kan, K.D. Walker, G.D. Thurston, R.B. Hayes, C.C. Lim, M.C. Turner, M. 
Jerrett, D. Krewski, S.M. Gapstur, W.R. Diver, B. Ostro, D. Goldberg, D.L. Crouse, R. 
V. Martin, P. Peters, L. Pinault, M. Tjepkema, A. van Donkelaar, P.J. Villeneuve, A.B. 
Miller, P. Yin, M. Zhou, L. Wang, N.A.H. Janssen, M. Marra, R.W. Atkinson, H. 
Tsang, T. Quoc Thach, J.B. Cannon, R.T. Allen, J.E. Hart, F. Laden, G. Cesaroni, F. 
Forastiere, G. Weinmayr, A. Jaensch, G. Nagel, H. Concin, J. V. Spadaro, Global 
estimates of mortality associated with long-term exposure to outdoor fine particulate 
matter, Proc. Natl. Acad. Sci. 115 (2018) 9592–9597. doi:10.1073/pnas.1803222115. 
[2] A.J. Cohen, M. Brauer, R. Burnett, H.R. Anderson, J. Frostad, K. Estep, K. 
Balakrishnan, B. Brunekreef, L. Dandona, R. Dandona, V. Feigin, G. Freedman, B. 
Hubbell, A. Jobling, H. Kan, L. Knibbs, Y. Liu, R. Martin, L. Morawska, C.A. Pope, 




H. Shin, K. Straif, G. Shaddick, M. Thomas, R. van Dingenen, A. van Donkelaar, T. 
Vos, C.J.L. Murray, M.H. Forouzanfar, Estimates and 25-year trends of the global 
burden of disease attributable to ambient air pollution: an analysis of data from the 
Global Burden of Diseases Study 2015, Lancet. 389 (2017) 1907–1918. 
doi:10.1016/S0140-6736(17)30505-6. 
[3] P. Vineis, What Is the Exposome and How It Can Help Research on Air Pollution, 
Emiss. Control Sci. Technol. 5 (2019) 31–36. 
[4] R.J. Levy, Carbon monoxide pollution and neurodevelopment : A public health 
concern, Neurotoxicol. Teratol. 49 (2015) 31–40. doi:10.1016/j.ntt.2015.03.001. 
[5] S.L. Zeger, D. Thomas, F. Dominici, J.M. Samet, J. Schwartz, D. Dockery, A. Cohen, 
Exposure measurement error in time-series studies of air pollution: Concepts and 
consequences, Environ. Health Perspect. (2000). doi:10.2307/3454382. 
[6] J.Y. Son, M.L. Bell, J.T. Lee, Individual exposure to air pollution and lung function in 
Korea: Spatial analysis using multiple exposure approaches, Environ. Res. 110 (2010) 
739–749. doi:10.1016/j.envres.2010.08.003. 
[7] J. Molitor, M. Jerrett, C.C. Chang, N.T. Molitor, J. Gauderman, K. Berhane, R. 
McConnell, F. Lurmann, J. Wu, A. Winer, D. Thomas, Assessing uncertainty in spatial 
exposure models for air pollution health effects assessment, Environ. Health Perspect. 
115 (2007) 1147–1153. doi:10.1289/ehp.9849. 
[8] M. Rosenlund, F. Forastiere, M. Stafoggia, D. Porta, M. Perucci, A. Ranzi, F. Nussio, 
C.A. Perucci, Comparison of regression models with land-use and emissions data to 
predict the spatial distribution of traffic-related air pollution in Rome, J. Expo. Sci. 
Environ. Epidemiol. 18 (2008) 192–199. doi:10.1038/sj.jes.7500571. 
[9] M. Jerrett, D. Donaire-Gonzalez, O. Popoola, R. Jones, R.C. Cohen, E. Almanza, A. de 
Nazelle, I. Mead, G. Carrasco-Turigas, T. Cole-Hunter, M. Triguero-Mas, E. Seto, M. 
Nieuwenhuijsen, Validating novel air pollution sensors to improve exposure estimates 
for epidemiological analyses and citizen science, Environ. Res. 158 (2017) 286–294. 
doi:10.1016/j.envres.2017.04.023. 
[10] J.A. Raub, R.S. Chapman, B.M. Comfort, W.G. Ewald, D.T. Mage, J.P. Pinto, R.R. 
Dickerson, M.P. Zelenka, P.G. Flachsbart, M.J. Hazucha, S.R. Thom, V. Benignus, Air 
Quality Criteria for Carbon Monoxide, 2000. 
[11] K. Gardiner, W.N. Trethowan, J.M. Harrington, I.A. Calvert, D.C. Glass, Occupational 
exposure to carbon monoxide and sulphur dioxide during the manufacture of carbon 
black, Ann. Occup. Hyg. 36 (1992) 363–372. doi:10.1093/annhyg/36.4.363. 
[12] E. Dos Santos, A. Villa, R. Garnier, L. Dufayet, J. Langrand, Surveillance and 
Analysis of Occupational Carbon Monoxide Poisoning in the Paris Region, Ann. Work 
Expo. Heal. 61 (2017) 986–993. doi:10.1093/annweh/wxx063. 
[13] B. Croxford, G.S. Leonardi, I. Kreis, Self-reported neurological symptoms in relation 
to CO emissions due to problem gas appliance installations in London: A cross-
sectional survey, Environ. Heal. A Glob. Access Sci. Source. 7 (2008) 1–6. 
doi:10.1186/1476-069X-7-34. 
[14] C.L. Townsend, R.L. Maynard, Effects on health of prolonged exposure to low 
concentrations of carbon monoxide, Occup. Environ. Med. 59 (2002) 708–711. 





[15] J. Wright, Chronic and occult carbon monoxide poisoning: we don’t know what we’re 
missing, Emerg Med J. 19 (2002) 386–390. 
[16] D.G. Penney, Carbon Monoxide Poisoning, 1st ed., CRC Press, Boca Raton, 2007. 
[17] S.E. Bartington, I. Bakolis, D. Devakumar, O.P. Kurmi, J. Gulliver, G. Chaube, D.S. 
Manandhar, N.M. Saville, A. Costello, D. Osrin, A.L. Hansell, J.G. Ayres, Patterns of 
domestic exposure to carbon monoxide and particulate matter in households using 
biomass fuel in Janakpur, Nepal, Environ. Pollut. 220 (2017) 38–45. 
doi:10.1016/j.envpol.2016.08.074. 
[18] L.J. McCann, R. Close, L. Staines, M. Weaver, G. Cutter, G.S. Leonardi, Indoor 
carbon monoxide: A case study in england for detection and interventions to reduce 
population exposure, J. Environ. Public Health. 2013 (2013). 
doi:10.1155/2013/735952. 
[19] L.D. Prockop, R.I. Chichkova, Carbon monoxide intoxication: An updated review, J. 
Neurol. Sci. 262 (2007) 122–130. doi:10.1016/j.jns.2007.06.037. 
[20] D. Shprecher, L. Mehta, The syndrome of delayed post-hypoxic leukoencephalopathy, 
NeuroRehabilitation. (2010). doi:10.3233/NRE-2010-0536. 
[21] D. Gorman, A. Drewry, Y.L. Huang, C. Sames, The clinical toxicology of carbon 
monoxide, Toxicology. (2003). doi:10.1016/S0300-483X(03)00005-2. 
[22] H.-L. Chen, P.-C. Chen, C.-H. Lu, N.-W. Hsu, K.-H. Chou, C.-P. Lin, R.-W. Wu, S.-
H. Li, Y.-F. Cheng, W.-C. Lin, Structural and cognitive deficits in chronic carbon 
monoxide intoxication: a voxel-based morphometry study, BMC Neurol. 13 (2013). 
doi:10.1186/1471-2377-13-129. 
[23] I.A. Kreis, A. Busby, G. Leonardi, J. Meara, V. Murray, Essentials of Environmental 
Epidemiology for Health Protection, 1st ed., Oxford University Press, Oxford, UK, 
2013. 
[24] M.J. Nieuwenhuijsen, Exposure assessment in environmental epidemiology, Oxford 
University Press, 2015. 
[25] U.S.E.P. Agency, Integrated Science Assessment for Carbon Monoxide, 2010. 
[26] World Health Organization, Environmental Health Criteria 213: Carbon Monoxide, 
1999. doi:10.1016/0160-4120(80)90163-4. 
[27] D.S. Fisher, G. Leonardi, R.J. Flanagan, Fatal unintentional non-fire-related carbon 
monoxide poisoning: England and Wales, 1979–2012, Clin. Toxicol. 52 (2014). 
doi:10.3109/15563650.2014.887092. 
[28] B.P. Leaderer, R.T. Zagraniski, M. Berwick, J.A.J. Stolwijk, Assessment of Exposure 
to Indoor Air Contaminants from Combustion Sources: Methodology and Application, 
Am. J. Epidemiol. 124 (1986) 275–289. doi:10.1093/oxfordjournals.aje.a114386. 
[29] S. Oliverio, V. Varlet, Carbon monoxide analysis method in human blood by Airtight 
Gas Syringe – Gas Chromatography – Mass Spectrometry (AGS-GC-MS): Relevance 
for postmortem poisoning diagnosis, J. Chromatogr. B. 1090 (2018) 81–89. 
doi:10.1016/j.jchromb.2018.05.019. 




[30] H. H, Z. H, Z. L, Z. Z, Y. Z, Headspace GC-MS Detection of Carbon Monoxide in 
Decomposed Blood and Hepatic Tissues, J. Forensic Sci. Criminol. 1 (2013) 1–6. 
doi:10.15744/2348-9804.1.302. 
[31] B. Widdop, Analysis of carbon monoxide, Ann. Clin. Biochem. 39 (2002) 122–125. 
[32] V. Varlet, E.L. De Croutte, M. Augsburger, P. Mangin, A new approach for the carbon 
monoxide (CO) exposure diagnosis: Measurement of total co in human blood versus 
carboxyhemoglobin (HbCO), J. Forensic Sci. 58 (2013) 1041–1046. 
doi:10.1111/1556-4029.12130. 
[33] G.T. Goldman, J.A. Mulholland, A.G. Russell, M.J. Strickland, M. Klein, L.A. Waller, 
P.E. Tolbert, Impact of exposure measurement error in air pollution epidemiology: 
effect of error type in time-series studies, (n.d.). doi:10.1186/1476-069X-10-61. 
[34] A. Blair, P. Stewart, J.H. Lubin, F. Forastiere, Methodological issues regarding 
confounding and exposure misclassification in epidemiological studies of occupational 
exposures, Am. J. Ind. Med. 50 (2007) 199–207. doi:10.1002/ajim.20281. 
[35] R.J. Carroll, Measurement Error in Epidemiologic Studies, Encycl. Biostat. (2005). 
doi:10.1002/0470011815.b2a03082. 
[36] M.T. Fahey, A.B. Forbes, A.M. Hodge, Correcting for the bias caused by exposure 
measurement error in epidemiological studies, Respirology. 19 (2014) 979–984. 
doi:10.1111/resp.12356. 
[37] B.G. Armstrong, Effect of measurement error on epidemiological studies of 
environmental and occupational exposures, Occup. Environ. Med. 55 (1998) 651–656. 
doi:10.1136/oem.55.10.651. 
[38] D. Spiegelman, Approaches to Uncertainty in Exposure Assessment in Environmental 
Epidemiology, Annu. Rev. Public Health. 31 (2010) 149–163. 
doi:10.1146/annurev.publhealth.012809.103720. 
[39] A.J. Silman, G.J. Macfarlane, T. Macfarlane, Which type of epidemiological study?, 
in: Epidemiol. Stud. A Pract. Guid., 3rd ed., Oxford University Press, Oxford, 2018. 
doi:10.1093/med/ 9780198814726.001.0001. 
[40] P. Kadam, S. Bhalerao, Sample size calculation, Int. J. Ayurveda Res. 1 (2010) 55–57. 
doi:10.4103/0974-7788.59946. 
[41] P. Vineis, V. Gallo, 1 . The epidemiological theory : principles of biomarker 
validation, in: Epidemiol. Concepts Valid. Biomarkers Identification/Quantification 
Environ. Carcinog. Expo., 2007: pp. 9–18. 
[42] E. White, Measurement error in biomarkers: Sources, assessment, and impact on 
studies, in: Mol. Epidemiol. Princ. Pract., 2012: pp. 143–161. 
[43] L.M. Thompson, M. Clark, B. Cadman, E. Canúz, K.R. Smith, Exposures to high 
levels of carbon monoxide from wood-fired temazcal (steam bath) use in highland 
Guatemala, Int. J. Occup. Environ. Health. 17 (2011) 103–112. 
doi:10.1179/oeh.2011.17.2.103. 
[44] M. Nicas, K.R. Smith, I. Ruiz-Mercado, C. Romero, L.M. Thompson, N. Lam, Non-
invasive measurement of carbon monoxide burden in Guatemalan children and adults 
following wood-fired temazcal (sauna-bath) use, J. Environ. Monit. 13 (2011) 2172. 





[45] C.A. Ochieng, S. Vardoulakis, C. Tonne, Are rocket mud stoves associated with lower 
indoor carbon monoxide and personal exposure in rural Kenya?, Indoor Air. 23 (2013) 
14–24. doi:10.1111/j.1600-0668.2012.00786.x. 
[46] A.A. Cynthia, R.D. Edwards, M. Johnson, M. Zuk, L. Rojas, R.D. Jiménez, H. Riojas-
Rodriguez, O. Masera, Reduction in personal exposures to particulate matter and 
carbon monoxide as a result of the installation of a Patsari improved cook stove in 
Michoacan Mexico, Indoor Air. 18 (2008) 93–105. doi:10.1111/j.1600-
0668.2007.00509.x. 
[47] E. Samoli, B.K. Butland, Incorporating Measurement Error from Modeled Air 
Pollution Exposures into Epidemiological Analyses, Curr. Environ. Heal. Reports. 4 
(2017) 472–480. doi:10.1007/s40572-017-0160-1. 
[48] S. Alm, K. Mukala, P. Tiittanen, M.J. Jantunen, Personal carbon monoxide exposures 
of preschool children in Helsinki, Finland - Comparison to ambient air concentrations, 
Atmos. Environ. 35 (2001) 6259–6266. doi:10.1016/S1352-2310(01)00442-3. 
[49] A.A. Commodore, S.M. Hartinger, C.F. Lanata, D. Mäusezahl, A.I. Gil, D.B. Hall, M. 
Aguilar-Villalobos, C.J. Butler, L.P. Naeher, Carbon monoxide exposures and kitchen 
concentrations from cookstove-related woodsmoke in San Marcos, Peru, Int. J. Occup. 
Environ. Health. 19 (2013) 43–54. doi:10.1179/2049396712Y.0000000014. 
[50] O. Potchter, M. Oz, S. Brenner, Y. Yaakov, I. Schnell, Exposure of motorcycle, car 
and bus commuters to carbon monoxide on a main road in the Tel Aviv metropolitan 
area, Israel, Environ. Monit. Assess. 186 (2014) 8413–8424. doi:10.1007/s10661-014-
4013-1. 
[51] A. Cattaneo, M. Taronna, D. Consonni, S. Angius, P. Costamagna, D.M. Cavallo, 
Personal exposure of traffic police officers to particulate matter, carbon monoxide, and 
benzene in the city of Milan, Italy, J. Occup. Environ. Hyg. 7 (2010) 342–351. 
doi:10.1080/15459621003729966. 
[52] T.L. Kirkham, M.W. Koehoorn, H. Davies, P.A. Demers, Characterization of noise 
and carbon monoxide exposures among professional firefighters in British Columbia, 
Ann. Occup. Hyg. 55 (2011) 764–774. doi:10.1093/annhyg/mer038. 
[53] L. Georgoulis, O. Hänninen, E. Samoli, K. Katsouyanni, N. Künzli, L. Polanska, Y. 
Bruinen de Bruin, S. Alm, M. Jantunen, Personal carbon monoxide exposure in five 
European cities and its determinants, Atmos. Environ. 36 (2002) 963–974. 
[54] B.J. Wylie, Y. Kishashu, E. Matechi, Z. Zhou, B. Coull, A.I. Abioye, K.L. Dionisio, F. 
Mugusi, Z. Premji, W. Fawzu, R. Hauser, M. Ezzati, Maternal exposure to carbon 
monoxide and fine particulate matter during pregnancy in an urban Tanzanian cohort, 
Indoor Air. 27 (2017) 136–146. doi:10.1111/ina.12289.Maternal. 
[55] K.L. Dionisio, S.R.C. Howie, F. Dominici, K.M. Fornace, J.D. Spengler, S. Donkor, 
O. Chimah, C. Oluwalana, R.C. Ideh, B. Ebruke, R.A. Adegbola, M. Ezzati, The 
exposure of infants and children to carbon monoxide from biomass fuels in the 
Gambia: A measurement and modeling study, J. Expo. Sci. Environ. Epidemiol. 22 
(2012) 173–181. doi:10.1038/jes.2011.47. 
[56] P.W. Brandt-Rauf, L.F. Fallon, T. Tarantini, C. Idema, L. Andrews, Health hazards of 




fire fighters: exposure assessment., Br. J. Ind. Med. 45 (1988) 606–612. 
[57] S. Niza, H.H. Jamal, Carbon monoxide exposure assessment among toll operators in 
Klang Valley, Kuala Lumpur, Malaysia, Int. J. Environ. Health Res. 17 (2007) 95–103. 
doi:10.1080/09603120701219303. 
[58] L.K. Weaver, S.K. Churchill, K. Deru, D. Cooney, False Positive Rate of Carbon 
Monoxide Saturation by Pulse Oximetry of Emergency Department Patients, Respir. 
Care. (2012) 232–240. doi:10.4187/respcare.01744. 
[59] J. Schimmel, N. George, J. Schwarz, S. Yousif, S. Suner, J.B. Hack, 
Carboxyhemoglobin Levels Induced by Cigarette Smoking Outdoors in Smokers, J. 
Med. Toxicol. 14 (2018) 68–73. doi:10.1007/s13181-017-0645-1. 
[60] S. Clarke, C. Keshishian, V. Murray, G. Kafatos, R. Ruggles, E. Coultrip, S. Oetterli, 
D. Earle, P. Ward, S. Bush, C. Porter, Screening for carbon monoxide exposure in 
selected patient groups attending rural and urban emergency departments in England: a 
prospective observational study., BMJ Open. 2 (2012) 9. doi:10.1136/bmjopen-2012-
000877. 
[61] H.B. Ramirez, R.F. Alvarez, G.R. Cuadrado, C.M. Gonzalez, F.R. Jerez, P.C. Clara, 
Elevated Carboxyhemoglobin : Sources of Carbon Monoxide Exposure, Arch. 
Bronconeumol. 50 (2014) 465–468. 
[62] R. Muhammad-Kah, Q. Liang, K. Frost-Pineda, P.E. Mendes, H.J. Roethig, M. Sarkar, 
Factors affecting exposure to nicotine and carbon monoxide in adult cigarette smokers, 
Regul. Toxicol. Pharmacol. 61 (2011) 129–136. doi:10.1016/j.yrtph.2011.07.003. 
[63] A.J. Cunnington, P. Hormbrey, Breath analysis to detect recent exposure to carbon 
monoxide, Postgrad. Med. J. 78 (2002) 233–237. doi:10.1136/pmj.78.918.233. 
[64] E.L. Leavens, E.I. Brett, S. Frank, R.A. Shaikh, T.R. Leffingwell, J.M. Croff, T.L. 
Wagener, Association between breath alcohol concentration and waterpipe lounge 
patrons’ carbon monoxide exposure: A field investigation, Drug Alcohol Depend. 170 
(2017) 152–155. doi:10.1016/j.drugalcdep.2016.11.010. 
[65] A.S. Lopez, A. Waddington, W.M. Hopman, M.A. Jamieson, The Collection and 
Analysis of Carbon Monoxide Levels as an Indirect Measure of Smoke Exposure in 
Pregnant Adolescents at a Multidisciplinary Teen Obstetrics Clinic, J. Pediatr. 
Adolesc. Gynecol. 28 (2015) 538–542. doi:10.1016/j.jpag.2015.04.007. 
[66] O.K. Caman, B.I. Erguder, H. Ozcebe, N. Bilir, Urinary cotinine and breath carbon 
monoxide levels among bar and restaurant employees in Ankara, Nicotine Tob. Res. 
15 (2013) 1446–1452. doi:10.1093/ntr/nts345. 
[67] W.A. Jȩdrychowski, U. Maugeri, J. Spengler, E. Mróz, E. Flak, M. Klimaszewska-
Rembiasz, R. Jacek, A. Sowa, Dose-dependent relationship between prenatal exposure 
to fine particulates and exhaled carbon monoxide in non-asthmatic children. A 
population-based birth cohort study, Int. J. Occup. Med. Environ. Health. 26 (2013) 
73–82. doi:10.2478/S13382-013-0076-4. 
[68] A.M.C. da Silva, G.P. Moi, I.E. Mattos, S. de Souza Hacon, Low birth weight at term 
and the presence of fine particulate matter and carbon monoxide in the Brazilian 
Amazon: A population-based retrospective cohort study, BMC Pregnancy Childbirth. 
14 (2014) 1–8. doi:10.1186/1471-2393-14-309. 




[69] S. Alm, A. Reponen, K. Mukala, P. Pasanen, J. Tuomisto, M.J. Jantunen, Personal 
exposures of preschool children to carbon monoxide: Roles of ambient air quality and 
gas stoves, in: Atmos. Environ., 1994. doi:10.1016/1352-2310(94)00203-W. 
[70] K.H. Dunn, S. Shulman, A.L. Stock, L.P. Naeher, Personal carbon monoxide 
exposures among firefighters at prescribed forest burns in the Southeastern United 
States, Arch. Environ. Occup. Heal. 68 (2013) 55–59. 
doi:10.1080/19338244.2011.633126. 
[71] V. Ashok, T. Gupta, S. Dubey, R. Jat, Personal exposure measurement of students to 
various microenvironments inside and outside the college campus, Environ. Monit. 
Assess. 186 (2014) 735–750. doi:10.1007/s10661-013-3413-y. 
[72] L. Wu, R. Wang, Carbon monoxide: endogenous production, physiological functions, 
and pharmacological applications., Pharmacol. Rev. 57 (2005) 585–630. 
doi:10.1124/pr.57.4.3.585. 
[73] S.I. Cohen, N.M. Perkins, H.K. Ury, J.R. Goldsmith, S.I. Cohen, Carbon monoxide 
uptake in cigarette smoking, Arch. Environ. Health. 22 (1971) 55–60. 
doi:10.1080/00039896.1971.10665815. 
[74] G. Scherer, Carboxyhemoglobin and thiocyanate as biomarkers of exposure to carbon 
monoxide and hydrogen cyanide in tobacco smoke, Exp. Toxicol. Pathol. 58 (2006) 
101–124. doi:10.1016/j.etp.2006.07.001. 
[75] G. Lindner, A.K. Exadaktylos, How Noninvasive Haemoglobin Measurement with 
Pulse CO-Oximetry Can Change Your Practice: An Expert Review, Emerg. Med. Int. 
(2013). doi:10.1155/2013/701529. 
[76] L. Dukić, L.M. Kopčinović, A. Dorotić, I. Baršić, Blood gas testing and related 
measurements: National recommendations on behalf of the Croatian society of medical 
biochemistry and laboratory medicine, Biochem. Medica. 26 (2016) 318–336. 
doi:10.11613/BM.2016.036. 
[77] J.J. Mahoney, H.J. Vreman, D.K. Stevenson, A.L. Van Kessel, Measurement of 
carboxyhemoglobin and total hemoglobin by five specialized spectrophotometers (CO-
oximeters) in comparison with reference methods, Clin. Chem. 39 (1993) 1693–1700. 
[78] B. Zou, J.G. Wilson, F.B. Zhan, Y. Zeng, Air pollution exposure assessment methods 
utilized in epidemiological studies, J. Environ. Monit. 11 (2009) 475–490. 
doi:10.1039/b813889c. 
[79] S. Kaur, M.J. Nieuwenhuijsen, R.N. Colvile, Fine particulate matter and carbon 
monoxide exposure concentrations in urban street transport microenvironments, 
Atmos. Environ. 41 (2007) 4781–4810. doi:10.1016/j.atmosenv.2007.02.002. 
[80] K.L. Dionisio, V. Isakov, L.K. Baxter, J.A. Sarnat, S.E. Sarnat, J. Burke, A. 
Rosenbaum, S.E. Graham, R. Cook, J. Mulholland, H. Özkaynak, Development and 
evaluation of alternative approaches for exposure assessment of multiple air pollutants 
in Atlanta, Georgia, J. Expo. Sci. Environ. Epidemiol. 23 (2013) 581–592. 
doi:10.1038/jes.2013.59. 
[81] K.R. Smith, J.P. McCracken, L. Thompson, R. Edwards, K.N. Shields, E. Canuz, N. 
Bruce, Personal child and mother carbon monoxide exposures and kitchen levels: 
Methods and results from a randomized trial of woodfired chimney cookstoves in 




Guatemala (RESPIRE), J. Expo. Sci. Environ. Epidemiol. 20 (2010) 406–416. 
doi:10.1038/jes.2009.30. 
[82] T. Montoya, P.L. Gurian, G. Velázquez-Angulo, V. Corella-Barud, A. Rojo, J.P. 
Graham, Carbon monoxide exposure in households in Ciudad Juárez, México, Int. J. 
Hyg. Environ. Health. 211 (2008) 40–49. doi:10.1016/j.ijheh.2006.12.001. 
[83] A. Klinmalee, K. Srimongkol, N.T. Kim Oanh, Indoor air pollution levels in public 
buildings in Thailand and exposure assessment, Environ. Monit. Assess. 156 (2009) 
581–594. doi:10.1007/s10661-008-0507-z. 
[84] G.W. Lee, M.J. Bae, J.Y. Yang, J.W. Son, J.L. Cho, S.G. Lee, B.M. Jang, H.W. Lee, 
J.S. Lim, D.C. Shin, Y.W. Lim, Decreased blood pressure associated with in-vehicle 
exposure to carbon monoxide in Korean volunteers, Environ. Health Prev. Med. 22 
(2017) 1–8. doi:10.1186/s12199-017-0622-y. 
[85] M. El-Fadel, L. Abi-Esber, In-vehicle exposure to carbon monoxide emissions from 
vehicular exhaust: A critical review, 2009. doi:10.1080/10643380701798264. 
[86] M. Apte, D. Cox, S. Hammond, L. Gundel, A new carbon monoxide occupational 
dosimeter: results from a worker exposure assessment survey, J. Expo. Sci. Environ. 
Epidemiol. 9 (1999) 546–559. doi:10.1038/sj.jea.7500058. 
[87] T. McLennon, C.Y. Hon, Exposure assessment of non-electric ice resurfacer operators 
in indoor ice rinks: a pilot study, Int. J. Occup. Environ. Health. 23 (2017) 228–233. 
doi:10.1080/10773525.2018.1468130. 
[88] W.O. Haflidson, C.S. Figueira, Carbon monoxide exposure of concrete finishers, Appl. 
Occup. Environ. Hyg. 12 (1997) 126–131. doi:10.1080/1047322X.1997.10389472. 
[89] M. Jerrett, A. Arain, P. Kanaroglou, B. Beckerman, D. Potoglou, T. Sahsuvaroglu, J. 
Morrison, C. Giovis, A review and evaluation of intraurban air pollution exposure 
models, J. Expo. Anal. Environ. Epidemiol. 15 (2005) 185–204. 
doi:10.1038/sj.jea.7500388. 
[90] M. Fryer, C.D. Collins, H. Ferrier, R.N. Colvile, M.J. Nieuwenhuijsen, Human 
exposure modelling for chemical risk assessment: A review of current approaches and 
research and policy implications, Environ. Sci. Policy. 9 (2006) 261–274. 
doi:10.1016/j.envsci.2005.11.011. 
[91] H. Özkaynak, T. Palma, J.S. Touma, J. Thurman, Modeling population exposures to 
outdoor sources of hazardous air pollutants, J. Expo. Sci. Environ. Epidemiol. 18 
(2008) 45–58. doi:10.1038/sj.jes.7500612. 
[92] T. Johnson, G. Mihlan, J. LaPointe, K. Fletcher, Estimation of Carbon Monoxide 
Exposures and Associated Carboxyhemoglobin Levels in Denver Residents Using 
pNEM/CO, 2000. doi:10.1017/CBO9781107415324.004. 
[93] T.R. Johnson, J.E. Langstaff, S. Graham, E.M. Fujita, E. David, E.P. Agency, A 
multipollutant evaluation of APEX using microenvironmental ozone, carbon 
monoxide, and particulate matter (PM2.5) concentrations measured in Los Angeles by 
the exposure classification project, Cogent Environ. Sci. 4 (2018). 
[94] P.L. Law, M.P. Zelenka, A.H. Huber, T.R. McCurdy, Evaluation of a Probabilistic 
Exposure Model Applied to Carbon Monoxide (pNEM/CO) Using Denver Personal 
Exposure Monitoring Data, J. Air Waste Manage. Assoc. 47 (1997) 491–500. 





[95] C.H. Hennekens, J.E. Buring, Epidemiology in medicine, Lippincott-Raven Publishers, 
Boston, 1987. 
[96] D.L. Sackett, Bias in analytic research, J. Chronic Dis. 32 (1979) 51–63. 
doi:10.1016/0021-9681(79)90012-2. 
[97] S. Oliverio, V. Varlet, Total Blood Carbon Monoxide: Alternative to 
Carboxyhemoglobin as Biological Marker for Carbon Monoxide Poisoning 
Determination, J. Anal. Toxicol. 43 (2019) 79–87. doi:10.1093/jat/bky084. 
[98] R. Damlapinar, F.I. Arikan, S. Sahin, Y. Dallar, Lactate Level Is More Significant 
Than Carboxihemoglobin Level in Determining Prognosis of Carbon Monoxide 
Intoxication of Childhood, Pediatr. Emerg. Care. 32 (2016) 377–383. 
doi:10.1097/PEC.0000000000000452. 
[99] G. Cervellin, I. Comelli, R. Buonocore, A. Picanza, G. Rastelli, G. Lippi, Serum 
bilirubin value predicts hospital admission in carbon monoxide-poisoned patients. 
Active player or simple bystander?, Clinics. 70 (2015) 628–631. 
doi:10.6061/clinics/2015(09)06. 
[100] Z. Cakir, S. Aslan, Z. Umudum, H. Acemoglu, A. Akoz, S. Turkyilmaz, N. Öztürk, S-
100β and neuron-specific enolase levels in carbon monoxide-related brain injury, Am. 
J. Emerg. Med. 28 (2010) 61–67. doi:10.1016/j.ajem.2008.10.032. 
[101] Y.S. Cha, H. Kim, H.H. Do, H.I. Kim, O.H. Kim, K.C. Cha, K.H. Lee, S.O. Hwang, 
Serum neuron-specific enolase as an early predictor of delayed neuropsychiatric 
sequelae in patients with acute carbon monoxide poisoning, Hum. Exp. Toxicol. 37 
(2018) 240–246. doi:10.1177/0960327117698544. 
[102] M.J. Jarvis, M. Russell, Y. Salojee, Expired air carbon monoxide : a simple breath test 
of tobacco smoke intake, Br. Med. J. 41 (1980) 886. 
[103] C.M. Ogilvie, W.S. Blakemore, R.E. Forster, J.W. Morton, A standardized breath 
holding technique for the clinical measurement of the diffusing capacity of the lung for 
carbon monoxide, J. Clin. Invest. 36 (1957) 1–17. doi:10.1172/JCI103402. 
[104] R.D. Stewart, R.S. Stewart, W. Stamm, R.P. Seelen, Rapid Estimation of Carbon 
Monoxide Level in Fire Fighters, J. Am. Med. Assoc. 235 (1976) 390–392. 
[105] K.R. Hardy, S.R. Thom, Pathophysiology and Treatment of Carbon Monoxide 
Poisoning, Clin. Toxicol. 32 (1994) 613–629. doi:10.1016/j.ncl.2009.04.002. 
[106] S.S. Tworoger, S.E. Hankinson, Use of biomarkers in epidemiologic studies: 
Minimizing the influence of measurement error in the study design and analysis, 
Cancer Causes Control. 17 (2006) 889–899. doi:10.1007/s10552-006-0035-5. 
[107] N.J. Wald, M. Idle, J. Boreham, A. Bailey, Carbon monoxide in breath in relation to 
smoking and carboxyhaemoglobin levels, Thorax. 36 (1981) 366–369. 
[108] S.C. Wu, B. Levine, J.C. Goodin, Y.H. Caplan, M.L. Smith, Analysis of spleen 
specimens for carbon monoxide, J. Anal. Toxicol. 16 (1992) 42–44. 
doi:10.1093/jat/16.1.42. 
[109] J.A. Timbrell, Principles of Biochemical Toxicology, 4th ed., CRC Press, Boca Raton, 





[110] T. Shimazu, H. Ikeuchi, H. Sugimoto, C.W. Goodwin, Half-Life of Blood 
Carboxyhemoglobin after Short-Term and, Heal. (San Fr. (2000) 1–6. 
[111] G.S. Zavorsky, J. Tesler, J. Rucker, L. Fedorko, J. Duffin, J.A. Fisher, Rates of carbon 
monoxide elimination in males and females, Physiol. Rep. 2 (2014) 1–10. 
doi:10.14814/phy2.12237. 
[112] B. Olas, Carbon monoxide is not always a poison gas for human organism: 
Physiological and pharmacological features of CO, Chem. Biol. Interact. (2014). 
doi:10.1016/j.cbi.2014.08.005. 
[113] G.S. Marks, H.J. Vreman, B.E. McLaughlin, J.F. Brien, K. Nakatsu, Measurement of 
endogenous carbon monoxide formation in biological systems., Antioxid. Redox 
Signal. 4 (2002) 271–277. doi:10.1089/152308602753666325. 
[114] P. Hill, N.J. Haley, E.L. Wynder, Cigarette smoking: Carboxyhemoglobin, plasma 
nicotine, cotinine and thiocyanate vs self-reported smoking data and cardiovascular 
disease, J. Chronic Dis. 36 (1983) 439–449. doi:10.1016/0021-9681(83)90136-4. 
[115] G.W. Kunsman, C.L. Presses, P. Rodriguez, Carbon monoxide stability in stored 
postmortem blood samples, J. Anal. Toxicol. 24 (2000) 572–578. 
doi:10.1093/jat/24.7.572. 
[116] T. Kojima, Y. Nishiyama, M. Yashiki, I. Une, Postmortem formation of carbon 
monoxide, Forensic Sci. Int. 19 (1982) 243–248. doi:10.1016/0379-0738(82)90085-8. 
[117] S. Oritani, B.L. Zhu, K. Ishida, K. Shimotouge, L. Quan, M.Q. Fujita, H. Maeda, 
Automated determination of carboxyhemoglobin contents in autopsy materials using 
head-space gas chromatography/mass spectrometry, Forensic Sci. Int. 113 (2000) 375–
379. doi:10.1016/S0379-0738(00)00227-9. 
[118] R.J. Lewis, R.D. Johnson, D. V Canfield, An Accurate Method for the Determinaiton 
of Carbon Monoxide in Posmortem Bloo Using GC/TCD, Washington, DC, 2002. 
[119] A. Ocak, J.C. Valentour, R. V Blanke, The effects of storage conditions on the stability 
of carbon monoxide in postmortem blood, J. Anal. Toxicol. 9 (1985) 202–206. 
doi:10.1093/jat/9.5.202. 
[120] D.H. Chace, L.R. Goldbaum, N.T. Lappas, Factors affecting the loss of carbon 
monoxide from stored blood samples, J. Anal. Toxicol. 10 (1986) 181–189. 
doi:10.1093/jat/10.5.181. 
[121] C.L. Winek, D.M. Prex, A COMPARATIVE STUDY OF ANALYTICAL 
METHODS TO DETERMINE POSTMORTEM CHANGES IN CARBON 
MONOXIDE CONCENTRATION, Forensic Sci. Int. 18 (1981) 181–187. 
[122] V. Varlet, E. Ryser, M. Augsburger, C. Palmiere, Stability of postmortem 
methemoglobin: Artifactual changes caused by storage conditions, Forensic Sci. Int. 
283 (2018) 21–28. doi:10.1016/j.forsciint.2017.12.009. 
[123] Y. Seto, M. Kataoka, K. Tsuge, Stability of blood carbon monoxide and hemoglobins 
during heating, Forensic Sci. Int. 121 (2001) 144–150. doi:10.1016/S0379-
0738(01)00465-0. 




[124] V. Varlet, E. Lagroy De Croutte, M. Augsburger, P. Mangin, Accuracy profile 
validation of a new method for carbon monoxide measurement in the human blood 
using headspace-gas chromatography-mass spectrometry (HS-GC-MS), J. 
Chromatogr. B Anal. Technol. Biomed. Life Sci. 880 (2012) 125–131. 
doi:10.1016/j.jchromb.2011.11.028. 
[125] M.A. Salicio, V.A.M. Mana, W.C.R. Fett, L.T. Gomes, C. Botelho, Variáveis 
ambientais e níveis de monóxido de carbono exalado e carboxihemoglobina em idosos 
praticantes de exercício, Cien. Saude Colet. 21 (2016) 1023–1032. doi:10.1590/1413-
81232015214.14502015. 
[126] C. Cronenberger, D.R. Mould, H.J. Roethig, M. Sarkar, Population pharmacokinetic 
analysis of carboxyhaemoglobin concentrations in adult cigarette smokers, Br. J. Clin. 
Pharmacol. 65 (2008) 30–39. doi:10.1111/j.1365-2125.2007.02974.x. 
[127] S. Oliverio, V. Varlet, Total Blood Carbon Monoxide: Alternative to 
Carboxyhemoglobin as Biological Marker for Carbon Monoxide Poisoning 
Determination, J. Anal. Toxicol. (2018) 1–9. doi:10.1093/jat/bky084. 
[128] A. Lee, T.R. Sanchez, M.H. Shahriar, M. Eunus, M. Perzanowski, J. Graziano, A 
cross-sectional study of exhaled carbon monoxide as a biomarker of recent household 
air pollution exposure, Environ. Res. 143 (2015) 107–111. 
doi:10.1016/j.envres.2015.09.017. 
[129] A.R. Eppler, C. Fitzgerald, S.C. Dorner, M. Aguilar-Villalobos, S.L. Rathbun, O. 
Adetona, L.P. Naeher, Using exhaled carbon monoxide and carboxyhemoglobin to 
evaluate the effectiveness of a chimney stove model in Peru, Int. J. Occup. Environ. 
Health. 19 (2013) 325–331. doi:10.1179/2049396713Y.0000000039. 
[130] R.F. Coburn, R.E. Forster, P.B. Kane, Considerations of the physiological variables 
that determine the blood carboxyhemoglobin concentration in man., J. Clin. Invest. 
(1965). doi:10.1172/JCI105296. 
[131] E.N. Bruce, M.C. Bruce, K. Erupaka, Prediction of the rate of uptake of carbon 
monoxide from blood by extravascular tissues, Respir. Physiol. Neurobiol. 161 (2008) 
142–159. doi:10.1016/j.resp.2008.01.004. 
[132] E.N. Bruce, M.C. Bruce, A multicompartment model of carboxyhemoglobin and 
carboxymyoglobin responses to inhalation of carbon monoxide, J. Appl. Physiol. 95 
(2003) 1235–1247. doi:10.1152/japplphysiol.00217.2003. 
[133] K. Erupaka, E.N. Bruce, M.C. Bruce, Prediction of extravascular burden of carbon 
monoxide (CO) in the human heart, Ann. Biomed. Eng. 38 (2010) 403–438. 
doi:10.1007/s10439-009-9814-y. 
[134] N.H. Gosselin, R.C. Brunet, G. Carrier, Determination of carboxyhaemoglobin in 
humans following low-level exposures to carbon monoxide, Inhal. Toxicol. 21 (2009) 
1077–1091. doi:10.3109/08958370902744848. 
[135] D.G. Penney, Carbon Monoxied Toxicity, CRC Press, Boca Raton, 2000. 
[136] Y. Ouahmane, J. Mounach, A. Satte, A. Bourazza, A. Soulaymani, N. Elomari, Severe 
poisoning with carbon monoxide (CO) with neurological impairment, study of 19 
cases, Toxicol. Anal. Clin. 30 (2018) 50–60. doi:10.1016/j.toxac.2017.10.003. 
[137] J.P. McCracken, J. Schwartz, N. Bruce, M. Mittleman, L.M. Ryan, K.R. Smith, 




Combining Individual- and Group-Level Exposure Information, Epidemiology. 20 
(2009) 127–136. doi:10.1097/EDE.0b013e31818ef327. 
[138] M. Ezzati, B.M. Mbinda, D.M. Kammen, Comparison of emissions and residential 
exposure from traditional and improved cookstoves in Kenya, Environ. Sci. Technol. 
34 (2000) 578–583. doi:10.1021/es9905795. 
[139] L.E. Venegas, N.A. Mazzeo, Carbon Monoxide Concentration in a Street Canyon of 
Buenos Aires City (Argentina), Urban Air Qual. Meas. Model. Manag. (2011) 417–
424. doi:10.1007/978-94-010-0932-4_45. 
[140] S. Karamchandani, Pervasive Monitoring of Carbon Monoxide and Methane using Air 
Quality Prediction, in: 10th INDIACom, 2016: pp. 1–6. 
[141] T.D. Hartwell, T.R. Johnson, G.G. Akland, R.W. Whltmore, Measuring Human 
Exposure to Carbon Monoxide in Washington, D.C., and Denver, Colorado, during the 
Winter of 1982-1983, Environ. Sci. Technol. 19 (1985) 911–918. 
doi:10.1021/es00140a004. 
[142] R. Noori, G. Hoshyaripour, K. Ashrafi, B.N. Araabi, Uncertainty analysis of developed 
ANN and ANFIS models in prediction of carbon monoxide daily concentration, 
Atmos. Environ. 44 (2010) 476–482. doi:10.1016/j.atmosenv.2009.11.005. 
[143] L.K. Baxter, R.J. Wright, C.J. Paciorek, F. Laden, H.H. Suh, J.I. Levy, Effects of 
exposure measurement error in the analysis of health effects from traffic-related air 
pollution, J. Expo. Sci. Environ. Epidemiol. 20 (2010) 101–111. 
doi:10.1038/jes.2009.5. 
[144] E. Batistatou, R. McNamee, Performance of bias-correction methods for exposure 
measurement error using repeated measurements with and without missing data, Stat. 
Med. 31 (2012) 3467–3480. doi:10.1002/sim.5422. 
[145] L. Sheppard, R.T. Burnett, A.A. Szpiro, S.Y. Kim, M. Jerrett, C.A. Pope, B. 
Brunekreef, Confounding and exposure measurement error in air pollution 
epidemiology, Air Qual. Atmos. Heal. 5 (2012) 203–216. doi:10.1007/s11869-011-
0140-9. 
[146] J.A. Raub, V.A. Benignus, Carbon monoxide and the nervous system, Neurosci. 
Biobehav. Rev. 26 (2002) 925–940. doi:10.1016/S0149-7634(03)00002-2. 
[147] J.A. Leifert, Anaemia and cigarette smoking, Int. J. Lab. Hematol. 30 (2008) 177–184. 
doi:10.1111/j.1751-553X.2008.01067.x. 
[148] E. White, B.G. Armstrong, R. Saracci, Exposure measurement error and its effects, in: 
Princ. Expo. Meas. Epidemiol. Collect. Eval. Improv. Meas. Dis. Risk Factors, 
Second, OXFORD UNIV PRESS INC, New York, 2008: pp. 65–96. 
doi:10.1093/acprof. 
[149] X. Wan, W. Wang, J. Liu, T. Tong, Estimating the sample mean and standard 
deviation from the sample size, median, range and/or interquartile range, BMC Med. 
Res. Methodol. 14 (2014) 1–13. doi:10.1186/1471-2288-14-135. 
[150] B.G. Armstrong, The effects of measurement errors on relative risk regressions, Am. J. 
Epidemiol. 132 (1990) 1176–1184. doi:10.1093/oxfordjournals.aje.a115761. 
[151] A.M. Hubbell, F.J. Jareczek, L. Vonnahme, J.M. Hockenberry, C. Buresh, Smoke 




exposure among women in Haiti: The case for improved stoves, Glob. Public Health. 8 
(2013) 822–830. doi:10.1080/17441692.2013.815793. 
[152] M.L. Bleecker, Carbon monoxide intoxication, in: Handb. Clin. Neurol., 3rd ed., 
Elsevier B.V., Oxford, UK, 2015: pp. 191–203. doi:10.1016/B978-0-444-62627-
1.00024-X. 
[153] J.E. Peterson, R.D. Stewart, Predicting the carboxyhemoglobin levels resulting from 
carbon monoxide exposures, J. Appl. Physiol. 39 (2017) 633–638. 
doi:10.1152/jappl.1975.39.4.633. 
[154] B. Armstrong, Study design for exposure assessment in epidemiological studies, Sci. 
Total Environ. 168 (1995) 187–194. doi:10.1016/0048-9697(95)98172-F. 
[155] B. Armstrong, X. Basagaña, Exposure Measurement Error, in: Expo. Assess. Environ. 
Epidemiol., Oxford University Press, 2015: pp. 201–226. 
doi:10.1093/med/9780199378784.003.0010. 
[156] K.L. Dionisio, H.H. Chang, L.K. Baxter, A simulation study to quantify the impacts of 
exposure measurement error on air pollution health risk estimates in copollutant time-
series models, Environ. Heal. A Glob. Access Sci. Source. 15 (2016) 1–10. 
doi:10.1186/s12940-016-0186-0. 
[157] S.W. Lagakos, Effects of mismodelling and mismeasuring explanatory variables on 
tests of their association with a response variable, Stat. Med. 7 (1988) 257–274. 
doi:10.1002/sim.4780070126. 
[158] S. Oliverio, V. Varlet, What are the limitations of methods to measure carbon 
monoxide in biological samples?, Forensic Toxicol. (2019). doi:10.1007/s11419-019-
00490-1. 
[159] A. Schnall, R. Law, A. Heinzerling, K. Sircar, S. Damon, F. Yip, J. Schier, T. 
Bayleyegn, A. Wolkin, Characterization of Carbon Monoxide Exposure during 
Hurricane Sandy and Subsequent Nor’easter, Disaster Med. Public Health Prep. 11 
(2017) 562–567. doi:10.1017/dmp.2016.203. 
[160] L. Tian, K. Ho, T. Wang, H. Qiu, V.C. Pun, C.S. Chan, P.K.K. Louie, I.T.S. Yu, 
Ambient Carbon Monoxide and the Risk of Hospitalization Due to Chronic 
Obstructive Pulmonary Disease, Am. J. Epidemiol. 180 (2014) 1159–1167. 
doi:10.1093/aje/kwu248. 
[161] J.H. Clower, N.B. Hampson, S. Iqbal, F.Y. Yip, Recipients of hyperbaric oxygen 
treatment for carbon monoxide poisoning and exposure circumstances, Am. J. Emerg. 
Med. 30 (2012) 846–851. doi:10.1016/j.ajem.2011.05.028. 
[162] G.M. Faé Gomes, F. Encarnação, The environmental impact on air quality and 
exposure to carbon monoxide from charcoal production in southern Brazil, Environ. 
Res. 116 (2012) 136–139. doi:10.1016/j.envres.2012.03.012. 
[163] Y. Chung, S.E. Park, K. Lee, Y. Yanagisawa, J.D. Spengler, Determinations of 
personal carbon monoxide exposure and blood carboxyhemoglobin levels in Korea., 
Yonsei Med. J. 35 (1994) 420–428. doi:10.3349/ymj.1994.35.4.420. 
[164] B.C. Leyenda, J.A. Rodriguez-Marroyo, J. Lopez-Satue, C.A. Ordas, R.P. Cubillo, J.G. 
V Vicente, Exposure to Carbon Monoxide in Wildland Firefighters during Wildfires 
Suppression, Rev. Esp. Salud Publica. 84 (2010) 799–807. doi:10.1590/S1135-





[165] P.W. Kwok, Evaluation and Control of Carbon Monoxide Exposure in Indoor Skating 
Arenas, Can. J. Public Heal. 74 (1983) 261–265. 
[166] M. Onodera, Y. Fujino, S. Kikuchi, M. Sato, K. Mori, T. Beppu, Y. Inoue, Utility of 
the Measurement of Carboxyhemoglobin Level at the Site of Acute Carbon Monoxide 
Poisoning in Rural Areas, Scientifica (Cairo). 2016 (2016). 
doi:10.1155/2016/6192369. 
[167] C. Keil, H. Kassa, A. Brown, A. Kumie, W. Tefera, Inhalation exposures to particulate 
matter and carbon monoxide during ethiopian coffee ceremonies in Addis Ababa: A 
pilot study, J. Environ. Public Health. 2010 (2010). doi:10.1155/2010/213960. 
[168] B. Koszowski, Z.R. Rosenberry, A. Kanu, L.C. Viray, J.L. Potts, W.B. Pickworth, 
Nicotine and carbon monoxide exposure from inhalation of cigarillo smoke, 
Pharmacol. Biochem. Behav. 139 (2015) 7–14. doi:10.1016/j.pbb.2015.10.007. 
[169] A.J. Nair, M. Nandini, S. Adappa, C. Mahabala, Carbon monoxide exposure among 
police officers working in a traffic dense region of Southern India, Toxicol. Ind. 
Health. 33 (2016) 46–52. doi:10.1177/0748233716654071. 
[170] J. Hang, Z. Luo, X. Wang, L. He, B. Wang, W. Zhu, The influence of street layouts 
and viaduct settings on daily carbon monoxide exposure and intake fraction in 
idealized urban canyons, Environ. Pollut. 220 (2017) 72–86. 
doi:10.1016/j.envpol.2016.09.024. 
[171] O.M. Morakinyo, A.S. Adebowale, M.I. Mokgobu, M.S. Mukhola, Health risk of 
inhalation exposure to sub-10 μm particulate matter and gaseous pollutants in an 
urban-industrial area in South Africa: An ecological study, BMJ Open. 7 (2017) 1–9. 
doi:10.1136/bmjopen-2016-013941. 
[172] M. Vigeh, M. Yunesian, M. Shariat, S. Niroomanesh, F. Ramezanzadeh, 
Environmental Carbon Monoxide Related to Pregnancy Hypertension, Women Heal. 
51 (2011) 724–738. doi:10.1080/03630242.2011.633599. 
[173] R. Neitzel, L.P. Naeher, M. Paulsen, K. Dunn, A. Stock, C.D. Simpson, Biological 
monitoring of smoke exposure among wildland firefighters: A pilot study comparing 
urinary methoxyphenols with personal exposures to carbon monoxide, particular 
matter, and levoglucosan, J. Expo. Sci. Environ. Epidemiol. 19 (2009) 349–358. 
doi:10.1038/jes.2008.21. 
[174] L. Dix-Cooper, B. Eskenazi, C. Romero, J. Balmes, K.R. Smith, Neurodevelopmental 
performance among school age children in rural Guatemala is associated with prenatal 
and postnatal exposure to carbon monoxide, a marker for exposure to woodsmoke, 
Neurotoxicology. 33 (2012) 246–254. doi:10.1016/j.neuro.2011.09.004. 
[175] D. Kim, A. Sass-Kortsak, J.T. Purdham, R.E. Dales, J.R. Brook, Associations between 
personal exposures and fixed-site ambient measurements of fine particulate matter, 
nitrogen dioxide, and carbon monoxide in Toronto, Canada, J. Expo. Sci. Environ. 
Epidemiol. 16 (2006) 172–183. doi:10.1038/sj.jea.7500446. 
[176] E.M. Fujita, B. Zielinska, D.E. Campbell, J.C. Sagebiel, W. Ollison, High-end 
exposure relationships of volatile air toxics and carbon monoxide to community-scale 
air monitoring stations in Atlanta, Chicago, and Houston, Air Qual. Atmos. Heal. 9 




(2016) 311–323. doi:10.1007/s11869-015-0345-4. 
[177] I. Gregorczyk-Maga, M. Maga, A. Wachsmann, M.K. Janik, O. Chrzastek-Janik, M. 
Bajkowski, L. Partyka, M. Koziej, Air pollution may affect the assessment of smoking 
habits by exhaled carbon monoxide measurements, Environ. Res. 172 (2019) 258–265. 
doi:10.1016/J.ENVRES.2019.01.063. 
[178] J.G. Casey, J. Ortega, E. Coffey, M. Hannigan, Low-cost measurement techniques to 
characterize the influence of home heating fuel on carbon monoxide in Navajo homes, 
Sci. Total Environ. 625 (2018) 608–618. doi:10.1016/j.scitotenv.2017.12.312. 
[179] L.P. Naeher, B.P. Leaderer, K.R. Smith, Particulate Matter and Carbon Monoxide in 
Highland Guatemala: Indoor and Outdoor Levels from Traditional and Improved 
Wood Stoves and Gas Stoves, Indoor Air. 10 (2000) 200–205. doi:10.1034/j.1600-
0668.2000.010003200.x. 
[180] M. Busch, Carbon Monoxide Exposure in Norwegian Rescue Helicopters, Air Med. J. 
34 (2015) 328–332. doi:10.1016/j.amj.2015.06.010. 
[181] B. Hooper, R. Parker, C. Todoroki, Exploring chainsaw operator occupational 
exposure to carbon monoxide in forestry, J. Occup. Environ. Hyg. 14 (2017) 1–12. 
doi:10.1080/15459624.2016.1229483. 
[182] O. Adetona, C.D. Simpson, G. Onstad, L.P. Naeher, Exposure of wildland firefighters 
to carbon monoxide, fine particles, and levoglucosan, Ann. Occup. Hyg. 57 (2013) 
979–991. doi:10.1093/annhyg/met024. 
[183] N.B. Hampson, T.G. Courtney, J.R. Holm, Ambulatory measurement of ambient 
carbon monoxide levels, Undersea Hyperb. Med. 42 (2015) 273–278. 
[184] A.A. Commodore, S.M. Hartinger, C.F. Lanata, D. Mäusezahl, A.I. Gil, D.B. Hall, M. 
Aguilar-Villalobos, L.P. Naeher, A pilot study characterizing real time exposures to 
particulate matter and carbon monoxide from cookstove related woodsmoke in rural 
Peru, 1Atmospheric Environ. 79 (2013) 380–384. doi:10.1016/j.pain.2013.06.005.Re-
Thinking. 
[185] R. Zeidan, S. Rachidi, S. Awada, A. Hajje, W. Bawab, J. Salamé, R. Bejjany, P. 
Salameh, Carbon monoxide and respiratory symptoms in young adult passive smokers: 
A pilot study comparing waterpipe to cigarette, Int. J. Occup. Med. Environ. Health. 
27 (2014) 571–582. 
[186] N.L. Benowitz, P. Jacob, L. Yu, R. Talcott, S. Hall, R.T. Jones, Reduced Tar, Nicotine, 
and Carbon Monoxide Exposure While Smoking Ultralow- but Not Low-Yield 
Cigarettes, J. Am. Med. Assoc. 256 (1986) 241–246. 
doi:10.1001/jama.1986.03380020103032. 
[187] H. Lawin, L. Ayi Fanou, V. Hinson, J. Wanjiku, N.K. Ukwaja, S.B. Gordon, B. 
Fayomi, J.R. Balmes, P. Houngbegnon, E. Avokpaho, A. Sanni, Exhaled carbon 
monoxide: a non-invasive biomarker of short-term exposure to outdoor air pollution, 
BMC Public Health. 17 (2017) 4–8. doi:10.1186/s12889-017-4243-6. 
[188] R.M. Harrison, C.A. Thornton, R.G. Lawrence, D. Mark, R.P. Kinnersley, J.G. Ayres, 
Personal exposure monitoring of particulate matter, nitrogen dioxide, and carbon 
monoxide, including susceptible groups, Occup. Environ. Med. 59 (2002) 671–679. 
doi:10.1007/978-3-0346-0277-8_2. 




[189] D.A. Leaf, M.T. Kleinman, Acute Exposure to Carbon Monoxide Does Not Affect 
Plasma Lipids, Lipoproteins, and Apolipoproteins, Angiology. 47 (1996) 337–341. 
[190] J.P. Loennechen, V. Beisvag, I. Arbo, H.L. Waldum, A.K. Sandvik, S. Knardahl, O. 
Ellingsen, Chronic Carbon Monoxide Exposure in vivo Induces Myocardial 
Endothelin-1 Expression and Hypertrophy in Rat, Pharmacol. Toxicol. 85 (1999) 192–
197. 
[191] N.L. Benowitz, P. Jacob, L.T. Kozlowski, L. Yu, Influence of smoking fewer 
cigarettes on exposure to tar, nicotine and carbon monoxide, N. Engl. J. Med. 315 
(1986) 1310–1313. doi:10.1056/NEJM198603063141003. 
[192] J.H. Ettema, R.L. Zielhuis, E. Burer, H.A. Meier, L. Kleerekoper, M.A. De Graaf, 
Effects of Alcohol , Carbon Monoxide and Trichloroethylene Exposure on Mental 
Capacity, Int. Arch. Occup. Environ. Heal. 35 (1975) 117–132. 
[193] A.K. Quinn, K.A. Ae-Ngibise, P.L. Kinney, S. Kaali, B.J. Wylie, E. Boamah, D. 
Shimbo, O. Agyei, S.N. Chillrud, M. Mujtaba, J.E. Schwartz, M. Abdalla, S. Owusu-
Agyei, D.W. Jack, K.P. Asante, Ambulatory monitoring demonstrates an acute 
association between cookstove-related carbon monoxide and blood pressure in a 
Ghanaian cohort, Environ. Heal. A Glob. Access Sci. Source. 16 (2017) 1–14. 
doi:10.1186/s12940-017-0282-9. 
[194] J.Y. Min, D. Paek, S. Il Cho, K.B. Min, Exposure to environmental carbon monoxide 
may have a greater negative effect on cardiac autonomic function in people with 
metabolic syndrome, Sci. Total Environ. 407 (2009) 4807–4811. 
doi:10.1016/j.scitotenv.2009.05.028. 
[195] E.N. Allred, E.R. Bleecker, B.R. Chaitman, T.E. Dahms, S.O. Gottlieb, J.D. Hackney, 
M. Pagano, R.H. Selvester, S.M. Walden, J. Warren, Short-term effect of carbon 
monoxide exposure on the exercise performance of subjects with coronary artery 
disease, N. Engl. J. Med. 321 (1989) 1426–1432. doi:10.1080/03009740701716868. 
[196] T.E. Dahms, L.T. Younis, R.D. Wiens, S. Zarnegar, S.L. Byers, B.R. Chaitman, 
Effects of carbon monoxide exposure in patients with documented cardiac 
arrhythmias, J. Am. Coll. Cardiol. 21 (1993) 442–450. doi:10.1016/0735-
1097(93)90687-V. 
[197] K.K. Johnson-Arbor, A.S. Quental, D. Li, A comparison of carbon monoxide 
exposures after snowstorms and power outages, Am. J. Prev. Med. 46 (2014) 481–486. 
doi:10.1016/j.amepre.2014.01.006. 
[198] A. Veronesi, V. Pecoraro, S. Zauli, M. Ottone, G. Leonardi, P. Lauriola, T. Trenti, Use 
of carboxyhemoglobin as a biomarker of environmental CO exposure: critical 
evaluation of the literature, Environ. Sci. Pollut. Res. 24 (2017) 25798–25809. 
doi:10.1007/s11356-017-0270-1. 
[199] L.D. Longo, Carbon Monoxide in the Pregnant Mother and Fetus and its Exchange 
across the Placenta, Ann. New York Acad. Sci. 174 (1970) 312–341. 
[200] B.C. Chen, L.K. Shawn, N.J. Connors, K. Wheeler, N. Williams, R.S. Hoffman, T.D. 
Matte, S.W. Smith, Carbon monoxide exposures in New York City following 
Hurricane Sandy in 2012, Clin. Toxicol. 51 (2013) 879–885. 
doi:10.3109/15563650.2013.839030. 




[201] L. V. Giles, M.S. Koehle, The health effects of exercising in air pollution, Sport. Med. 
44 (2014) 223–249. doi:10.1007/s40279-013-0108-z. 
[202] R.H. Jungers, G.G. Akland, H.B. Sauls, A Human Exposure Assessment Study 



















































Table A5.1a: List of observational carbon monoxide (CO)-related exposure studies with description of the used type of exposure assessment method, measure 
of exposure, measurement device and detailed assessment method; BM: biological monitoring, PM: personal monitoring, MON: environmental monitoring, 
MOD: environmental modelling, Q: questionnaires, pCO: personal CO monitor, airCO: air CO monitor, exCO: exhaled breath CO monitor, COHb: 
carboxyhaemoglobin, PM2.5: particulate matter with a diameter of 2.5µm, Na: not applicable or reported in the study.     
Article Type of exposure 
assessment  method 
Measure of 
exposure 
Measurement device Assessment method 
[43] BM. PM, Q ExCO, pCO MicroCO monitor and HOBO CO data logger Questionnaire 
[159] MON, Q COHb, symptoms Measurement device not specified Syndromic surveillance and 
surveys, based on expert 
classification of symptoms and CO 
levels  
[18] MON Number of CO 
alarm activations 
Na Incidents of CO alarm activation 
[58] BM COHb Pulse-oximeter and Blood Gas Analyser Na 
[126] BM, MON COHb CO-oximetry  Nonlinear mixed-effects modelling 
program to create prediction 
method  
[54] PM, MON, Q pCO (and PM 2.5) Draeger CO passive diffusion tubes (ppm/h)  Questionnaires about cooking 
appliances, GM and SD 
calculations 
[160] MON AirCO Monitoring stations ED admission data 
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Article Type of exposure 
assessment  method 
Measure of 
exposure 
Measurement device Assessment method 
[161] Q COHb, symptoms, 
number of HBO 
therapy recipients 
Measurement of COHb not specified (but 
performed in hospitals) 
Detailed patient level data 
[162] PM pCO Portable gas detector Na 
[163] BM, PM COHb, pCO  CO-oximeter, CO passive sampler (then 
analysed via GC-FID)  
Na 
[164] PM pCO Personal Monitor Na 
[82] MON AirCO  HOBO CO logger Na 
[165] MON AirCO Multigas detectors Na 
[70] PM, Q pCO CO monitors (Draeger PAC) Questionnaires, mixed-effect model 
for statistical analysis  
[50] PM pCO and AirCO Personal portable CO monitors  Na 
[166] PB COHb Pulse CO-oximeter (arterial), BGA (venous) Na 
[61] BM, Q COHb BGA (arterial)  Questionnaire 
[55] PM, MOD pCO Passive color stain diffusion tubes Na 
[67] BM ExCO Breath CO monitor Na 
[167] PM, MON AirCO and pCO CO monitor (installed in home) and portable 
personal monitor  
Na 
[168] BM ExCO BreathCO monitor Na 
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Article Type of exposure 
assessment  method 
Measure of 
exposure 
Measurement device Assessment method 
[64] BM ExCO Breath CO monitor Na 
[62] BM COHb CO-oximetry  Na 
[169] BM COHb UV-Spectrophotometer Na 
[170] MON AirCO Ambient monitors  According to microenvironment 
categories 
[171] MON, MOD AirCO Fixed ambient air quality monitoring station  Scenario assessment  method 
(average and continuous exposure 
for 24h and annual exposure for 
different age groups) 
[65] BM, Q ExCO CO breath analyser  Questionnaire about smoking status 
and SHS exposure 
[172] MON AirCO Air monitoring stations  Na 
[128] BM, PM ExCO/COHb and 
pCO 
microCO monitor and personal CO 
monitoring with EasyLog CO Monitor  
Results input into CFK-equation to 
predict COHb 
[68] MOD AirCO Regional atmospheric modelling system Na 
[173] BM pCO Personal Monitor Na 
[174] PM, MON pCO, air CO, exCO personal monitors (48h monitoring), ambient 
monitors in kitchen and microCO monitors  
Na 
[6] MON, MOD AirCO Fixed ambient monitors Estimated daily CO ambient 
concentrations, based on four 
different estimation approaches: (1) 
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average across values from all 
monitors in the city, (2) use of the 
value at the monitor nearest to the 
study subject’s residence, (3) 
inverse distance weighting of 
monitors’ values, and (4) kriging  
Article Type of exposure 
assessment  method 
Measure of 
exposure 
Measurement device Assessment method 
[17] MON, Q AirCO CO data logger (and PM2.5) Questionnaires 
[175] PM, MON, Q pCO, airCO Portable passive diffusion data-logger and 
ambient monitors  
Questionnaires 
[176] MON AirCO Micrenvironments and ambient monitor  Also other volatile toxics measured 
[177] BM, MON ExCO, airCO Breath CO and ambient monitor Na 
[66] BM, Q ExCO piCO Smokerlyzer  Questionnaires 
[71] PM pCO Portable multiple gas monitor  In different microenvironments 
[178] MON, Q AirCO  CO sensors in air quality monitoring 
platforms  
Quesionnaires 
[51] BM, MON, Q pCO, airCO Portable personal CO monitors and fixed 
monitoring stations  
 Personal diaries  
[129] BM, PM ExCO, COHb, tHb, 
pCO 
CoVITa electrochemical sensor, HemoNIR 
and Draeger PAC III  
Na 
[179] PM, MON AirCO, pCO Draeger CO electrochemical sensor and CO 
passive diffusion tube 
Na 
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Article Type of exposure 
assessment  method 
Measure of 
exposure 
Measurement device Assessment method 
[52] PM pCO Draeger confined space monitor Na 
[44] BM, MON, Q COHb, exCO, 
airCO 
CO-oximetry, breath CO analyser and 
ambient monitors 
Estimation of COHb by measuring 
ME concentrations with CO 
monitor and time-diaries 
[60] BM COHb pulse CO-oximeter in blood (Masimo RAD-
57) 
Na 
[86] PM, MON, Q pCO, airCO LOCD and Draeger CO diffusion tubes Questionnaires 
[57] BM, MON, Q COHb and airCO real-time CO detector and UV/vis-
spectrophotometry 
Questionnaires 
[87] PM, MON, Q pCO and airCO Q-trak CO monitor and Multigas monitors Questionnaires 
[56] PM pCO Drager CO Diffsion Tubes - 
[83] MON AirCO Indoor Air Quality Meter - 
[45] PM, MON, Q pCO and airCO Portable real-time CO Logger and CO 
monitors 
Questionnaires 
[46] PM, MON, Q pCO and airCO HOBO CO logger Questionnaires 
[53] PM, MON, Q pCO and airCO Personal Monitor (Langan) and fixed-site 
monitors 
Questionnaires 
[48] PM, MON pCO and airCO Passive electrochemical CO monitor and non-
dispersive infrared monitors (CO 10-M and 
11-M) 
- 
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Article Type of exposure 
assessment  method 
Measure of 
exposure 
Measurement device Assessment method 
[88] PM pCO Draeger CO Monitor - 
[59] BM COHb Pulse CO-oximeter Na 
[180] BM, Q COHb Handheld pulse CO-oximeter Questionnaires 
[181] PM pCO Personal monitor  Na 
[182] PM pCO Real time gas monitor Na 
[63] PM, Q End respiratory CO Handheld breath analyser Questionnaires 
[49] PM, MON AirCO and pCO Passive diffusion CO tubes (3 per household, 
2 personal (mother and child) and 1 ambient) 
Na 
[183] PM pCO Personal monitors Na 
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Table A5.b: List of experimental carbon monoxide (CO)-related exposure studies with description of the used type of exposure assessment method, measure 
of exposure, measurement device and detailed assessment method; BM: biological monitoring, PM: personal monitoring, MON: environmental monitoring, 
MOD: environmental modelling, Q: questionnaires, pCO: personal CO monitor, airCO: air CO monitor, exCO: exhaled breath CO monitor, COHb: 
carboxyhaemoglobin, PM2.5: particulate matter with a diameter of 2.5µm, TBCO: total blood CO, Na: not applicable or reported in the study.     




Measurement device Assessment method 
[80] MON, MOD AirCO Central Site Monitors AERMOD simulated concentrations, 
local- and regional-scale modeling, 
APEX and SHEDS model to estimate 
population exposure to CO 
[134] PM, MOD COHb Not specified Model for individual COHb exposure 
estimation 
[185] BM, Q ExCO, respiratory 
symptoms 
Breath CO analyser Questionnaires on sociodemographic 
info, respiratory symptoms and 
exposure to second hand smoke 
[186] BM, Q COHb CO-oximetry Questionnaires 
[187] BM, MON, Q ExCO, airCO Breath CO analyser and portable CO data 
logger 
Questionnaires 
[63] PM, Q End respiratory CO Handheld breath analyser Questionnaires 
[188] PM, MOD pCO  Personal monitors (shadowing for kids)  Modeling of monitoring in 
microenvironment (personal vs static 
concentrations) 
[84] BM COHb and air CO 
(in car) 
Method for COHb in blood measurement 
not specified, CO monitor for air CO 
Na 
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Article Type of exposure 
assessment  method 
Measure of 
exposure 
Measurement device Assessment method 




CO-oximeter and GC-RGA Na 
[190] BM Endothelin-1 
mRNA levels 
Fluorescence detection after PCR and 
electrophoresis separation 
Na 
[191] BM COHb CO-oximeter Na 
[192] BM COHb PdCl2-method Na 
[94] PM, MOD pCO Personal monitors  Comparison of computer-simulated 
exposure distributions to distributions 
of the population through personal 
exposure monitoring study 
[193] PM pCO and blood 
pressure 
Personal CO monitors and BP 
measurement  
Na 
[81] PM, MON, Q pCO and airCO Personal CO diffusion tubes and fixed 
monitoring at different locations  
Questionnaires 
[194] MON AirCO, heart rate Ambient CO monitors and heart rate 
variability 
Na 
[137] PM, MOD pCO Passive diffusion tubes  Prediction model based on validation 
study  
[97] BM COHb, TBCO CO-oximetry and GC-MS Na 
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Article Type of exposure 
assessment  method 
Measure of 
exposure 
Measurement device Assessment method 
[195] BM AirCO, CO, COHb IR CO analyser, GC, CO-oximeter Na 
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Table A5.1c: List of reviews on carbon monoxide (CO)-related exposure studies with description of the used type of exposure assessment method, measure of 
exposure, measurement device and detailed assessment method; BM: biological monitoring, PM: personal monitoring, MON: environmental monitoring, MOD: 
environmental modelling, Q: questionnaires, pCO: personal CO monitor, airCO: air CO monitor, exCO: exhaled breath CO monitor, COHb: 
carboxyhaemoglobin, PM2.5: particulate matter with a diameter of 2.5µm, TBCO: total blood CO, Na: not applicable or reported in the study.   




Measurement device Assessment method 
[197] BM, Q COHb, symptoms CO-oximetry, hospital data Categorize patients CO exposures based 
on their characteristics 
[198] BM COHb Mainly spectrophotometric methods (CO-
oximetry, pulse CO-oximetry) but also 
breath CO  
Na 
[79] PM, MON pCO and air CO Personal CO monitors and fixed site 
monitoring 
Comparison between two measures in 
different microenvironments 
[12] BM AirCO, exCO, 
COHb, symptoms 
Ambient monitors, breath CO monitors, 
CO-oximetry and questionnaires 
Data for occupational CO intoxications 
from surveillance database 
[199] BM COHb Hopcalite method of Linderholm and 
Sjöstrand, Van Slyke method, and others 
Fetal and maternal COHb in blood 
[200] MON Number of CO 
exposure cases 
Exposure cases from NYC Poison Control 
Center and Syndromic Surveillance Unit 
Na 
[201] BM, MON AirCO and COHb Measurement device not specified Na 
[85] PM, MON pCO and airCO CO Loggers, Infrared Spectrometric 
Monitors and Passive diffusion tubes 
Critical Review 









Figure  A5.1: Summary of frequencies for exposure assessment methods in CO exposure studies 
identified in literature review; BM: biological monitoring, MON: environmental monitoring, PM: 
personal monitoring, Q: questionnaire, MOD: environmental modelling. 
 
 




Figure  A5.2: Overview for conceptual map of methods used in CO exposure assessment studies, based on investigated literature. 
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Table A5.2: Overview of results for calculation process to determine the impact of classical measurement error improvement on the relative risk (RR). See 
protocol in chapter 5 for detailed description of variables and how they are derived/calculated.  



















1 5 9.07 82.23 57.23 7.56 0.05 0.80 0.96 0.92 52.74 77.74 0.30 0.32 5.46% 1.22 1.234 1.15% 
2 5 9.07 82.23 57.23 7.56 0.05 0.50 0.98 0.95 54.40 79.40 0.30 0.31 3.44% 1.22 1.229 0.71% 
3 5 9.07 82.23 57.23 7.56 0.05 0.20 0.99 0.98 56.09 81.09 0.30 0.31 1.38% 1.22 1.223 0.28% 
4 5 9.07 82.23 57.23 7.56 0.10 0.80 0.92 0.85 48.44 73.44 0.30 0.34 10.69% 1.22 1.249 2.41% 
5 5 9.07 82.23 57.23 7.56 0.10 0.50 0.95 0.90 51.65 76.65 0.30 0.33 6.79% 1.22 1.238 1.46% 
6 5 9.07 82.23 57.23 7.56 0.10 0.20 0.98 0.96 54.96 79.96 0.30 0.31 2.76% 1.22 1.227 0.57% 
7 5 9.07 82.23 57.23 7.56 0.20 0.80 0.84 0.71 40.38 65.38 0.30 0.38 20.49% 1.22 1.284 5.26% 
8 5 9.07 82.23 57.23 7.56 0.20 0.50 0.90 0.81 46.36 71.36 0.30 0.35 13.22% 1.22 1.258 3.08% 
9 5 9.07 82.23 57.23 7.56 0.20 0.20 0.96 0.92 52.74 77.74 0.30 0.32 5.46% 1.22 1.234 1.15% 
10 5 9.07 82.23 57.23 7.56 0.30 0.80 0.76 0.58 33.06 58.06 0.30 0.43 29.40% 1.22 1.325 8.63% 
11 5 9.07 82.23 57.23 7.56 0.30 0.50 0.85 0.72 41.35 66.35 0.30 0.38 19.31% 1.22 1.279 4.87% 
12 5 9.07 82.23 57.23 7.56 0.30 0.20 0.94 0.88 50.57 75.57 0.30 0.33 8.10% 1.22 1.242 1.77% 
13 5 9.07 82.23 57.23 7.56 0.50 0.80 0.60 0.36 20.60 45.60 0.30 0.55 44.54% 1.22 1.431 17.32% 
14 5 9.07 82.23 57.23 7.56 0.50 0.50 0.75 0.56 32.19 57.19 0.30 0.44 30.45% 1.22 1.331 9.10% 
15 5 9.07 82.23 57.23 7.56 0.50 0.20 0.90 0.81 46.36 71.36 0.30 0.35 13.22% 1.22 1.258 3.08% 
16 5 9.07 82.23 57.23 7.56 0.70 0.80 0.44 0.19 11.08 36.08 0.30 0.69 56.12% 1.22 1.573 28.96% 
17 5 9.07 82.23 57.23 7.56 0.70 0.50 0.65 0.42 24.18 49.18 0.30 0.51 40.19% 1.22 1.394 14.30% 


















19 5 7.60 57.82 32.82 5.73 0.05 0.80 0.96 0.92 30.25 55.25 0.43 0.45 4.45% 1.22 1.231 0.93% 
20 5 7.60 57.82 32.82 5.73 0.05 0.50 0.98 0.95 31.20 56.20 0.43 0.44 2.80% 1.22 1.227 0.58% 
21 5 7.60 57.82 32.82 5.73 0.05 0.20 0.99 0.98 32.17 57.17 0.43 0.44 1.13% 1.22 1.223 0.23% 
22 5 7.60 57.82 32.82 5.73 0.10 0.80 0.92 0.85 27.78 52.78 0.43 0.47 8.72% 1.22 1.243 1.92% 
23 5 7.60 57.82 32.82 5.73 0.10 0.50 0.95 0.90 29.62 54.62 0.43 0.46 5.53% 1.22 1.234 1.17% 
24 5 7.60 57.82 32.82 5.73 0.10 0.20 0.98 0.96 31.52 56.52 0.43 0.44 2.25% 1.22 1.226 0.46% 
25 5 7.60 57.82 32.82 5.73 0.20 0.80 0.84 0.71 23.16 48.16 0.43 0.52 16.71% 1.22 1.270 4.07% 
26 5 7.60 57.82 32.82 5.73 0.20 0.50 0.90 0.81 26.58 51.58 0.43 0.48 10.78% 1.22 1.250 2.43% 
27 5 7.60 57.82 32.82 5.73 0.20 0.20 0.96 0.92 30.25 55.25 0.43 0.45 4.45% 1.22 1.231 0.93% 
28 5 7.60 57.82 32.82 5.73 0.30 0.80 0.76 0.58 18.96 43.96 0.43 0.57 23.98% 1.22 1.299 6.47% 
29 5 7.60 57.82 32.82 5.73 0.30 0.50 0.85 0.72 23.71 48.71 0.43 0.51 15.75% 1.22 1.266 3.79% 
30 5 7.60 57.82 32.82 5.73 0.30 0.20 0.94 0.88 29.00 54.00 0.43 0.46 6.61% 1.22 1.237 1.42% 
31 5 7.60 57.82 32.82 5.73 0.50 0.80 0.60 0.36 11.82 36.82 0.43 0.68 36.33% 1.22 1.367 12.01% 
32 5 7.60 57.82 32.82 5.73 0.50 0.50 0.75 0.56 18.46 43.46 0.43 0.58 24.83% 1.22 1.303 6.79% 
33 5 7.60 57.82 32.82 5.73 0.50 0.20 0.90 0.81 26.58 51.58 0.43 0.48 10.78% 1.22 1.250 2.43% 
34 5 7.60 57.82 32.82 5.73 0.70 0.80 0.44 0.19 6.35 31.35 0.43 0.80 45.77% 1.22 1.443 18.28% 
35 5 7.60 57.82 32.82 5.73 0.70 0.50 0.65 0.42 13.87 38.87 0.43 0.64 32.78% 1.22 1.344 10.18% 
36 5 7.60 57.82 32.82 5.73 0.70 0.20 0.86 0.74 24.27 49.27 0.43 0.51 14.78% 1.22 1.263 3.51% 




Table A5.3: List of abbreviations and descriptions of parameters used for calculation of measurement 
error improvement. 
Abbreviation Name 
EMM Exposure measurement 
method 
Set Combination of variables 
over different ranges 
σT True standard deviation 
σX Total observed standard 
deviation 
σ2X Total observed variance 
σ2E Variance of the error 
σE SD of the error 
σEconrel Modifiable fraction of 
relative contribution to error 
SD 
σEconrelimp Fraction of σEconrel reduced 
in improved x 
σENetImp Net remaining fraction of 
error SD in improved x 
σ2ENetImp Net remaining fraction of 
error variance in improved x 
σ2Eimp Improved error variance 
σ2Ximp Improved variance of x 
ρXX Reliability coefficient 
ρXXimp Improved reliability 
coefficient  
RRX Observed relative risk 
RRXImp Improved relative risk  




























































Chapter 6 - General Discussion and Conclusions 
 
 187 





With this doctoral research, some of the most pressing concerns related to CO poisonings were 
addressed, which include frequent misdiagnoses and unsuitability of current measurement 
methods, especially for low-level CO exposures, that lead to underreported morbidity and 
mortality rates as well as errors in the measurement. Consequently, these lead to 
underestimating the true risk that CO poses on the population and the part it contributes to the 
global burden of disease (for further details, see Chapters 1 and 5).  
The main approach was to first investigate the literature on CO exposures and the methods 
adopted for quantification, in order to obtain an overview of the current state-of-the-art and 
identify issues related to these methods from an analytical point of view (Publication 1[1]). The 
main and most commonly employed biomarker of exposure is COHb [2, 3]. This is due to the 
high-affinity Hb has for CO as well as the simplicity in measuring it in an individual, which is 
through a spectrophotometric technique [4]. The use of a spectrophotometer is more simple, 
easy and cheap compared to GC methods, and, thus, the current method of choice to determine 
levels of CO exposure in a subject (Publication 1 [1]). However, several issues were identified 
related to the use of an optical quantification method. One main problem when measuring a 
biological sample based on its optical appearance is that biochemical alterations tend to occur 
as soon as the biospecimen leaves the in vivo status and becomes in vitro and also during 
transport and prolonged storage of the sample [5, 6]. This alters the optical sample quality, 
affecting the results obtained by measurement with a spectrophotometer, which is the main 
instrument used in the majority of EDs (BGA) and forensic laboratories (CO-oximeter/UV-
spectrophotometer). Therefore, these results might give an inaccurate account of the real COHb 
concentration present in the sample analysed. When looking at a sample from a patient in the 
ED, this could lead the main clinician to a misdiagnosis or to the wrong necessary therapeutic 
action, potentially putting the patient at risk of further poisoning. In forensic cases, inaccurate 
results can have legal consequences, since different levels of COHb can determine whether CO 
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poisoning was the main cause of death, whether it contributed to death or whether it was 
unrelated to the fatality [7, 8].  
Another crucial point in question of the use of COHb as the main biomarker of CO exposure 
that was identified is the fact that the assumptions behind its use as a biomarker have not been 
fully elucidated and might be lacking some important information. Several studies have shown 
that CO binds to Hb as well as to many other hemoproteins in the body; therefore, the main 
toxicity mechanism of CO is not only through reduced oxygen-transport but also through other 
pathways (see Figure 1.2 in Chapter 1 for more details). This has raised several discussions 
regarding the amount of CO bound to Hb versus the amount of CO in free form in blood that 
is transported directly to the tissues and their relative contribution to CO toxicity. Some 
research groups have suggested that the amount of free CO might be higher than previously 
reported and, thus, might contribute to a higher extent than assumed so far to CO toxicity [9–
11]. Groups lead by Bruce and Bruce [12, 13] and Gosselin et al. [14] have been working on 
determining these amounts by setting up a toxicokinetic compartment-based model for the 
absorption, distribution, metabolization and elimination of CO in the body, which was also 
intended to improve the main model introduced in the 1960s by Coburn, Foster and Kane [15]. 
No successful quantifications of free CO were reported, even though several groups have 
proposed CO measurement through the use of GC methods, such as Collison et al. [16], 
Vreman et al. [17], Cardeal et al. [18], and Varlet et al. [19]. In these studies, CO was quantified 
through GC-RGA, GC-FID or GC-MS and back calculated to equivalent reference COHb 
levels, which solved the problems related to sample quality, but not the one regarding 
misdiagnoses and underestimations. One conceptual error that I identified in them is their 
intention to relate the measured CO to COHb levels, which on the one hand is sensible 
considering that COHb is the main biomarker of CO exposure, but on the other hand, does not 
get closer to the true CO exposure levels. The main issue in the majority of these studies is that 
to obtain a correlation between CO and COHb, they flush the calibrators prior to analysis to 
remove the excess amount of CO in the blood sample. Since we are interested in exactly this 
‘excess’ amount of CO, I have investigated alternative biomarker and measurement methods 
for the determination of CO in biological samples that would be able to determine not only CO 
bound to Hb but also free CO.  
For this purpose, I have taken the GC-based studies as a starting point for the development of 
an alternative measurement method. During this phase, several factors were taken into 
consideration, including the quantities of sample and reagents (liberating agent, calibration 
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solution, internal standard solution, etc.) required to obtain sufficient accuracy and reliability, 
sample preparation steps (heating time, heating temperature, type of releasing agent, type of 
calibrator, type of internal standard, etc.) and instrumental conditions (GC temperature, run 
time, etc.). The analytical method developed (Figure 6.1) is based on AGS-GC-MS and was 
optimized in the initial phase of this research project and then validated according to the 
guidelines of a scientific society (SFSTP) (see Chapter 3).  
 
Figure 6.1: Overview of developed analytical method to determine TBCO in blood via AGS-GC-MS. Procedure: 
100µL of the blood sample to be analysed are inserted into a 20mL HS vial, followed by 10µL of IS solution 
(isotopically labelled formic acid; for calibration samples, formic acid solution is also added in required 
concentrations); 100µL of sulphuric acid are inserted into an aluminium cap, which is then carefully inserted into 
the HS vial and hermetically sealed; the vial is vigorouslyy vortexed prior to heating for 1h at 100°C; during this 
time, the reaction taking place is that the sulphuric acid not only liberates the CO from the blood (both bound to 
Hb and unbound), but also generates 13CO from the IS solution, which is used for quantification; 1mL of the HS 
is sampled with an AGS and analysed via GC-MS; quantification of TBCO occurs through the ratio of CO to 
13CO.     
Given the broad concentration spectrum of CO, which can extend from clinically relevant to 
fatally toxic concentrations, and the general difficulty of quantification methods to be linear 
over a long concentration range, the method was validated separately for clinical (2-60 
nmol/mL HS/0.5-15µmol/mL blood) and postmortem (PM) (10-200 nmol/mL HS/2-
40µmol/mL blood) ranges. Similar to real-life cases, where CO concentrations found in some 
clinical cases were fatal in other ones and vice versa, the ranges overlap. Compared to previous 
GC-based studies, this quantification method for CO has improved the method’s sensitivity 
(lower LOD and LOQ) and lowered the cost through reduction of reagents required for analysis 
(100µL of H2SO4 used as liberating agent and reagent to generate the IS) as well as the quantity 
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of sample required (200µL to 100µL). The latter is especially relevant for forensic cases, where 
sample availability might be limited. The main novelty of this method is the introduction of a 
novel biomarker, TBCO, which is derived from the method’s ability to measure the total 
amount of CO in blood, as opposed to only CO bound to Hb. This is an essential step since it 
provides a valuable tool with the potential to get closer to the true CO levels in a blood 
specimen, which to some extent should reflect the subject’s exposure levels.  
To determine whether the validated methods are applicable to real cases, a number of PM and 
clinical samples were obtained and their CO concentrations determined via the newly 
developed AGS-GC-MS method and compared to CO-oximetry (Publication 2 [20]). Results 
confirmed the successful application of the novel approach to real cases. However, a concern 
that might arise when comparing the two methods is the different units they are measured in; 
while COHb is measured as a percentage, TBCO is measured as a concentration in µmol/mL. 
For this purpose, several of the previously mentioned studies developed and proposed formulae 
to back calculate the obtained CO concentration into COHb% levels [17, 18, 21]. As an 
example, I have tested the formula proposed by Cardeal et al. [18] by inputting the TBCO 
concentrations obtained for some PM cases with the novel method and comparing the results 
to the spectrophotometric measurements. Results showed that for all cases, the equivalent 
COHb% concentrations obtained were significantly above 100%, which from a 
pathophysiological perspective is not very sensible. The problem with these formulae is that 
flushed calibrators were used for their development and, thus, are not applicable to our 
measurements that quantify the total CO amounts. Nevertheless, what these tests proved is that 
the quantity of CO measured with the novel approach is higher than when measuring COHb 
only.  
The subsequent step was to quantify this difference, which corresponds to the free CO quantity. 
This was achieved by obtaining access to samples from a study in which the subjects were 
exposed to a known amount of CO. Blood samples were obtained before and after the exposure, 
to determine the baseline CO levels in the study individuals and then confirm the total increase 
of CO through the exposure. After the exposure, two samples were collected, of which one was 
directly analysed, while the other was flushed with a N2 stream prior to analysis. With this 
approach, I was able to measure the amount of CO bound to Hb (with flushing) and the amount 
of TBCO (no flushing) and determine the free CO part by calculating the difference of the two 
(Publication 3 [22]). The results confirmed that in all study subjects, significant amounts of CO 
were present in free form, which ranged from 10% in some individuals to most extreme values 
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such as 80%. This is the first successful quantification of free CO, which can have significant 
impacts on the diagnosis of CO poisonings when supported by instrumental analysis.  
However, I must recognize that the number of samples investigated was limited for both 
clinical and PM cases; it can be argued that sufficient study power was not achieved. 
Considering that CO poisoning cases in a small country such as Switzerland are not very 
frequent, and less frequent in only a part of the country (canton Vaud), it is not surprising that 
higher sample size was not achieved. A longer study period could have been an option to 
increase sample size, but it is recommendable to perform this kind of study in other countries 
and world areas where the population and CO poisoning incidence are higher, such as 
Mediterranean countries in Europe and developing or less developed countries in Latin-
America, Asia or Africa. In these countries, the number of CO poisoning cases is higher not 
only due to the larger population size but also due to the more widespread usage of gas-, wood- 
and fuel-based cooking stoves and heating systems, less access and popularity of motor 
vehicles with a gas filter as well as less ventilated facilities, such as underground parking lots, 
where CO is accumulated very rapidly [23]. The major steps into improving these issues on a 
more global level would include the implementation of air quality guidelines, more frequent 
and controlled security and maintenance regulations and more substantial support into 
generating prevention strategies. Since these take more time and involve more cost, a first step 
could be represented by improving the diagnosis and appropriate treatment of CO poisoning 
cases, which makes this study highly valuable for these countries. Another research group in 
Colombia has employed our GC-MS method for a group of bus drivers and confirmed the 
concentration range I found in my clinical samples, further substantiating the applicability and 
importance of measuring TBCO (unpublished data).     
Another aspect to contemplate is the feasibility from a technical and cost efficiency perspective 
of a GC-MS instrument as part of an ED or forensic laboratory. Most hospitals do not have the 
manpower and resources to buy a GC-MS instrument and train personnel on how to use it. 
Additionally, it is much faster and cheaper to obtain results from a BGA than a GC-MS analysis 
(see Publication 1 [1]). Currently, I do not have evidence that is strong enough to support a 
permanent switch from COHb to TBCO, but it is recommendable to use confirmation by GC-
MS in doubtful cases, for example when results reported by the BGA and symptoms shown by 
the patient are in disagreement. Many hospitals have collaborations with universities and other 
laboratories, where the samples can be sent to for confirmatory analysis. From a forensic 
perspective, GC-MS and gas analysis are routinely part of most forensic laboratories and, 
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therefore, there are only minimal costs associated with the addition of CO quantification, which 
is highly recommended. 
To further investigate another concerning point identified in the literature review, the effects 
that changes originating from storage under different conditions and for prolonged periods have 
on the results obtained for the newly developed method and the routine spectrophotometric one 
were determined (Publication 4 [24]). The aim hereby was to determine the changes that can 
be associated to certain storage conditions and storage periods, in order to compare the two 
methods but also allow the formulation of guidelines to propose for routine usage in 
laboratories. The parameters tested included different temperatures, preservatives, volumes of 
tube HS, freeze- and thaw-cycles, reopening cycles and time. Results of this study showed that 
generally, TBCO is less affected by storage than COHb, with TBCO being more stable during 
storage over a period of one month. This represents a significant result especially for clinical 
analyses, where storage if required, does usually not exceed a few days, but in this case, can be 
supported for at least one month. From a forensic perspective, taking into account that trials 
have the tendency to be long-lasting, storage might be required for longer periods, such as for 
one year or more. Therefore, this type of study should be extended to longer periods to confirm 
their validity in medico-legal circumstances.  
Additionally, this study generated correction and prediction formulae with the available 
dataset. The first is to be used in cases where optimal storage conditions cannot be guaranteed 
either due to cost or the circumstances surrounding the sampling. The latter is a proposition to 
back calculate the measured TBCO into COHb, in order to obtain a value that potentially could 
be used for comparison and understanding purposes. It is clear that both models represent a 
tentative study based solely on the dataset collected in our study and, therefore, needs to be 
tested and corroborated by other research groups and in real clinical and PM cases, in order to 
confirm its validity and robustness. However, this should not undermine the importance of this 
part of the work, which can be used as a basis for other scientists to continue working in this 
line of research. Based on the results of this study, I recommend and propose as a guideline for 
all laboratories performing CO analyses the storage of blood samples for CO analysis in EDTA 
blood tubes that are at least half-filled and stored in the freezer. In addition, these guidelines 
should also include a standard operating procedure for CO analysis by GC-MS, which should 
complement and update the International Organization for Standardization (ISO) standard 
27368 from 2008 for CO and hydrogen cyanide that still lists UV-spectrophotometry as 
standard method for CO determination. This will enable a unified and standardized approach 
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to CO analysis via GC-MS, as opposed to the variety of approaches presented in the past, thus 
potentially further reducing the quantification errors deriving from instrumental differences.     
A major aspect that the clinical and PM analyses as well as the study of the storage conditions 
highlight is that there is a significant difference in CO quantifications obtained between the 
measurement methods but also based on different storage parameters.  This means that if using 
non-optimal storage conditions or using a spectrophotometric approach, errors in the 
measurement are bound to occur. These measurement errors affect the results of individuals by 
potentially under- or overestimating them, which leads to the frequently occurring 
misdiagnoses. However, these errors have implications not only from a clinical and forensic 
perspective (as shown in the previous studies) but also from a global public health viewpoint. 
Errors in the individual measurements lead to errors in the association of certain individuals 
into the exposure group (exposed vs non-exposed) and to errors in the estimation of exposures 
for groups of individuals (classical measurement error). This then leads to erroneous population 
exposure estimates, which affects the relative risks for morbidity and mortality caused by CO 
exposure [25–28]. In order to have an impact on public health, it is thus very important to 
determine the consequences of different sources of error, such as measurement error, on 
exposure estimates. Therefore, the issues identified in the experimental studies performed in 
this doctoral work were applied to data from epidemiologic studies, so that the effect that 
changes in the measurement method and conditions can have on measurement error could be 
evaluated. Measurement error is a major fraction of the total errors that affect exposure 
estimates in epidemiologic studies and, consequently, has the potential to significantly alter 
relative risks (Chapter 5). To approach this from a methodological perspective, I have first 
investigated the literature on types of exposure measurements, exposure measurement devices, 
and sources of error present in CO exposure studies. Considering the general aim of this 
doctoral thesis to tackle especially chronic low-level exposures to CO, which tend to occur in 
indoor environments and occupational settings, the focus was put on indoor and occupational 
CO exposure assessments. Indoor exposure assessments are very complex due to the high 
amount of factors that need to be accounted for during the study design phase and implemented 
into the execution of the study and interpretation of the results. Considering that most of the 
population spends the majority of their time indoors, it makes exposure assessments of indoor 
environments the more important. In the case of CO exposure, numerous sources of 
measurement error arising in the different exposure assessment types (biological monitoring, 
personal monitoring, etc.) were idenfitied, which have been extensively discussed in Chapter 
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5. Out of the studies identified in the literature review, only 7 studies were found to correspond 
to our criteria of a valid and robust epidemiological exposure study [29–34]. One of these 
studies was then selected to perform a follow-up step, which was to use the data from the 
method development studies (Chapters 3 and 4) and apply them to the sources of measurement 
error identified in this study [29]. For this purpose, a calculation model based on classical 
measurement error as described by Armstrong in his paper from 1998 [35] and later improved 
by Armstrong and Basagana [36] and Emily White [37] in their book chapters was developed. 
Results of the calculations performed with the developed model and the data from the method 
and literature review showed that for small error contributions, the relative risk was not altered 
significantly, but for higher error sources, the risk increased quite substantially. Since no 
“golden standard” exposure measurement method is available to determine true CO exposure, 
the calculations were a simulation based on the assumption of a true exposure estimate and do 
not correspond to exact data. However, this model can be used for future studies and act as a 
reference for researchers performing CO exposure assessments, since the relative changes 
observed are likely to be similar or higher for CO exposures. A similar approach can also be 
applied to exposures to other pollutants; after determining the sources of error and if data from 
validation or reliability studies are available, calculations of relative risk changes can be carried 
out on an epidemiological study. Relative risks are the fundamental tool that public health 
institutes and occupational and environmental safety authorities use to generate air quality 
guidelines and reference levels of air pollutants in different settings (indoor, outdoor, 
occupational, urban areas, areas with high density of children or elderly, etc.). Therefore, this 
study has valuable information that these institutions and authorities can and should make use 
of in their strategical plans to assess and improve the part that CO exposure poses on the global 
burden of disease.         
6.2 Conclusion and future perspective    
 
Exposure to CO in indoor and outdoor environments and the resulting CO poisonings pose a 
threat to public health both presently and for the foreseeable future, which is until the use of 
wood-, fuel- and gas-fired stoves, heating and motor vehicles is still in place. Even though there 
have been reductions in CO emissions in many countries, CO poisonings still occur and remain 
a challenging problem for public health authorities. It is therefore essential that research into 
improving CO exposure assessments and measurements continues, in order to help tackle the 
issue by reducing the sources and quantity of errors currently present and, thus getting closer 
to the true exposure estimate. Exposure assessments are the fundamental tool employed by 
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government bodies to assess the health risks associated with an exposure. They provide the 
evidence necessary to inform stakeholders and keep them up-to-date, but also to help them 
inform the population about the dangers posed by exposure to certain contaminants. Despite 
increasing research carried out in the field of CO exposures, awareness of the health risks 
associated with it continues to be relatively limited in the general population and, thus, needs 
to be increased. It is very important that both legislators and citizens are informed on how to 
handle possible cases of intoxication, how to recognize them and how to minimize the exposure 
by taking appropriate precautions and regular controls. The best way to obtain the information 
and data required to provide this evidence is given by performing studies that undertake the 
issues related to CO exposure from all sides, which involves looking at it from the point of 
view of the individual as well as from the population perspective.  
The work carried out in this doctoral research provided a strategical pathway to approach the 
CO issue from both points of view: the individual one, in which analytical and methodological 
errors in the quantification of CO poisoning cases were identified, which have an impact for 
clinicians and forensic laboratories and can help improve the situation from the ‘bottom-up’; 
the population one, where this study helped identify the errors that can mostly affect the relative 
risk of CO exposures in the population and quantify the effect that improving a part of these 
analytical errors has on the exposure estimates, thus ameliorating the problem from the 
‘top+down’. As one of the first in its kind, this research not only provided the necessary data 
and information on both the analytical/toxicological and epidemiological issues related to CO 
exposure, it also employed these findings to generate a linkage between the two fields, allowing 
us to directly observe the effects that changes in the laboratory can have on the population 
health.  
A lot of work still needs to be carried out to improve CO exposure assessments and 
measurements even further and a lot more funding needs to go into research in this field to 
achieve results with even higher impact. Nevertheless, with this work I have established a 
foundation and provided some valuable tools to help future researchers to continue towards 
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